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Chapter I 
 
INTRODUCTION 
 
Current data project obesity prevalence within the United States to reach ~42% by 2030 
(73). As of 2008, the financial burden of obesity translated to $147 billion in extra healthcare 
expenditures, independent of comorbidities (74). Prolonged obesity is detrimental to many 
aspects of health (27) and the liver represents a keystone in development of obesity related 
pathologies. It is directly associated with aggregates of the metabolic syndrome (166) including 
dyslipidemia (239), hyperglycemia (293), insulin resistance (33, 57), and nonalcoholic fatty liver 
disease (NAFLD) (44). NAFLD is relatively new as an appreciated consequence of over-nutrition. 
NAFLD contributes to end stage liver disease (71), type 2 diabetes (T2D) (283), and 
cardiovascular disease (250). Estimates indicate 55 million adults in the United States have 
NAFLD with incidence predicted to increase parallel with rates of obesity (154). Additionally 
NAFLD is projected as the primary cause for liver transplants in the United states by 2030 (39). 
Despite the impacts of NAFLD on public health at the national and global levels there are currently 
no therapeutic options available for primary treatment of NAFLD (81). Given the immense effects 
on quality of patient lives and the current lack of therapeutic options, research efforts aimed at 
understanding pathologic mechanisms of NAFLD are imperative.   
Hepatic insulin resistance (IR) is typically described as the loss of insulin’s inhibitory 
effects on hepatic glucose output. This condition is highly correlated with both NAFLD and T2D 
(31, 57). Over last 15 years hepatic IR has also become increasingly associated with extracellular 
matrix (ECM) expansion (32). ECM deposition was formerly considered a sign of advanced 
disease progression in many liver pathologies including NAFLD. However, the fibrotic program is 
now thought to initiate early, parallel many progressive components of the disease, and play an 
active role in disease progression.  
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Hepatocytes are the primary site of insulin action and metabolic integration within the liver. 
Alterations in ECM during hepatic IR and NAFLD (9) has prompted research on the cadre of 
signals emanating from hepatocyte-ECM interactions that influence these pathologies. Studies 
have now demonstrated that integrins, the primary cell-ECM signaling receptors, have variegated 
effects on IR in different tissues during diet-induced obesity (DIO) (279). Integrin-linked kinase 
(ILK) is an intracellular signaling protein immediately downstream of integrin receptors that is 
requisite for development of hepatic IR during DIO (280). Hepatic IR and NAFLD are rooted in 
deficient hepatic glucoregulation and altered metabolism. Therefore, understanding ILK within the 
contexts of these processes serves to clarify the role of ILK, integrins, and ECM in these 
pathologies, but also in normal physiology.  
Hypotheses, experiments, and resulting conclusions related to this work were formulated 
as the logical progression of historical interests within our research environment with 
modifications as new information became available. In this regard, the introduction acts as an 
orientation for the efforts and concepts that serve as the foundation of this body of work. Initially 
this section describes hepatic development as this establishes the liver as a center for metabolic 
function and maintenance of physiologic homeostasis. Next, control of hepatic metabolism 
through endocrine systems is introduced. This offers insight in to typical physiologic function as 
well as the aspects of this control that can go awry during pathology. Associations of ECM 
deposition with several pathologic states, including insulin resistance and NAFLD, are then 
discussed. In order to better approach hepatic ECM and its contributions to these pathologies the 
typical structure, contents, and organization of this compartment within the liver are briefly 
reviewed. Also considered are the means that cells interact with and interpret the ECM, 
emphasizing integrin receptors and their downstream signaling components. Amongst these 
components is integrin-linked kinase, whose actions serves as the primary molecular focus of this 
dissertation. Specifically the functions of this protein in cellular biology and how it impacts insulin 
resistance, hepatic metabolism as well as injury and regeneration. 
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The liver as a metabolic hub  
The liver is a critical hub for numerous physiological processes. These include whole-body 
glucose homeostasis, blood volume regulation, immune system support, endocrine control of 
growth signaling pathways, lipid and cholesterol homeostasis, and the breakdown of xenobiotic 
compounds including many current drugs (4). Processing, partitioning, and metabolism of 
macronutrients provide energy for the aforementioned processes and are therefore among the 
liver’s most critical functions (223, 255).  
The liver’s capacity to store glucose in the form of glycogen, with feeding, and assemble 
glucose via the gluconeogenic pathway, in response to fasting, are critical to whole body glucose 
homeostasis (99). The liver oxidizes lipids for provision of energy (177, 223) and maintenance of 
metabolite pools (200), while also packaging excess lipid for secretion to and storage in other 
tissues (107), such as the adipose. Finally, the liver is a major handler of protein and amino acid 
metabolism (28) as it is responsible for the majority of proteins secreted in the blood (whether 
based on mass or range of unique proteins), the processing of amino acids for carbon, and 
disposal of nitrogenous waste from protein degradation in the form of urea metabolism (2). This 
diverse array of metabolic integrations is determined through an intricate hierarchy of transcription 
factors and signaling processes that are initiated during development and reinforced throughout 
the life of the organism.  
 
Initiation of liver development 
As the function and organization of the liver are critical to so many processes it is important 
to understand how these aspects of the liver arise developmentally. Described here is the general 
organization of hepatic development that occurs in many animals including zebra fish, mice, rats, 
and humans. Duration and identity of signals involved in each of these developmental aspects 
may vary between species. The goal of this section is to give a general overview of hepatic 
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development in common model organisms and humans.  For simplicity, specific proteins and 
transcription factors referenced have been derived from studies in mice and rats except where 
specifically noted.  
The definitive endoderm, ectoderm, and mesoderm make up the three major cell layers 
established during embryonic gastrulation. Cells from the definitive endoderm proceed to form the 
epithelium of the respiratory and digestive tracts as well as associated organs such as liver and 
pancreas (88). The primary metabolic cell population of the liver, hepatocytes, and the bile duct 
lining epithelial cells, cholangiocytes, arise from the posterior foregut region within the definitive 
endoderm (258). Definitive endoderm specification and segregation require a complex array of 
extracellular growth factor signals in proper temporal organization. Some of the earliest signals 
for initiation of hepatic bud outgrowth from the posterior foregut endoderm include fibroblast 
growth factor (FGF) (61), and bone morphogenic proteins (BMPs) (172), which are provisioned 
from the overlying mesodermally-derived cardiac mesoderm and septum transversum. Other 
signals influencing this process include transforming growth factor β (TGF-β) (6), Wnt (55), and 
NOTCH. These signals are supported by expression and activity of transcription factors in the 
FoxA and GATA families within the endodermally-derived epithelium. Specific members of these 
families, notably FoxA1 and GATA4 (46), act as pioneer factors, interacting with their DNA binding 
motifs within compact chromatin to modify nucleosome localization. This alteration of chromatin 
conformation creates an environment of transcriptional competence for these and other 
downstream transcription factors. The sum of these epigenetic modifications results in a “footprint” 
of transcriptional access leading to establishment and maintenance of gene expression critical for 
differentiation and mature function (Figure 1.1). 
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Cell patterning and maturation during liver development 
Cells of the hepatic bud give rise to bipotential progenitor cells known as hepatoblasts, 
which further differentiate into the liver parenchymal cells: hepatocytes and cholangiocytes (88, 
91, 240). Importantly, prior to the formation of the bone marrow, the developing liver bud serves 
as the center of fetal hematopoiesis. Signals from hematopoietic cells, such as oncostatin M, can 
also govern hepatoblast proliferation (135) and E-cadherin-mediated cell junction formation (173) 
in hepatoblasts. While there are several other contributors to hepatoblast differentiation the 
gradient of TGF-β secreted from the portal vein mesenchyme is integral to cholangiocyte and 
hepatocyte differentiation (88). This contributes to the hepatoblast fates that are dependent on 
portal vein proximity. Mechanistically, higher TGF-β signaling in portal vein proximal hepatoblasts 
drives cholangiocyte fate by decreasing expression of CCAAT/Enhancer Binding Protein (C/EBP) 
α (291) and promoting expression of HNF6 (aka Oc1) and HNF1β (48). This transcription factor 
profile promotes cholangiocyte-specific gene transcription through HNF6 and HNF1β, while 
suppressing hepatocyte specific genes by decreasing C/EBPα levels.  Hepatoblasts located 
further from the portal vein develop into hepatocytes, forming chords across the developing 
hepatic lobules. These cells receive lower levels of TGF-β, which leads to a higher level of 
C/EBPα. In turn C/EBPα inhibits the expression of TGF-β receptor II creating a positive feedback 
loop of TGF-β signal inhibition (48, 240). C/EBPα also regulates expression of HNF1α and 
HNF4α, which act as feed forward co-activators in a number of hepatocyte specific genes.  
Finalization of hepatocyte differentiation is linked to oncostatin M (135), glucocorticoids (68), 
hepatocyte growth factor (HGF) (234), Wnt/β-catenin (8, 55), and yes-associated protein signaling 
(YAP) (236).  
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Figure 1.1- A model of hepatic epithelial cell development with supporting signals and 
transcription factors. A) Gastrulation and endoderm specification is driven by nodal signaling of 
the bipotential mesendoderm (ME). BMP inhibits nodal signaling and segregates brachyury (BRY) 
positive mesoderm from definitive endoderm (DE). B) DE cells expressing pioneering 
transcription factors FOXA2 and GATA4/6 (GATA) are driven by gradients of bone morphogenic 
proteins (BMPs), fibroblast growth factors (FGFs), and Wnt ligands through endoderm and gut 
tube patterning. DE cells will give rise to mid-gut/hind-gut (MG/HG) intestinal progenitors, anterior 
foregut (AFG) lung progenitors, and hepato-pancretic progenitors (HPP). C) Hepatoblast 
specification separates pancreatic progenitors (Pp) from hepatoblasts (Hb). Action of BMPs and 
Wnts drive the bipotential Hb population through expression of the biliary transcription factor 
hepatocyte nuclear factor 1β (HNF 1β) and the hepatocyte transcription factor HNF4α. D) Wnt 
ligands and transforming growth factor β (TGFβ) derived from the portal vein mesenchyme couple 
with BMP, Notch, FGF, and Hippo signals to drive cholangiocyte fate. These signals reinforce 
HNF1β while initiating activity of the definitive biliary transcription factors HNF6 and SRY-box 9 
(SOX9). Hb cells distant from the portal vein mesenchyme are influenced by glucocorticoids, 
hepatocyte growth factor (HGF), Oncostatin M (OSM), and tumor necrosis factor α (TNFα) to 
finalize hepatocyte (H) differentiation. 
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Many of the transcriptional factors involved in the finalizing of hepatocyte development are 
critical to the establishment of hepatocyte glucoregulatory functions. C/EBPα cooperates with the 
insulin sensitive transcription factor Foxo1 in the establishment of gluconeogenic functions (235). 
Wnt/β-catenin signaling has also been implicated in establishment of differential metabolic 
functions based on hepatocyte localization within the liver known as metabolic zonation (98). In 
fact, a balance of stimulation and suppression of genes by HNF4α is influenced by the β-catenin 
activated transcription factor LEF1 to establish zonal specific expression of various enzymes (e.g. 
glutamine synthetase) (49). More recently a paradigm where glucagon and wnt/β-catenin 
signaling exist on opposing gradients across the liver sinusoid have been established. Glucagon 
signaling is stronger in the portal area and preserves a number of oxidative and gluconeogenic 
metabolic processes. Whereas, Wnt/β-catenin signaling drives expression of periportal metabolic 
genes such as glutamine synthetase (41). This is a complementary arrangement as glucagon is 
a major driver of amino acid utilization and nitrogen waste production within the liver while 
glutamine synthesis is a high affinity sink for nitrogenous waste that escapes the urea cycle (106). 
While these transcriptional programs are emphasized during development their importance in a 
number of mature physiologic processes are also becoming increasingly apparent. This is 
emphasized by the discovery that mutations in the classic hepatocyte developmental transcription 
factors, HNF4α and HNF1α, underlie genetic forms of diabetes known as maturity-onset diabetes 
of the young (MODY) (290). Furthermore, heterozygosity for MODY mutations in these 
transcription factors can influence glucose and insulin homeostasis, potentially contributing to 
increased risk of diabetes development (203). 
 
Liver cellular anatomy and organization with respect to metabolism 
Hepatic capacity for such a wide range of metabolic processes is rooted in its unique 
structure and organization as a result of the described developmental programming. Therefore,  
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Figure 1.1- The organization and cellular populations of the liver sinusoid. A) A number of 
cell types exist within the sinusoid including hepatocytes, biliary epithelial cells (cholangiocytes), 
endothelial cells, Kupffer cells, and stellate cells. Blood flows through the sinusoid leading to a 
number of gradients along the length of this vessel. Liver endothelial cells do not form tight 
junctions, but instead have sieve plate networks between them. This allows for maximum 
exchange of macromolecules between the circulating blood and hepatocytes, which conduct a 
majority of the hepatic metabolic functions.  
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spatial components of hepatocellular anatomy and physiology serve as a critical foundation for 
understanding hepatic metabolism while informing critical points of pathologic progression.  
The liver is composed of several cell types of different embryological origin including 
hepatocytes, biliary epithelial cells (cholangiocytes), stellate cells, Kupffer cells, and liver 
sinusoidal endothelial cells (Figure 1.2) (240). Each of these cell types possesses unique roles 
that cooperatively regulate hepatic function at multiple levels. Hepatocytes are the primary 
epithelial cell population of the liver. They make up the majority of the liver volume (21) and 
perform many of the functions, including metabolism, ascribed to the liver. Cholangiocytes are 
the second most abundant epithelial population of the liver and have a more traditional epithelial 
function as the cells lining the lumen of the bile ducts. Stellate cells represent a dynamic cell 
population that can exist in a quiescent or activated state (80). In the quiescent state stellate cells 
store Vitamin A in lipid droplets (230); however, other functions in this quiescent state remain 
unclear. Damage to the liver leads to activation of stellate cells (95). Upon activation stellate cells 
proliferate and progressively lose vitamin A stores. Stellate cells are also responsible for 
deposition and organization of ECM in the injured liver. This process contributes to fibrosis of the 
liver during various pathologies (139), which can progress to cirrhosis and contribute to end stage 
liver disease. Kupffer cells are the resident macrophage population of the liver. These cells 
recognize the many pathogenic stimuli introduced through the portal circulation and can attain 
pro- or anti-inflammatory roles in liver wound healing (209). Finally, liver sinusoidal endothelial 
cells are a specialized endothelial population with unique characteristics (59, 60). These cells 
form fenestrated sieve plates at the sinusoidal lumen (286). This structure creates pores ranging 
in size from 50-180 nm in humans or 50-280 nm in mice and rats (285). This organization is critical 
for exchange of metabolites, proteins, and particles within these size limits between plasma and 
the cell types of the liver, while maintaining certain barrier functions.  
The cells of the liver are organized around the functional structural unit of the liver, the 
lobule or acinus (130). This consists of chords of hepatocytes organized in a typically hexagonal  
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Figure 1.2- General structure and organization of a typical hepatic lobule. Appearing roughly 
hexagonal in shape the vertices represent the portal triad area. Each triad contains branches of 
the portal vein, hepatic artery, and bile duct. Oxygenated blood from the general arterial circulation 
enters the hepatic artery and mixes with nutrient rich blood from the portal circulation in the gut.  
Upon mixing this blood equilibrates and flows across the lobule through a sinusoidal network 
before draining in to branches of the central vein.
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 shape around the central vein (Figure 1.3). At the vertices of this hexagon are the portal triads 
consisting of closely grouped branches of the hepatic artery, portal vein, and bile ducts. 
Circulatory units within the hepatocyte chords differ from a typical capillary bed in that the 
endothelial cells of the liver do not form tight junctions (286). This creates a sinusoidal network 
that minimizes barriers between hepatocytes and the blood traversing the sinusoid (169, 285). 
Oxygen rich blood from the hepatic artery mixes with nutrient rich blood from the portal circulation 
in the sinusoid before flowing over the cells of the lobule and draining into the central vein (130, 
255). This organization causes the blood composition exiting the lobule to have different 
characteristics than the blood entering the lobule (Figure 1.4). As blood progresses across the 
lobule, cells utilize oxygen, and process nutrients while generating metabolites and waste 
products. Blood becomes deoxygenated and metabolic byproducts are secreted from cells along 
the length of the sinusoid. This creates gradients of oxygen, nutrients, and waste presented to 
cells of the liver based on their lobular location. These and other gradients formed across the 
sinusoids of the lobule result in a partitioning of functions based on localization, such as increased 
oxidative metabolism in areas with higher blood oxygen content. This partitioning of functions has 
been termed metabolic zonation and typically classifies the lobule into one of three “zones” (84, 
110, 130). Each zone possesses hepatocytes with differential metabolic gene expression and 
functionality. These metabolic zones are typically depicted as discrete regions, but hepatic 
zonation actually exists on a flexible spectrum (50).  For example, hepatocytes from Zone 2 can 
assume the functional attributes of Zone 1 hepatocytes in the face of damage or loss of function 
(85). This may occur in response to various liver damaging pathologies such as viral hepatitis 
(189).  Flexibility in functionality is a permeating theme relative to hepatocyte metabolism. This 
flexibility supports the variable metabolic requirements of normal physiologic shifts in nutrient 
intake and energy expenditure. This paradigm also ensures maintenance of metabolic 
homeostasis under the stresses of various pathophysiologic states that were likely encountered 
throughout evolution.    
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Figure 1.3- Hepatic lobular organization causes gradients in oxygen, hormones, nutrients, 
and waste products. This gradient formation and the consequential organization of relevant 
metabolic processes has been dubbed metabolic zonation. These zones are depicted as roughly 
equal, but can shift in size and location based on a number of factors (e.g. hepatocellular damage 
or altered blood flow). These gradients generally adopt opposing metabolic functionalities such 
as the gluconeogenic functions localizing to the periportal areas mirrored by more glycolytic 
processes in the perivenous areas. 
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 Metabolism and glucoregulatory functions of the liver 
Functional flexibility is embodied in the hepatic capacity to store, synthesize, metabolize, 
and release glucose as necessary for establishment and maintenance of circulating glucose 
levels (99, 128, 188, 255). Hepatic maintenance of circulating glucose homeostasis is supported 
by a highly regulated physiologic balancing act of nutrient and hormonal controls that vary with 
states of feeding and fasting. Spatial organization within the lobule integrates these controls with 
appropriate cellular behaviors creating a dynamic and highly regulated system of glucoregulatory 
functions.  
During feeding water soluble nutrients enter the portal venous circulation from the 
intestine. Pancreatic interpretation of circulating glucose and nutrient results in increased 
secretion of insulin coupled with decreased secretion of glucagon. At the liver, the insulin to 
glucagon ratio is elevated driving net hepatic glucose uptake and storage (Figure 1.5) (188). This 
has been quantified by splanchnic balance studies in humans (72) and hepatic balance studies 
in dogs (1, 187). These studies are in general agreement that the liver is responsible for the 
disposal of 25-40% of an oral glucose load (1, 72, 187). Glucose may undergo glycolysis or may 
be stored as glycogen. Glycolysis serves to replenish depleted metabolites while restoring 
energetic content of the liver through oxidative and non-oxidative pathways (287). Glycogen 
stored in the liver serves as a source of glucose with relatively low energy requirements for release 
in to the circulation upon transitioning from the fed to postabsorptive state.  
Processing of glucose at the liver does not occur in a vacuum and is supported by an 
intricate network of metabolism, which serves to appropriate metabolites and energy within the 
liver, but also throughout the body. Within this network amino acids may be utilized as anaplerotic 
substrates for the tricarboxylic acid (TCA) cycle (129), which can contribute to hepatic 
gluconeogenesis (257, 269, 270) or the synthesis of proteins. Ingested fats are assembled to form 
triglycerides from fatty acids and glycerol. These triglycerides are packaged on to chylomicrons,  
 
14 
 
 
 
 
 
 
 
Figure 1.4- Hepatic hormonal drive and metabolic functions in the fed state. During feeding 
water soluble nutrients enter the portal venous circulation from the intestine. At the liver, the insulin 
to glucagon ratio is elevated leading to net hepatic glucose uptake. Glucose may undergo 
glycolysis, as a means of ATP production, or may be stored as glycogen. Amino acids may be 
oxidized for energy production or utilized as anaplerotic substrates for the TCA cycle. Once again 
these amino acids, as in the fasted state, may be used for synthesis of local or secreted proteins. 
Ingested fats are assembled to form triglycerides from fatty acids and glycerol. These triglycerides 
are packaged to on to chylomicrons, which then enter the lymphatic system. Chylomicrons drain 
from the lymphatics to the circulation and, upon reaching the liver, are unloaded of remaining fatty 
acids and glycerol. Fatty acids can be used for restoration of energy state, repletion of TCA cycle 
intermediates, or re-esterified to triglycerides. Triglycerides can be loaded on to very low density 
lipoproteins, which shuttle lipid to other tissues including muscle and adipose depots. 
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which then enter the lymphatic system.  Chylomicrons are delivered from the lymphatics to the 
circulation through the thoracic duct. These particles are unloaded of remaining fatty acids and 
glycerol via lipoprotein lipase. Fatty acids can be used for restoration of energy state, repletion of 
TCA cycle intermediates, or re-esterified to triglycerides. Triglycerides can be loaded on to very 
low density lipoproteins, which shuttle lipid to other tissues including muscle and adipose depots.  
As an organism transitions from an absorptive state to a post-absorptive/fasting state the 
ratio of insulin to glucagon decreases (Figure 1.6). This shifts the liver from glucose storage to 
net glucose output. Hepatic glucose output involves glycogen breakdown (glycogenolysis) and de 
novo synthesis of glucose molecules (gluconeogenesis). Contributions of glycogenolysis and 
gluconeogenesis to hepatic glucose output exist on a spectrum as the fasted state is extended. 
Whereas glycogenolysis is a major component of HGO early in the post-absorptive state the 
glycogen pool is finite and gradually depleted in the absence of nutrient intake. Gluconeogenesis 
replaces glycogenolysis as the primary contributor to HGO the more extended a fast becomes.  
While this process maintains circulating glucose levels for energetic provision throughout the body 
it requires sufficient carbon based substrates and energy to proceed.  
Gluconeogenic substrates are provided in the form of amino acids (gut and muscle), 
lactate (muscle), pyruvate (muscle), and glycerol (adipose tissue). Fatty acids from adipose tissue 
lipolysis are also directed to several pathways, such as beta-oxidation and the TCA cycle. These 
processes support gluconeogenesis through production of ATP and reducing equivalents.  Ketone 
bodies may also be produced from lipid oxidation acting as an additional energy shuttle between 
the liver and other organs. Amino acids can also enter the TCA cycle as anaplerotic substrates 
and be utilized for synthesis of proteins. Nitrogen released as a result of de-amination during 
amino acids metabolism is disposed of during ureagenesis. Urea is released from the liver where 
it is excreted by the kidneys. Glucose output is dynamic and responsive to the energy needs 
throughout the body (e.g. brain, skeletal muscle, and immune system).  
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Figure 1.5- Hepatic hormonal drive and metabolic functions in the fasted state. During 
fasting the liver is a net glucose producer due to the low insulin to glucagon ratio. Glucose is 
derived from both glycogen and gluconeogenesis. Gluconeogenic substrates are provided in the 
form of amino acids (gut and muscle), lactate (muscle), pyruvate (muscle), and glycerol (adipose 
tissue). Fatty acids from adipose tissue lipolysis are also directed to several pathways, such as 
beta-oxidation and the TCA cycle. These processes support gluconeogenesis through production 
of ATP and reducing equivalents.  Ketone bodies may be produced from lipid oxidation acting as 
an additional energy shuttle from liver to other organs. Amino acids can enter the TCA cycle as 
anaplerotic substrates or be utilized for protein synthesis. Nitrogen released amino acid 
deamination are disposed of during ureagenesis. Urea is released from the liver where it is 
excreted by the kidneys. 
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Hormonal control of hepatic glucoregulatory processes 
 In addition to metabolic support and contributions to the dynamic glucose handling 
properties of the liver there are a number of hormones that enable physiologic regulation of the 
liver’s glucoregulatory programs. Among these hormonal inputs insulin and glucagon are the 
primary mediators of hepatic glucose handling and output. Both of these hormones are 
synthesized in the sub-organ endocrine compartments of the pancreas known as islets of 
Langerhans. Localization of these hormone-producing compartments in the pancreas is 
physiologically relevant as they are directly upstream of the hepatic portal vein circulatory input. 
Therefore, the liver is the first major site of action for these hormones.  
 
Insulin signaling and control of hepatic glucomodulatory processes  
Insulin secretion is primarily determined by circulating glucose. Immediately after 
consumption of a meal circulating glucose and nutrients drain from the gut to the portal circulation. 
Elevated glucose is interpreted by the insulin synthesizing β-cells of the pancreas resulting in a 
coordinated release of insulin in to the portal circulation. Elevated levels of insulin and glucose 
act on the hepatocytes of the liver to drive a host of metabolic processes that shift the liver to a 
state of net hepatic glucose uptake (Figure 1.1 & 1.3).  
 Insulin acts on the hepatocytes of the liver through the insulin receptor expressed on the 
cell membrane surface (79). The insulin receptor is a tetrameric protein consisting of two 
extracellular α subunits which are bound to two membrane spanning β subunits with receptor 
tyrosine kinase activity (118, 120, 242). Binding of insulin to its receptor commences a cascade 
of intracellular post-translational modifications and biochemical events, which mediate the diverse 
functional controls of insulin.  
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Figure 1.6- Insulin signaling and control of hepatic glucoregulatory processes. Depicted 
are the prominent signaling processes involved in the action of insulin within the hepatocyte. In 
general insulin acts to promote glycogen storage by releasing inhibitory tone upstream of 
glycogen synthase. Insulin inhibits gluconeogenic processes by sequestering FoxO1 in the 
cytosol, which limits its ability to transcribe gluconeogenic genes. Insulin also enhances mTORC1 
signaling and activity resulting in enhanced protein synthesis. While enhanced protein synthesis 
is not directly linked to glucose homeostasis it constitutes a major sink for amino acid utilization, 
which will shift the flow of amino acids from gluconeogenic processes.  
  
19 
 
Following binding of a single insulin molecule to the extracellular α subunits the receptor 
undergoes conformational changes leading to intracellular β subunit trans-phosphorylation of 
tyrosine residues (141). Phosphorylated insulin receptor recruits intracellular signaling proteins 
with phosphotyrosine binding (PTB) or Src-homology 2 (SH2) domains (119). Among the 
immediate interaction partners of the insulin receptor the insulin receptor substrate (IRS) proteins 
1 and 2 are attributed with the initiation of many metabolic and glucoregulatory aspects of insulin 
signaling in hepatocytes (97).  
 IRS1 and IRS2 propagate signals through recruitment of the lipid-modifying enzyme 
phosphoinositide 3-kinase (PI3K) (26). Recruitment and activation of PI3K results in rapid 
localized conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to generate 
phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 is a potent second messenger that binds 
and activates 3-phosphoinositide-dependent protein kinase 1 (PDK1). PDK1 is the primary input 
signal for a group of AGC kinases including protein kinase B (Akt), p70 ribosomal S6 kinase 
(S6K), serum- and glucocorticoid-induced protein kinase (SGK), and atypical isoforms of protein 
kinase C (PKC). While many of these proteins exert metabolic effects that can alter glucose 
handling in the liver Akt represents the primary direct driver of hepatocyte glucomodulatory 
behaviors.  
 Phosphorylation of Akt at Thr308 by PDK1 leads to a partial activation of Akt kinase 
activity. However, for complete activation of Akt a second phosphorylation at Ser473 by 
mammalian target of rapamycin complex 2 (mTORC2) must occur. Upon complete activation, Akt 
acts as a kinase for proteins in multiple signaling pathways. Akt phosphorylates tuberous sclerosis 
complex protein 2 (TSC-2) causing degradations of the TSC complex. This removes the inhibitory 
action of the TSC complex on mTORC1 resulting in a plethora of anabolic actions including protein 
synthesis. Akt also phosphorylates glycogen synthase kinase 3 beta (GSK3β). This 
phosphorylation event inhibits the activity of GSK3β that acts as an inhibitor of glycogen synthase 
(GS). Overall this results in decreased inhibitory phosphorylation of GS and promotion of glycogen 
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synthesis. Finally, the target of Akt phosphorylation which drives the inhibition of hepatic glucose 
output by insulin is the transcription factor Forkhead box O1 (FoxO1). FoxO1 is responsible for 
the transcription of phosphenolpyruvate carboxykinase (PEPCK) and the catalytic subunit of 
glucose-6 phosphatase (G6pc). Phosphorylation of FoxO1 by Akt results in its interaction with 14-
3-3 proteins outside of the nucleus. This interaction sequesters FoxO1 in the cytoplasm resulting 
in decreased transcription of PEPCK and G6pc. As PEPCK and G6pc levels decrease 
gluconeogenesis is also usually decreased. While FoxO1-Akt signaling controls the pathway 
associated with classical hepatic insulin sensitivity elegant studies from Drs. Morris Birnbaum and 
Paul Titchenell at University of Pennsylvania have shed further light on the role of this pathway in 
insulin sensitivity. They have shown that loss of Akt signaling in the liver leads to an inability of 
insulin to inhibit hepatic glucose output indicating a potential role in insulin resistance. However, 
simultaneous knockout of Akt and Foxo1 from hepatocytes restores normal glucoregulatory 
function and insulin sensitivity. Therefore, there seem to be alternative or compensatory pathways 
supporting hepatic glucose output and insulin sensitivity.   
 
Glucagon signaling repurposes carbon to guard against hypoglycemia  
 Glucagon is the antithetic force to insulin on hepatic glucoregulation and serves to 
maintain circulating glucose levels apropos of physiologic demand during fasting (43) and 
exercise (108). Glucagon secretion from the pancreas is mediated by a host of factors including 
nutrients, hormones, and nervous system control (213). Pancreatic α-cells sense decreasing 
insulin and glucose in the circulation as an organism transitions from the fed to the postabsorptive 
and fasting states or engages in energetically demanding behaviors, such as exercise. As with 
insulin, glucagon is secreted in to the portal vein circulation and acts directly upstream on the liver 
to stimulate glucose production. Stimulation of HGO exists on a spectrum of glycogenolysis and 
gluconeogenesis (42). Whereas glycogenolysis is the primary source of HGO early in the fasted 
state, gluconeogenesis gradually takes over as the primary source of HGO. Illustrative of the 
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critical feedback mechanisms between glucagon and insulin are the responses to glucagon in a 
typical fasted state. Exogenous introduction of glucagon in the fasted setting will elevate 
circulating glucose levels. However, in an organism with intact physiology this will stimulate 
release of insulin and its downstream glucose lowering effects, including the glucagon-stimulated 
actions at the liver. This feedback network creates difficulties in studying glucagon in the 
physiologic context of simple fasting and has limited the scientific pursuit towards an 
understanding of glucagon signaling and action, equivalent to that of insulin.  
 Despite the paucity of research on glucagon relative to insulin there have been critical 
studies conducted to elucidate the physiologic and molecular mechanisms of glucagon action 
(247). Glucagon action and signaling are initiated through the glucagon receptor (GcgR), a typical 
7-trans-membrane spanning G-protein coupled receptor (10).  GcgR is linked to the intracellular 
Gαs subunit. Stimulation of Gαs signaling propagates a classically defined pathway through 
activation of adenylate cyclase (219). Production of cyclic adenosine monophosphate (cAMP) by 
adenylate cyclase results in activation of the primary target of this pathway protein kinase A (PKA). 
PKA acts to modify a host of proteins involved in hepatic metabolism and glucose output including 
glycogen phosphorylase and fructose-2,6-bisphosphatase. These two enzymes catalyze two 
glucomodulatory functions of glucagon the stimulation of glycogenolysis, through modification of 
glycogen phosphorylase, and the inhibition of glycolysis, through modification of fructose-2,6-
bisphosphatase. These functionalities of glucagon oppose those of insulin.  
 In addition to acute effects on glycogenolysis and glycolysis, glucagon stimulates the de 
novo synthesis of glucose by a sequence of reactions diametrically opposed to glycolysis. This 
process is known as gluconeogenesis and enables a repurposing of carbon metabolites and 
byproducts in to glucose molecules as a means to maintain circulating glucose for energetic 
provision to other tissues. Amino acids represent a primary source of carbons for 
gluconeogenesis. Glucagon facilitates amino acid contributions to gluconeogenesis by stimulating 
extraction (108, 270) via the A and N amino acid transport systems (36, 195), as well as utilization 
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within metabolic pathways (184). These amino acids are primarily derived from the gut (281) and 
the skeletal muscle (267). Lactate and glycerol represent the other primary metabolic precursors 
of gluconeogenesis utilized by the liver. Lactate is a glycolytic byproduct from skeletal muscle and 
other sources. Glycerol is the remaining backbone of triglycerides that have undergone lipolysis 
from various adipose depots. Glycerol serves as a significant contributor to gluconeogenesis 
which parallels rates of lipolysis (210).  
 Capacity to repurpose diverse carbon substrates for energetic exchange requires a 
centralized system of metabolic processes to maximize processing efficiency. While there are 
diverse metabolic pathways in action within the liver the TCA cycle is a central hub of carbon 
processing that serves to integrate metabolism and energy balance within the cell. The previously 
described gluconeogenic substrates are metabolized within the hepatocyte for entry in to the TCA 
cycle (i.e. anaplerosis). This enables the production of reducing equivalents through the TCA 
cycle, maintenance of TCA cycle intermediate metabolite levels, and finally the ability to provide 
PEP as a 3-carbon substrate for gluconeogenesis.   
 
Metabolic, energetic, and mitochondrial considerations in gluconeogenesis 
 This de novo synthesis of glucose is energetically demanding. Energetic requirements of 
this process are met through provision of high energy phosphate bonds from nucleoside 
triphosphates, including ATP (19). TCA cycling from several metabolite sources including lactate, 
amino acids, and lipids maintains reducing equivalents in the form of NADH and FADH2 (282).  
NADH and FADH2 are requisite for oxidative phosphorylation (oxphos) (204). Oxphos is the set 
of biochemical processes coupled to chemiosmotic gradients enabling conversion of energy from 
various molecules to transferable phosphate bonds of ATP.  Through processing of reducing 
equivalents, electrons are transferred to molecular oxygen and protons are exuded from the 
mitochondrial inner membrane. Exuding protons creates a pH gradient across the inner 
mitochondrial membrane. Potential energy from this gradient is harnessed by ATP synthase. This 
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complex enables the controlled flow of protons while harnessing proton movement to synthesize 
ATP from ADP and phosphate. Gluconeogenesis requires 6 high energy phosphate bonds, in the 
form of ATP and GTP, to synthesize each molecule of glucose (19). Therefore, appropriate TCA 
cycling and oxphos meet tandem requirements of provisioning energy and carbon for synthesizing 
glucose molecules.  
 Processing of metabolites through the TCA cycle and energetic intermediates through 
oxphos for support of gluconeogenesis occurs entirely within the mitochondria. Dynamic 
capabilities of this organelle determine cellular metabolic homeostasis and by doing so contribute 
to virtually every cellular process. Extensive integration of mitochondria across cell biology 
invokes a need for flexibility in function. Functional flexibility enables responsiveness to the 
variable demands placed on a cell. Mitochondria demonstrate this flexibility with regards to 
hepatic gluconeogenesis in several ways. In the acute setting mitochondria will alter processing 
of metabolites based on dynamic shifts in substrate availability (29, 149). These shifts in substrate 
availability will shift respiratory control of complex I and II (29) while also altering biophysical 
structure of mitochondrial membranes (149). Consistent increases in demand of energetic 
production by mitochondria, such as occurs during extensive exercise training, will lead to a shift 
in mitochondrial programming (25, 67, 96, 159, 214, 215, 257). This can be shown by indicators 
of increased mitochondrial content. Mitochondria from an exercise trained liver also have an 
increased capacity for complete oxidation of lipid based substrates (25, 159, 214, 215).  
 Mitochondria are often depicted as individual bacteria-like organelles. These organelles 
actually exist as a network with the capacity for dynamic integration or dissociation depending on 
the cellular requirements at a given time (111). Incorporation of mitochondrial organelles together 
as a means of increased networking has been termed fusion. These networks are hypothesized 
as a means to enhance oxidative extraction of ATP (225), but also as  buffering system against 
mitochondrial damage (111). Mitochondrial fission can be invoked as a mechanism for removing 
damaged mitochondrial from a network (261), but is also required for distribution of daughter 
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mitochondria during cell division. Furthermore, mitophagy is a specific form of autophagy targeted 
at mitochondria that recycles organelle macromolecules for energy or synthetic functions (272). 
Loss of mitochdnrial membrane potential is a primary signal of organelle damage that stimulates 
interaction with mitophagy receptors, such as BNIP3, or stabilization of the mitophagy protein 
PINK1 at the outer mitochondrial membrane (272). These signals have distinct downstream 
pathways for promotion of mitophagy. One recently appreciated controller of mitochondrial 
dynamics is the integrin-actin cytoskeleton signaling system (22, 90, 143, 160). This system 
influences metabolic responses to integrin engagement or loss of ECM contact. In conjunction 
the actin cytoskeleton also mediates the physical organization and localization of mitochondrial 
networks. This is critical for minimization of diffusion limitations on metabolites and ATP delivery.  
Defects in these processes have now been linked to diseases including NAFLD (82) and insulin 
resistance (127). Therefore, consideration of metabolism and mitochondria can better inform our 
understanding of the plethora of diseases derived from overnutrition and obesity.  
 
Pathologic dysregulation of hepatic metabolic functions 
 As highlighted previously the ability of the liver to maintain glucose homeostasis is a 
delicate balance between nutrient availability and hormone levels. Variability in food abundance 
and consumption throughout evolution underlies this intricately controlled network. 
Industrialization and contemporary lifestyle have altered variables in the equation of nutrient 
balance and given rise to disease states of overnutrition. Individuals in developed countries are 
exceedingly exposed to an increase in caloric density of food while engaging in significantly less 
physical activity in their daily routines. Imbalance in nutrient intake and expenditure has tipped 
the scales towards caloric excess. In the short term the body is well equipped to deal with this 
excess through storage of carbon substrates in to lipids in specialized adipose depots. However, 
as with all physiologic processes, there is an upper limit to the amount of storage that can occur 
before adverse effects become apparent. Consistent caloric excess of modern times has 
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manifested as an epidemic of obesity a condition with an array of pathologic associations and 
immense public health ramifications.  
With the liver as a primary site of nutrient uptake, sensing, recycling and storage. It is 
hardly surprising that a disease state rooted in consistent overloading of these processes 
manifests as a pathologic sequelae. Perhaps the most recognized pathologic consequence of 
over nutrition is insulin resistance. Insulin resistance presents with differential effects in the tissues 
classically associated with insulin action (e.g. skeletal muscle, adipose tissue, and liver). Hepatic 
insulin resistance is most commonly associated with the loss of insulin’s inhibitory effects on 
hepatic glucose output (57). Despite loss of typical insulin action on glucoregulatory processes, 
insulin maintains the capacity to stimulate lipogenesis (114, 237). This disconnect between gluco- 
and lipo- regulatory functions of insulin has been termed selective insulin resistance (30). This 
concept of selective insulin resistance has been recognized in other organs as early as 1991 
(186), but has been popularized by Brown & Goldstein in relation to hepatic pathologies (30). 
Selective insulin resistance contributes to pathologic metabolism through two primary 
mechanisms: 1) altered kinetics of circulating glucose leading to increased hyperglycemic burden; 
2) increased hepatic lipid synthesis, which compounds with overloading of adipose stores to 
cause inappropriate deposition of lipid within the liver. These pathologic shifts in metabolic 
homeostasis underlie the strong correlation of hepatic insulin resistance with both T2D and 
NAFLD (31, 57).   
Insulin resistance and NAFLD have multisystem pathologic consequences and have been 
linked to a broad range of diseases including T2D, cardiovascular disease, chronic kidney 
disease, Alzheimer’s disease, and cancer. This conglomeration of pathologies represent an 
immense burden on quality of life and economic outcomes around the world. Therefore, 
understanding mechanisms underlying metabolic pathologies of the liver and the associated 
network of pandemics are imperative. Efforts have aimed to understand the contributions of 
genetics, molecular signaling, metabolism, physiology, behavior, and socioeconomic factors to 
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these pathologies. This has resulted in an integrated view of hepatic glucoregulation in normal 
and pathophysiologic settings. Knowledge derived from this integrated view has resulted in 
therapeutic options for aspects glucose homeostasis and insulin resistance such as glucagon like 
peptide 1 (GLP-1) agonists (178), sodium glucose co-transporter 2 (SGLT2) (38) antagonists, and 
the ever effective metformin. Despite this renaissance in treatment of pathologic glucose 
homeostasis, no primary therapeutic option for NAFLD currently exists (245) and a trail of failed 
clinical trials have been left in the wake of this disease (126). To remedy this gap in therapeutic 
options research has broadened its scope in an attempt to solve the riddle of NAFLD with the 
hopes of improving therapeutic outcomes for this growing at-risk population. Over the past decade 
expansion of scientific considerations in NAFLD therapy has increased interest in the ECM and 
its related signals (139, 152, 196, 201, 278). This emphasis stems, in part, from observations 
linking ECM deposition and remodeling to states of metabolic dysregulation including insulin 
resistance (15, 109, 137, 243). Incorporating insights from metabolism and physiology with 
newfound understanding of the ECM and related cell signaling pathways serves as a means 
towards fruitful progress in therapeutic development for NAFLD.  
 
Extracellular matrices of the liver in health and disease 
Within all organs of the body are cells performing the specialized functions of the organ 
and a vast network of supporting extracellular components known as the extracellular matrix 
(ECM) (78, 252). ECMs present physical and biochemical cues to cells throughout the body (78, 
252).  Through these cues ECMs govern numerous aspects of cellular biology including survival, 
proliferation, migration, differentiation, and organization. Proteins with varying levels of 
glycosylation (e.g. collagens, fibronectins, laminins, and elastin) interact in differential 
combinations to form ECM compartments (24, 78, 252). Epithelia are one of the basic tissue 
classifications of the body and are typically in contact with a specialized ECM compartment known 
as a basement membrane (BM). BMs primarily consist of  collagen IV, laminins, nidogens, 
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perlecan, and agrin (24, 208). These areas exist as highly organized ECM that, in addition to 
classical ECM signals, maintain significant barrier functions between epithelial cells and biological 
lumens (220).  
As with many aspects of the liver, hepatic ECM is unique in its organization and 
composition compared to other epithelial organs (13, 169, 285, 286). The primary epithelial 
population of the liver, hepatocytes, line sinusoids in the absence of a true BM (13, 169). In lieu 
of a true BM the space of Disse occupies perisinusoidal areas between hepatocytes and 
sinusoidal epithelial cells. Fibronectin (FN) represents the primary ECM component within the 
space of Disse (47, 171, 243). FN is a glycoprotein dimerized by sulfide bonds. It can be 
alternatively spliced at the transcriptional level to form a number of different FN isoforms (275), 
which contribute to the two pools of FN termed cellular (cFN) and plasma (pFN). The liver, is the 
primary site of pFN synthesis and export. This function of the liver is speculated to be the reason 
for the high FN content of the sinusoidal ECM.  
In addition to FN, several types of collagens have been detected within the space of Disse.  
Collagens comprise the most abundant set of proteins in vertebrates (14, 182, 216). The collagen 
family is represented by 28 different proteins encoded by at least 45 unique genes. Each gene 
encodes a collagen alpha chain, which can partner homotrimerically or heterotrimerically with 
alpha chains of the same collagen type to form the standard triple helix structure of an individual 
collagen unit (14, 182, 216). This creates diversity at the level of collagen types, but also at the 
biochemical level creating differential alpha chain compositions. Collagen IV illustrates this 
concept as there are 6 different collagen IV alpha chain genes in mammals (Col4A1, Col4A2, 
Col4A3, Col4A4, Col4A5, Col4A6) (89). Differential expression of these alpha chains results in 
formation of distinct trimeric combinations (e.g. collagen IV α1α1α2, α3α4α5, and α5α5α6) (144). 
This allows for distinct biochemical characteristics of collagens within a unified structural 
framework. Collagen I is typically the second most abundant ECM protein within the space of 
Disse and presents as small bundles. Collagens III and VI can be detected as intermittent fibers, 
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while collagen IV only presents with occasional deposits. Other glycoproteins such as perlecan, 
tenascin, or laminin β2 may present sparsely or adjacent to the vascular areas (i.e. periportal or 
pericentral).  
This organization of ECM within the space of Disse has direct links to physiologic functions 
of the liver (13) and represents a critical intersection of ECM and metabolism. Specifically, low 
ECM density and fenestrated endothelial cells allow for free exchange of macromolecules (e.g. 
glucose, amino acids, lipids, and various transport proteins) between the sinusoidal plasma and 
hepatocytes (286). Within this space, perisinusoidal ECM molecules are in direct contact with the 
basal surface of hepatocytes (259). Basal surfaces contain up to 70% of the hepatocyte 
membrane surface area (21) indicating potential for extensive cell-ECM interactions. These 
interactions enable two-way communication between sinusoidal cells and ECM within the space 
of Disse. Communication between these compartments is vital as the ECM of the liver is not a 
static construct. Rather, the ECM is modified and turns over as a result of stimuli including 
biomechanical forces, protein damage, or chemical toxicity (56, 139, 140). Despite a constitutively 
changing ECM compartment, the general contents and organization are maintained to support 
physiologic homeostasis of the organ.  
Open exchange between hepatic circulation and hepatocytes is advantageous for rapid 
interaction, interpretation, and responses to a number of stimuli including nutritional and 
hormonal. However, the open barrier between sinusoidal blood and hepatocytes is not without 
caveats. In the absence of endothelial tight junctions and a true BM the liver risks exposure to 
toxic molecules and pathogens (179). Exposure to toxic compounds through ingestion was likely 
a common occurrence throughout evolution and remains an issue in current medical practice (45, 
271). Elevated exposure to toxic compounds at the liver coupled with an immense functional 
repertoire required for health and viability likely pressured evolution of unique aspects of liver 
physiology. One likely result of these pressures is the hepatic capacity for processing and 
excreting exogenous toxins through a system of modifying enzymes (4). This limits the potential 
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for circulation of reactive and toxic compounds to other organs, such as the central nervous 
system. In conjunction with hepatic processing of toxic compounds, the liver also evolved an 
incredible capacity for regenerative responses.  
Hepatic regenerative capacity is truly legendary with representation in the Greek 
mythologies of Prometheus and Tityus alike (254). Hepatic regeneration served as a tool of torture 
in these myths, but hepatic regeneration has garnered considerable interest as a means to better 
understand and treat diseases of the liver. Aggregate research on hepatic regeneration in a 
number of models has produced a general consensus on the time course and processes 
contributing to typical liver restoration (136, 179, 251). Priming is the initial phase of hepatic 
regeneration that prepare hepatocytes for entry to the cell cycle and ensures maintenance of 
hepatocyte function during regenerative demand(185). This early phase of liver regeneration is 
characterized by elevated ECM turnover and cytokine signaling. Elevated urokinase-type 
plasminogen activator (uPA) activity occurs within 5-10 minutes of partial hepatectomy (PHx) and 
causes appearance of plasminogen and fibrinogen breakdown products. These breakdown 
products can initiate activation of matrix metalloproteinase (MMP) cascades resulting in ECM 
remodeling. The cytokines Tumor Necrosis Factor α (TNFα) and interleukin 6 (IL6) are also 
elevated rapidly after PHx (147, 181). TNF-α and IL6 activate NF-κB and STAT3 transcription 
factors through interconnected mechanisms promoting G0 to G1 cell cycle transition. Completion 
of hepatocyte priming is denoted by initiation of DNA synthesis, which occurs 24h after PHx in 
mice and is delayed by approximately 12h in carbon tetrachloride (CCl4) exposure models. This 
second stage is characterized by high anabolic activity leading to a wave of mitotic events across 
the hepatic lobule. The switch from priming to mitogenic events requires stimulation and recession 
of several growth factor pathways.  HGF activates the c-Met receptor while epidermal growth 
factor (EGF) and TGF-α are primary mitogenic ligands for the EGF receptor (EGFR)(122, 192). 
Stimulation of these receptors produces pleiotropic signals including activation of the intracellular 
AKT and ERK. These signals promote replication while opposing apoptotic signals. Upon 
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complete restoration of hepatocyte mass organization of the liver remnant is reestablished until 
indistinguishable from normal livers.  
One of the hallmarks of the hepatic damage response is a distinctly altered dynamic of 
ECM components within the parenchyma of the organ (170, 171). This is an altered expression 
of certain ECM components including cyclical deposition of FN and several types of collagen (148, 
171). ECM of the liver is heavily modified by uPA and MMPs during regeneration (185). Cycles of 
degradation, deposition, and altered localization of ECM components occur throughout this 
process. After PHx this cycle can be observed for FN. FN undergoes decreases in protein content 
at 1-5min, 30-60min, and 6-12hours after PHx with restoration of protein levels between each 
interval (147). Restoration of FN content 12 hours after PHx also corresponds to an increased 
level of FN bound to hepatocyte membranes at this time point (211). This deposition typically 
persists up to 4 days post PHx and resolves as the organ restores cellular mass and function by 
9-10 days after PHx. However, under conditions of severe or chronic hepatic insult ECM 
deposition and reorganization may become pathologic in nature leading to a fibrotic disease state 
(52, 139). This and returns to minimal levels  Levels of the primary FN binding receptor, Integrin 
α5β1, at hepatocyte membranes follow a similar timeline to FN (211). This indicates increased 
binding activity of Integrin α5β1 binding of FN at the hepatocyte membrane from 12-96h post PHx, 
a period denoted by elevated DNA synthesis and proliferation. Given that increased FN binding 
to Integrin α5β1 coincides with times of elevated proliferation this signal may be relevant to the 
restoration of hepatocytes during regeneration. 
As discussed earlier, fibrotic disease states have now been linked to pathologies rooted 
in overnutrition and obesity (152). This accumulation of excess ECM seems to occur 
predominantly in tissues that have a high metabolic activity and insulin action (278). Initially this 
metabolically-linked fibrosis was observed and studied in the adipose tissue (109, 246). However, 
fibrosis and altered ECM have now been documented in the insulin resistant liver (243) and 
skeletal muscle (137). Preceding gross changes in physical matrix of the liver, states of over-
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nutrition upregulate transcriptional programs for ECM components, such as collagen alpha chain 
subunits and related proteins (224). Chronic exposure to overnutrition also causes metabolic 
stress at the cellular level through increased levels of toxic metabolites (53). Even simple 
exposure of hepatocytes to excess free fatty acids, a set of compounds that hepatocytes are 
equipped to handle in moderation, can cause apoptosis. This may be linked to production of 
reactive oxygen species (ROS) during periods of elevated TCA cycling (165, 202, 229). Eventually 
exposure to these metabolites and reactive molecules will exceed the cell’s tolerance and 
succumb to apoptosis. 
While a healthy liver would likely overcome a low-grade cell death, as occurs during 
NAFLD, a secondary consequence of over-nutrition in the liver is a relative inhibition of hepatocyte 
proliferation and regeneration capacity (54, 117, 222, 249). Induction of fatty liver through a 
number of over-nutrition paradigms generally hampers the liver’s ability to respond to injury. This 
results in a delayed entry of hepatocytes in to the cell cycle and a dampened proliferative 
response during the synthetic phase of regeneration. Particularly relevant to hepatic disease 
progression during insulin resistance and NAFLD is the ability of hyperglycemia to limit hepatic 
regeneration after surgical resection (117). Under this paradigm, hyperglycemia may abrogate 
the requisite hypoglycemic signal for appropriate initiation and drive of hepatocyte proliferation.  
ECM alteration and deposition are typical consequences of hepatic regeneration (148, 
171). However, during NAFLD extensive propagation of chronic low-grade cell death couples with 
a general inhibition of hepatocyte proliferation causing organ damage in excess of hepatic 
regenerative capacity. This contributes to progression along the NAFLD spectrum towards a more 
advanced form of liver disease known as non-alcoholic steatohepatitis (NASH). Therefore, 
attempts to regenerate from constant loss of cell mass likely drive consistent ECM deposition 
during progression of NAFLD/NASH causing fibrotic phenotypes. Compounding this are the 
ongoing inflammatory responses, which evoke upregulated ECM transcriptional programs further 
driving expression, translation, and deposition of ECM proteins. Left unchecked this ECM 
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deposition will progressively distort the typical sinusoidal architecture towards that of a typical 
capillary (51, 232). This capillarization of the hepatic sinusoid is a hallmark of end stage liver 
diseases and cirrhosis.  
Until recently, deposition of ECM during liver pathologies, including NAFLD, was seen as 
a disease endpoint with little possibility of resolution. This dogma was likely perpetuated by the 
methodologies available at the time. Classic histologic stains of fibrosis and liver damage would 
become apparent only during advanced disease states, but more subtle progressions in ECM 
alterations were likely overlooked. More recently advances in immunohistochemistry, multiplexed 
immunofluorescence imaging, and large-scale “omics” analyses have become regularly 
implemented in analyses of NAFLD and other liver pathologies. This has led to a shift in the 
general understanding of ECM and its contributions to hepatic disease. Rather than an endpoint 
of tissue damage, ECM is seen as an active participant in pathologic, but also regenerative 
processes (139, 148, 277). This acknowledgement of ECM as an active participant has expanded 
scientific interests in the ways that ECM elicits its effects on cells. As a results the various 
mechanisms and signaling components relating to cell-ECM interactions have become focal 
points in a number of research areas including metabolic disease (278), wound repair (244), and 
cancer (231).  
 
Integrins facilitate two-way communication between ECM and intracellular space 
 Interactions of cells with their surrounding ECMs are mediated through multiple cell 
surface proteins including integrins, discoidin domain receptors, and several proteoglycans (78). 
Of these proteins, the family of integrin receptors represent the primary means for cell-ECM 
interactions (104). Integrins are cell surface receptors involved in cell-cell and cell-ECM 
interactions (124, 248). Integrin receptors bind to ECM components and span the cell membrane. 
Through this organization the ECM is coupled to cytosolic signaling events that regulate internal 
cellular physiology (35, 104, 284) and assembly of local ECM (125, 131, 156).   
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Integrin receptors consist of a heterodimeric α and β subunit pair (Figure 1.8). The integrin 
family in humans consists of 18 α and 8 β subunits, which form 24 identified heterodimeric pairs 
(Figure 1.9) (125). Integrins maintain specificity at several levels including variations in subunit 
pairing, ligand binding, and subunit expression (123). Integrin α subunits are more variable and 
provide the ligand binding specificity for the receptor. Integrin β subunits are less variable, but 
can pair with multiple α subunits to form several integrin receptors and interact with different matrix 
proteins. Integrin β subunits also possess a more extended intracellular tail domain. This enables 
an expanded set of interactions for the tail of β subunits with intracellular signaling components. 
Integrin facilitated connection of the ECM and intracellular environment serves as a two-way 
communication line. Integrins relay the composition, amount, and organization of the pericellular 
ECM to the intracellular environment. This flow of information is termed outside-in integrin 
signaling. Internally-derived cues can also influence conformational activation of integrins and 
influence forces applied by the cell to the ECM. This represents the second form of integrin 
signaling known as inside-out. Integrins physically interact with the matrix and span the cell 
membrane, but are inherently lacking in enzymatic activity. Therefore, integrins rely on 
intracellular proteins and biochemical processes to transduce their externally-derived information. 
Integrin β subunit intracellular tail interacts with cellular adhesion signaling proteins termed the 
“adhesome” (284). The adhesome consists of more than 200 proteins organized in distinct 
signaling nodes, which determine critical cellular processes including survival, proliferation, cell 
cytoskeletal engagement, and cell organization. Ligation of integrins to ECM results in a clustering  
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Figure 1.7- Depiction of an integrin receptor and its activations states within the cell 
membrane. Integrin receptors exist as heterodimers of α and β subunits at the cell membrane. 
These receptors are also in an equilibrium of states at the cell membrane. These states can be 
shifted by a variety of signals including exposure to ECM ligands or cytokine interactions. Upon 
exposure to an activating stimulus the receptor will extend, which enhances its capacity for 
interaction with ECM ligands in the pericellular environment. ECM-integrin interactions vary in 
their affinity and may constitute transient or stable interactions based quantity of matrix 
components, intracellular signaling state, or the mechanical properties of the matrix. 
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Figure 1.8- Integrin receptor heterodimer pairs and their ECM ligands. Integrin α and β 
subunits pair in a multitude of ways. Integrin α subunits determine specificity for of ECM ligands 
within a specific subgroup. Whereas the β subunit can determine the subgroup of the receptor as 
well as the types of intracellular signaling pathways that are engaged by the receptor.  
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of integrin receptors and assembly of focal adhesion complexes by adhesome proteins. Focal 
adhesion kinase (FAK), proto-oncogene tyrosine-protein kinase Src (Src), PI3K, and growth factor 
receptor-bound protein 2 (Grb2) are among the proteins recruited to focal adhesions. These 
proteins also perform critical roles in insulin signaling and action (18, 93, 115, 233). Influence of 
integrin signaling on these insulin signaling proteins is also contingent on integrin engagement 
with the ECM (92, 233). Given the link between integrin signaling and insulin action as well as 
alterations to ECM during insulin resistance studies are needed to better assess the role of 
integrin receptors in insulin resistant states in vivo.   
 
Integrin receptors as modulators of in vivo insulin action 
Whole body and tissue specific knockouts of integrin receptor subunits have revealed a 
variegated role of integrin receptors in insulin action. Knockout of the integrin β1 subunit from 
striated muscle of lean mice demonstrate a deficiency in insulin stimulated glucose uptake (295). 
This insulin resistant phenotype was associated with decreased Akt phosphorylation at Ser473. 
Engagement of integrin receptors containing the integrin β1 subunit have demonstrated effects 
on activation of the insulin receptor and IRS-1 (92). Loss of this signal reinforcement may limit 
complete activation of insulin signaling in the muscle compartment. Studies went on to assess 
the role of two collagen binding partners of the integrin β1 subunit, the integrin α1 (itgα1) and α2 
(itgα2) subunits, in obesity-derived insulin resistance. Mice lacking either  itgα1 (itgα1-/-) or itgα2  
(itgα2-/-) subunits at the whole body level were shown to have no obvious metabolic phenotypes 
when fed a normal rodent chow (chow) diet (137, 279). However, itgα2-/-mice demonstrated  
protection from skeletal muscle insulin resistance during obesity caused by a HF diet (137). This 
was linked to elevated phosphorylation of IRS-1 at Tyr612 and Akt at Ser473 in skeletal muscle 
of HF-fed itgα2-/- mice during insulin stimulation. Maintenance of insulin signaling in skeletal 
muscle of itgα2-/- mice during HF feeding occurred despite similar levels of collagens compared  
 
37 
 
 
 
 
 
 
 
 
Figure 1.9- Simplified model of signaling crosstalk between insulin and integrin receptors 
to effect insulin action. 
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to itgα2+/+ mice. This indicates a pathologic role for integrin α2β1 receptors in the promotion of 
skeletal muscle insulin resistance, perhaps through altered ECM signaling during obesity. In 
contrast to this finding itgα1-/- had no effect on muscle, but demonstrated a worsened hepatic 
insulin resistance during obesity (279). Hepatic insulin resistance of obese itgα1-/- mice was 
associated with decreased phosphorylation of IRS-1 at Tyr612 and Akt at Ser473. These results 
show a supportive role for integrin α1β1 receptors in hepatic insulin action during diet-induced 
obesity.  Additionally, the opposing functions of two collagen binding integrins, α1β1 and α2β1, 
on insulin action indicate complex roles for these receptors in metabolic physiology. It is also 
important to re-iterate that alteration of these integrin receptors revealed no apparent metabolic 
phenotypes in the absence of obesity. It is likely that integrins play an enhanced role during the 
metabolic stress of obesity by mechanisms that are yet to be understood.  
Mice lacking integrin α2 subunits demonstrated enhanced skeletal muscle insulin action 
during obesity. Whereas mice lacking integrin α1 subunits demonstrated hepatic insulin 
resistance during obesity with a somewhat paradoxical decrease in hepatic lipid deposition. 
Understanding mechanisms by which specific integrins impact insulin resistance and nutrient 
metabolism are clearly an important objective. Intracellular signaling components of the integrin 
adhesome were a logical starting point as they had been shown to modify aspects of insulin 
signaling and action in previous studies (18, 93, 115, 233). Interestingly, a central hub of integrin 
signaling, integrin-linked kinase (ILK), had been demonstrated to interact and affect signaling 
through PI3K, Akt, GSK3β, and mTORC1. This represented a clear overlap between ILK and 
insulin signaling. However, whether there was a requirement for ILK in insulin action had never 
been performed.  
Within the adhesome, ILK is a central coordinator of integrin signaling (176). Protein 
scaffolding functions of ILK link the intracellular tails of β integrin subunits to cytoskeletal and cell 
signaling networks. ILK is able to engage signaling pathways as a result of its three structural 
domains. The kinase-like domain of ILK is at the C-terminus interacts with cytoplasmic tails of 
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integrin β1 and β3 subunits as well as the focal adhesion associated paxillins and parvins. The 
centrally located pleckstrin homology domain of ILK interacts with phosphoinositides and 
contributes to localization of ILK and its complexing partners. Finally the N-terminal contains 5 
ankyrin repeats and this domain is responsible for interactions with particularly interesting new 
cysteine-histidine (PINCH) isoforms and several other signaling proteins. Isoforms of PINCH and 
parvin are often found in complex with ILK forming the ILK-PINCH-parvin or IPP complex. 
Complexing of these proteins is required for stabilization and incorporation of the complex in to 
focal adhesions (155, 176, 276).  Beyond the classical IPP complex a number of proteins have 
been demonstrated to interact with ILK. Protein kinase B (Akt)(58) and glycogen synthase kinase 
3-β (GSK3β)(260) are among ILK interacting proteins. These proteins mediate effects of ILK on 
proliferation and cell survival, but they also represent key points of insulin signaling in 
hepatocytes. These characteristics indicate the potential for ILK to coordinate integrin and insulin 
signaling crosstalk. 
 
Integrin-linked kinase in hepatic injury, repair, and insulin resistance 
With possible connections between ILK and hepatic insulin resistance it was necessary to 
assess the role of ILK in in vivo insulin action. ILK is a ubiquitously expressed protein and whole-
body knockout of ILK results in pre-implantation embryonic lethality (226). In order to avoid this 
effect of ILK a mouse line with genetic insertion of loxp sites flanking the ILK1 gene was created 
(ILKlox/lox). This model enables specific induction of genetic knockout in the presence of the cre-
recombinase (cre). With the goal of assessing the role of ILK in obesity related pathologies of the 
liver, including insulin resistance, a hepatocyte-specific model of ILK-KO (hepILK-KO) was 
created (280). In order drive hepatocyte specific cre expression, and consequent hepILK-KO, 
mice expressing cre under control of the albumin promoter (alb-cre) were used (206). These mice 
were designed to assess hepatic insulin resistance and NAFLD progression in relation to obesity, 
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but other studies have used them to evaluate ILK in relation to hepatic development, injury, and 
regeneration. 
 The Michalopoulos group at University of Pittsburgh have studied aspects of the ECM and 
integrin signaling in relation to hepatic regeneration (86, 146, 147). This had prompted studies on 
the role of ILK in hepatic injury and regeneration (7, 17, 63, 65, 86, 87). Initial studies utilized an 
adenoviral vector to drive hepatocyte-specific cre expression and remove ILK from hepatocytes 
(87). While ILK-KO promoted hepatocyte apoptosis and hepatitis, these studies were complicated 
by mild apoptotic phenotypes with control adenovirus (87). To avoid this complication, a 
developmental model of hepatic ILK-KO was implemented, hereafter referred to as “liver ILK-KO” 
(86). Studies of liver ILK-KO mice demonstrate a consistently upregulated hepatic proliferative 
drive (7, 63, 86). Despite this no cancerous developments have been reported in liver ILK-KO 
mice. Inappropriate proliferative drive can lead to hepatomegaly and other complications (86). 
However, appropriately harnessed this proliferative drive enhances the regenerative capacity of 
the liver. The ability to harness this capacity of liver ILK-KO mice was demonstrated in several 
models of surgical and hepatotoxic damage (7, 17, 64, 65).  
These studies utilized an alternative model for “hepatocyte” ILK-KO in mice. Specifically, 
cre expression was driven by an albumin promoter linked with an alfa-fetoprotein enhancer (alf-
alb-cre). There are significant temporal differences in the alf-alb-cre and alb-cre systems. The alf-
alb-cre becomes active early in development with expression of cre detectable by embryonic day 
10.5 (E10.5) (142). This causes cre expression and genetic KO prior to differentiation of biliary 
epithelial cells from the bipotential hepatoblast progenitor population (~E13.5) (157, 238), which 
give rise to hepatocytes later in development. This system results in cre expression and 
consequent KO in hepatocytes derived from the developing hepatoblast population, as well as in 
biliary epithelial cells. Influence of this phenomenon on previous alf-alb-cre ILK-KO models is 
acknowledged as a potential contributor to observed phenotypes (86). 
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To avoid complications associated with the alf-alb-cre promoter assessment of hepatocyte 
ILK as a mediator of insulin resistance were performed in alb-cre driven hepILK-KO mice (280). 
For these studies control (ILKlox/lox) and hepILK-KO mice were either maintained on a chow diet 
or fed a HF diet from 3 to 19 weeks of age. This diet length is known to induce hepatic steatosis 
and insulin resistance. As with itgα1-/- and itgα2-/- mice no phenotypes were observed in in hepILK-
KO on a chow diet. However, HF-fed hepILK-KO mice were largely protected from hepatic insulin 
resistance (280). This maintenance of insulin sensitivity in the face of obesity was not attributable 
to alterations in insulin-stimulated phosphorylation of IRS-1, Akt, or FoxO1. Despite no altered 
activation of these signaling proteins HF-fed hepILK-KO livers had lower lipid content and 
increased expression of lipogenic genes. Parallel studies also demonstrated that ILK-KO from 
skeletal muscle resulted in a similar protection of the skeletal muscle compartment from insulin 
resistance during obesity (138). Together, these findings indicated ILK contributes to insulin 
resistance in a tissue-independent manner. With ILK-KO preventing insulin resistance and other 
pathologic complications of obesity in liver and skeletal muscle ILK has become a possible 
therapeutic target for treatment of these conditions. 
 
Hypotheses 
Pleiotropic metabolic benefits in tissue-specific ILK-KO models (138, 280) prompted 
interest in the mechanisms underlying these effects. In addition to the metabolic benefits of 
hepILK-KO we also understand there to be alternative functions of ILK in hepatic injury and repair 
(7, 17, 65, 86). Of particular note was a clear age-dependent effect of liver ILK-KO on hepatic 
histological organization, transcriptional profiles, and signaling (86). As these are definitive 
contributors to hepatic metabolism and pathologic progression, I hypothesized an age-dependent 
role for ILK in hepatic metabolism and glucoregulation. The results of Chapter III demonstrate 
that, indeed, hepatocyte ILK determines glucose homeostasis, resistance to obesity, and 
protection from steatosis in an age-dependent manner. These represent desirable therapeutic 
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endpoints in combatting these pathologies. However, the mechanisms driving these phenotypes 
in the absence of hepatocyte ILK are unknown. I hypothesized a diminished capacity for oxidative 
metabolism may improve glucoregulation in hepatocyte ILK-KO mice based on glucose tolerance 
and RNA-seq analyses. Chapter IV demonstrates a setting of reduced hepatic oxidative 
metabolism resulting in metabolic compensation and signaling pathway activation that modify 
hepatic glucoregulation in mice lacking hepatocyte ILK.  
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Chapter II 
 
RESEARCH MATERIALS AND METHODS 
 
Animal models 
The Vanderbilt University Animal Care and Use Committee approved all procedures and 
animal protocols. Mice were maintained in a facility accredited by the Association for Assessment 
and Accreditation of Laboratory Animal Care. Mice were housed in a temperature- and humidity-
controlled room on a 12:12 hour light/dark cycle. Male C57BL/6J mice with loxP sites flanking the 
ILK gene (ILKlox/lox) (226) were kindly provided by Dr. Roy Zent. ILKlox/lox mice were crossed to 
transgenic mice heterozygous for expression of Cre recombinase under control of the albumin 
(Alb) promoter (Albcre, Tg(Alb-cre)21Mgn, The Jackson Laboratory, Bar Harbor, ME, USA) to 
generate ILKlox/loxAlbcre+/- mice (referred to as hepILK-KO) and ILKlox/lox littermates (280).  Alb-cre 
was utilized for hepatocyte-specific knockout due to temporal organization of cre expression and 
completion of hepatocyte specific knockout in this system (206).These mice were utilized for all 
experiments performed within the dissertation.  Mice were removed from their mother’s cage for 
weaning and separated by gender at 3 weeks of age. Upon weaning mice were provided free 
access to rodent chow (5.5% kcal from fat, PicoLab Laboratory Rodent Diet 5L0D, Purina, 
Richmond, IN, USA) and water. For diet induced obesity studies in chapter I mice were switched 
to high fat diet (60% kcal from fat; F3282, BioServ, Flemington, NJ, USA) at 6 weeks of age.  Mice 
were weighed and handled weekly to monitor body weight and minimize stress due to handling 
during studies. Studies were performed on mice at 6, 9, 12, 18, and 32 weeks of age in chapter 
I. Studies in chapter II and III were performed in mice at 6 weeks of age. 
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Surgical procedures 
Catheter implantation procedures (11, 12) were performed on 5 week old mice in 
preparation of metabolic flux experiments using stable isotopes. Arterial catheters are made from 
polyethylene tubing (BPE-10, Instech Labs, Plymouth Meeting, PA, USA ) attached to silicone 
tubing (0.3mm ID, 0.64mm OD, Dow Silicones, Midland, MI, USA). Jugular vein catheters are 
made from the same silicone tubing. These catheters were connected to an assembly (called a 
MASATM) consisting of stainless steel tubing (0.3mm ID, 0.41mm OD, 15mm, Dow Silicones) bent 
90and attached to polyethylene tubing (BPE-20, Instech Labs) and anchored with Silastic 
medical adhesive (Silicone Type A, Lakeside, AZ, USA). The catheters and the MASA™ were 
sterilized with ethylene oxide (). Mice were anesthetized using isoflurane (Piramal Critical Care, 
Bethlehem, PA, USA). After a surgical plane of anesthesia was achieved, the interscapular and 
neck areas were depilated and sterilized with betadine and 70% alcohol. Ketoprofen (Zoetis, 
Parsippany, NJ, USA) was administered subcutaneously at a dose of 5-10mg/kg. An incision was 
made midline, 5mm above the sternum. The left carotid artery was isolated and exposed after 
blunt dissection of connective tissues followed by ligation of the cephalic end with silk suture (6-
0, Ethicon, Somerville, NJ, USA). The caudal end of the exposed artery was then loosely knotted 
with suture. The artery was clamped with micro-serrefines and cut below the ligated end with 
spring scissors. The catheter was inserted into a small incision on the artery, advanced 9mm, 
secured with silk suture (6-0, Ethicon), tested for patency, and temporarily plugged with wire 
(0.61mm OD, Ziggy’s Wires and Tubes, Sparta, TN, USA). Another incision was made 5mm to 
the right of the midline. The right jugular vein was isolated and exposed after blunt dissection of 
connective tissues followed by ligation of the cephalic end with silk suture (6-0, Ethicon). The 
caudal end of the exposed vein was then loosely knotted with suture. The artery was clamped 
with micro-serrefines and cut below the ligated end with spring scissors. The catheter was 
inserted into a small incision on the vein, advanced 11mm, secured with silk suture (6-0, Ethicon), 
tested for patency, and temporarily plugged with wire (0.61mm OD, Ziggy’s Wires and Tubes). 
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The mouse was turned to its stomach and a small incision was made between the scapulae. A 
14-gauge needle (EXELINT, Los Angeles, CA, USA) was inserted through the ventral (stomach 
side) incisions and tunneled subcutaneously to the dorsal (back side) incision. Catheters were 
passed through the needle and exteriorized through the dorsal incision between the scapulae. 
Ventral incisions were sutured with nylon (7-0, Ethicon). The venous and arterial catheters was 
then clamped with micro-serrefine at the dorsal incision, cut 1cm above the clamp, and connected 
to the MASA™. The base of the MASA™ was then placed within the dorsal incision space and 
the incision was sutured with nylon (7-0, Ethicon). Catheters were filled with a 5mg/mL ampicillin 
(AuroMedics Pharma, Windsor, NJ, USA) and 200U heparin (Sagent Pharmaceuticals, 
Schaumburg, IL, USA) / ml saline (0.9%, Hospira, Lake Forest, IL, USA) solution. Following 
surgery, mice were housed individually in a warmed, cleaned cage for seven days prior to study. 
 
In vivo experiments 
 
Oral glucose tolerance tests 
On the day of the study, mice were weighed and placed in bedded containers without food 
or water. Glucose solutions for oral gavaging were prepared by diluting 1.6mL of 50% glucose 
solution (Hospira) with 2.4 mL of tap water (Vanderbilt University, Nashville, TN, USA) to obtain 
a 20% glucose solution. After 5 hours of fasting, tails of mice were nicked and baseline samples 
(Time = -10 minutes) were taken for measurement of glucose (2uL) and future measurement of 
Insulin (20uL). Glucose was determined using Accu-chek Aviva glucometers (Roche Diabetes 
Care, Indianapolis, IN, USA) and Accu-chek Aviva Plus glucose test strips (Roche Diabetes 
Care). After the initial glucose sample a second pre-gavage glucose sample (Time = -5 minutes) 
was taken to establish effects of handling and sampling on the baseline glucose samples. An oral 
glucose gavage volume was equal to 10uL of glucose per mg of mouse body weight to achieve a 
2g of glucose per kg of body weight dosing of glucose. For oral gavaging mice were scruffed, 
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restrained manually, and animal feeding needles (Cadence Science, Cranston, RI, USA) attached 
to syringes (1mL, luer slip, Becton-Dickinson, Franklin Lakes, NJ, USA) containing individual 
glucose doses were inserted in to the esophagus. Glucose doses were then introduced slowly 
(~100µL/s) while monitoring for indications of tracheal insertion such as bubbling from the nose. 
Samples of glucose concentrations were taken 9 more times over the next 120 minutes (Time = 
5, 10, 15, 20, 30, 45, 60, 90, and 120 minutes). Plasma samples for insulin measurements were 
also taken 3 more times (Time = 10, 30, and 120 minutes) and all insulin samples were stored at 
-80°C prior to analysis. At the conclusion of the study mice are placed back in their previous 
housing and monitored for any adverse events. 
 
Whole body indirect calorimetry and activity 
Indirect calorimetry, activity, and associated behaviors were assessed in mice at 6 weeks 
of age in a Promethion Metabolic Analyzer (Sable Systems, North Las Vegas, NV, USA) at an 
ambient temperature (20-22°C). 1 week prior to study mice were acclimatized to individual 
housing. Cages contained Pure-O’ Cel bedding (The Andersons Inc, Maumee, OH, USA) and 
were maintained in a temperature- and humidity-controlled room on a 12:12 hour light/dark cycle. 
Upon acclimatization, cages were transferred the the Promethion system. Mice had ad libitum 
access to chow diet and water throughout the study. Whole body VO2, VCO2, food intake, water 
intake, body weight, and cage behavior (XYZ beam breaks) were measured continuously in free-
roaming mice over a 9 day period.  Assessment of energy expenditure (EE) was calculated by 
the Weir formula (273) and is presented as kilocalories. Respiratory quotient (RQ; VCO2/VO2) is 
used as a surrogate for substrate utilization bounded by the theoretical limits of 0.7, 100% 
utilization of lipid for energy, and 1.0, 100% utilization of carbohydrate for energy. Analysis of 
covariance (ANCOVA) for EE was performed to assess interactions between lean body mass and 
genotypes in relation to EE (132–134). Energy intake (EI) was calculated using the equation {food 
intake (g) * energy content of rodent chow (cal/g)}.  
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Stable isotope infusions for metabolic flux analysis 
On the day of the study, mice that had been catheterized 1 week prior were placed in 
bedded containers without food or water and fasted for 3h. After this initial fast mice were 
connected to a swivel sample-infusion apparatus (Figure 2.1). Upon connection to sampling and 
infusion lines an 80-μl arterial blood sample was drawn to determine the natural isotopic 
abundance of circulating glucose. Continuous infusates of [6,6-2H2]glucose and [13C3]propionate 
were prepared in 0.9%NaCl-4.5%2H2O solution. Venous infusions were performed as previously 
described (105). After the baseline sample, a bolus of [2H2]water (99.9%, Cambridge Isotopes 
Laboratories, Tewksbury, MA, USA) with 0.9% NaCl was delivered over 25 minutes to enrich total 
body water to 4.5%. A [6,6-2H2]glucose (Cambridge Isotopes Laboratories) prime (440 μmol•kg-1) 
was dissolved in the bolus. Following the prime a continuous infusion (4.4 μmol•kg−1•min−1) of 
[6,6-2H2]glucose was administered for the duration of the study. At time=120 min after the 
[2H2]water-0.9%NaCl bolus sodium [13C3]propionate (Cambridge Isotopes Laboratories)  was 
delivered as a continuous infusion. Blood glucose was monitored (Roche) and donor erythrocytes 
were infused to maintain hematocrit throughout the study. At time=90 min after the onset of the 
[13C3]propionate infusion blood samples (100 μl each) were collected at 10 minute intervals over 
30 minutes. Samples were centrifuged in EDTA-coated tubes for plasma isolation. The samples 
were stored at −80°C prior to glucose derivatization and GC-MS analysis. The duration between 
the [2H2]water-0.9%NaCl bolus/[6,6-2H2]glucose prime and steady-state isotopic sampling was 
3.5 to 4 hours resulting in a fasting period of ~7 hours. Mice were then euthanized for liver 
extraction and analyses. 
 
Hepatocyte isolation 
 Hepatocytes were isolated via a 2-step collagenase perfusion technique as 
previously described (76). Briefly, livers were perfused via the inferior vena cava with 50 ml of  
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Figure 2.1- Depiction of the conscious catheterized mouse, experimental setup, and study 
design for metabolic flux analyses using stable isotopic tracers. 
49 
 
wash buffer (137 mM NaCl, 7 mM KCl, 0.7 mM Na2HPO412H2O, 10 mM Hepes, 50 mM EDTA) 
followed by 50 ml of digestion buffer (137 mM NaCl, 7 mM KCl, 0.7 mM Na2HPO412H2O, 10 mM 
Hepes, 0.75 mg/ml CaCl2, and 0.4 mg/ml collagenase from Clostridium histolyticum 
(MilliporeSigma, Burlington, MA, USA)) at 5 ml/min and 37°C. Digested livers were carefully 
extracted from the peritoneal cavity and placed in a 35mM round cell culture dish (Becton-
Dickinson) containing 3mL of 4°C DMEM (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) 
on ice. The liver capsule was torn and removed from the cell suspension with fine forceps. Cells 
were screened with a 70 µm nylon cell strainer (Corning, Corning, NY, USA) in to a 50mL sterile 
tube (Corning) and centrifuged for 5 minutes at a speed of 50g to pellet hepatocytes. Cell 
supernatant containing media and enriched for non-parenchymal liver cells (Liver sinusoidal 
endothelial cells, Kupffer cells, stellate cells, and erythrocytes) was aspirated and remaining 
pelleted hepatocytes were resuspended in DMEM (Gibco) containing 1.125 g/L glucose and 584 
mg/L L-glutamine for respirometry analyses. Cell counts and viability were obtained via trypan 
blue (Gibco) exclusion method. 3 separate 500µL aliquots of this suspension were then added to 
1.5mL microcentrifuge tubes (VWR, Radnor, PA, USA) and centrifuged at a speed of 13000g to 
pellet cells for future molecular analyses.  
 
Ex vivo experiments 
 
Hepatocyte respirometry 
To evaluate the functional oxidative metabolism of hepatocytes a method assessing the 
respiratory characteristics of O2 consumption in intact hepatocytes was implemented (62, 204). 
This methodology was chosen so as to avoid the documented selection biases that are introduced 
by protocols in isolated mitochondria (113, 151) such as disruption of mitochondrial network 
interactions (227) and selection for specific populations of mitochondria (205). Hepatocyte O2 
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consumption was evaluated using an Oxygraph-2k (O2K, Oroboros Instruments Corp.; Innsbruck, 
Austria) at 37°C.  Prior to introduction of hepatocytes each chamber of the O2K instrument were 
filled with media (DMEM (Gibco) containing 1.125 g/L glucose and 584 mg/L L-glutamine) and 
equilibrated with atmospheric oxygen. Upon equilibration a volume of media no greater than 
100µL containing 75,000 hepatocytes were injected in to each of the 2 O2K chambers. Routine 
respiration was measured in the suspension media alone. The ATP synthase inhibitor Oligomycin 
(2.5 mM, MilliporeSigma) was used to assess futile (LEAK) respiration, which is respiration that 
occurs without production of ATP.  Maximal respiration by the electron transfer system (ETS) was 
determined via step-wise titrations (0.5 μM) of carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP, MilliporeSigma). 
 
Tissue processing and analyses 
 
Liver histology and immunohistochemistry 
Upon sacrifice a portion of mouse liver (4-16mm3) was placed in a tissue fixation cassette 
(Thermo Fisher Scientific) and submerged in 10% zinc buffered formalin (Thermo Fisher 
Scientific). Liver histology, immunohistochemistry, and pathologic evaluation were performed with 
the assistance of the Vanderbilt Translational Shared Pathology Resource Core. Fixed tissues 
were paraffin embedded and sectioned at a thickness of 5 μm on to glass slides. Slides were 
placed on the Bond Max IHC stainer (Leica Biosystems, Buffalo Grove, IL, USA). Dehydration, 
clearing, and coverslipping were the only procudures not performed on the Bond Max. Slides 
were deparaffinized followed by heat induced antigen retrieval using Epitope Retrieval 2 solution 
(Leica Biosystems) for 20 minutes. Slides were then placed in a Protein Block (DAKO, Carpinteria, 
CA, USA) for 10 minutes. Liver sections were stained with hematoxylin and eosin (H&E) for 
assessment of gross liver histology as well as Masson’s trichrome stain for evaluation of fibrosis. 
For immunohistochemistry, anti-cytokeratin 19 (Proteintech Group, Rosemont, IL, USA, Cat# 
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14965-1-AP, RRID:AB 2133324) coupled to 3,3′-Diaminobenzidine (DAB) staining, was used to 
assess biliary hyperplasia and anti-Ki67 (Cell Signaling Technology, Danvers, MA, Catalog 
#12202S  RRID:AB_2620142) coupled to nuclear (DAB) staining, was used to assess 
proliferation. The Bond Refine Polymer detection system was used for visualization.  
 
Immunoblotting 
Proteins were obtained from lysates of Liver (15-25mg), gastrocnemius muscle (15-
25mg), or isolated hepatocytes (pellet of ~4-5x106 cells). All were lysed in extraction buffer 
containing 50mM Tris, 1mM EDTA, 1mM EGTA, 10% glycerol, 1% Triton X-100 (pH 7.5), and a 
1:100 dilutions of Halt™ protease and phosphatase single-use inhibitor cocktail (Thermo Fisher 
Scientific). Tissues were homogenized using 0.5 mm zirconium oxide beads (Next Advance, Troy, 
NY, USA) for liver or 0.9-2.0mm stainless steel beads (Next Advance) for gastrocnemius. 
Samples were homogenized for 5 minutes in a Bullet Blender (Next Advance). Samples were 
centrifuged at 13,000g for 15 minutes at 4°C and supernatant was extracted while avoiding upper 
lipid layer. Hepatocytes were vortexed in extraction buffer and frozen at -80°C for lysis. Upon 
thawing samples were centrifuged at 13,000g for 15 minutes at 4°C and supernatant was 
extracted while avoiding upper lipid layer.  
Proteins levels from each of these sample types were quantified using Pierce™ BCA 
Protein Assay Kit (Thermo Fisher Scientific). Proteins were denatured and reduced at 70 °C, 
separated on a NuPAGE 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA, USA), and transferred to 
a PVDF membrane.  Membranes were probed with the antibodies obtained from Cell Signaling 
Technology; (Danvers, MA) for ILK (Cat# 3856, RRID:AB_2233861), glycogen synthase kinase 
3 β (GSK3β, Cat# 9315, RRID:AB_490890), GSK3β phosphorylated at ser9 (Cat# 9323, 
RRID:AB_2115201), protein kinase B (Akt, Cat# 9271, RRID:AB_329825),  Akt phosphorylated 
at ser473 (Cat# 9272, RRID:AB_329827), Glycogen synthase (GS) (Cat# 3893, 
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RRID:AB_2279563), GS phosphorylated at Ser641 (Cat# 3891, RRID:AB_2116390), 5’ AMP-
activated protein kinase  (AMPK, Cat# 2532, RRID:AB_330331),  AMPK phosphorylated at Thr172 
(Cat# 2535, RRID:AB_331250), acetyl-CoA carboxylase (ACC, Cat# 3662, RRID:AB_2219400), 
ACC phosphorylated at Ser79 (Cat# 3661, RRID:AB_330337), sequestosome 1 (p62, Cat# 5114, 
RRID:AB_10624872), and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (Bnip3, 
Cat# 3769, RRID:AB_2259284). Mitochondrial complexes were detected using the total OXPHOS 
rodent WB antibody cocktail (abcam, Cat# MS604-300). Membranes were exposed to a 
chemiluminescent horseradish peroxidase (HRP)-substrate (MilliporeSigma) after incubating with 
a HRP-conjugated secondary antibody or quantified on a Li-cor imaging system (Li-cor 
Biotechnology, Lincoln, NE, USA) after incubation with IRDye® 800CW secondary antibody (Li-
cor).  ImageJ software was used for densitometry measurements.   
 
RNA isolation 
RNA was extracted by homogenization in TRIzol® (Thermo Fisher Scientific) from livers 
or isolated hepatocytesof hepILK-KO or ILKlox/lox mice. For liver, 0.5 mL of TRIzol was added to 
15-20 mg of liver in tubes containing 0.5 mm RNase-free zirconium oxide beads (Next Advance). 
Samples were homogenized for 5 minutes in a Bullet Blender (Next Advance). For hepatocytes, 
pelleted cells, (Hepatocyte Isolation) were resuspended in 0.4mL of TRIzol, vortexed, and frozen 
at -80°C. Homogenized liver or thawed, lysed hepatocytes were incubated for 5 minutes at room 
temperature. A volume equal to 10% of the homogenate volume of 1-Bromo-3-chloropropoane 
were added to homogenates and vortexed vigorously for 15 seconds. Samples were incubated 
for 1 minute at room temperature, vortexed vigorously for another 15 seconds, and centrifuged at 
4° C and 12,000 g to separate phase layers. The upper phase was removed from the tube, 
combined with an equal volume of 70% ethanol, vortexed vigorously, and added directly to 
RNeasy columns (Qiagen, Hilden, GER). Columns for RNA sequencing included an on-column 
DNase (Qiagen).  
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RNA sequencing 
For RNA sequencing studies total RNA quality was assessed using the 2100 Bioanalyzer 
(Agilent, Santa Clara, California). 200 ng of DNase-treated total RNA with an RNA integrity 
number greater than seven was used to generate polyA-enriched mRNA libraries using KAPA 
Stranded mRNA sample kits with indexed adaptors (Roche, Basel, Switzerland). Library quality 
was assessed using the 2100 Bioanalyzer (Agilent) and libraries were quantitated using KAPA 
Library Quantification Kits (Roche). Pooled libraries were subjected to 75 bp paired-end 
sequencing according to the manufacturer’s protocol (HiSeq3000, Illumina; San Diego, 
California). Bcl2fastq2 Conversion Software (Illumina) was used to generate de-multiplexed Fastq 
files. Fastq data files were uploaded to Galaxy (3) and converted to fastqsanger files. Low quality 
reads were removed from fastqsanger files using trimmomatic v0.36.3 (23). Reads were aligned 
to the mm10 mouse reference genome with Hisat v1.1.2 (145). Counts of overlapping reads and 
gene exons from mm10 were determined using the counts function of HTseq v0.6.1p1 (5). Count 
expression levels were filtered and assessed for differential expression using edgeR v (218). 
Enrichment of gene ontology terms and KEGG pathways were determined for genes significantly 
increased or decreased in hepILK-KO livers compared to control livers using the limma v3.36.2 
goana and kegga functions (217). 
 
Quantitative polymerase chain reaction 
For quantitative PCR (qPCR) analyses RNA was reverse transcribed using the iScript 
cDNA synthesis kit (Bio-Rad; Hercules, CA). qPCR was performed using TaqMan (Applied 
Biosystems; Foster City, CA) Universal PCR Master Mix as well as TaqMan probes for glucose-
6-phosphatase catalytic subunit (G6pc, Cat# Mm00839363_m1), phosphoenolpyruvate 
carboxykinase (Pck1, Cat# Mm00440636), mitochondrial dynamin-like GTPase (Opa1, 
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Cat#Mm01349707_g1), mitofusin 2 (Mfn2, Cat# Mm00500120_m1), dynamin-1-like protein, 
(Dnm1l, Cat# Mm01342903_m1), and  fibroblast growth factor 21 (Fgf21, Mm00840165_g1). 
 
Hepatic adenine nucleotides 
Rapid sacrifice-excision procedures were implemented to minimize degradation and shifts 
in the nucleotide pools. Mice were sacrificed via cervical dislocation and a portion of the liver was 
excised and freeze clamped within 30s. Livers were maintained at or below -80°C prior to 
homogenization.  
 For homogenization 50-70mg of rapidly excised liver were added to 1.5mL Safe-Lock 
microcentrifuge tubes (Eppendorf, Hamburg, GER) containing 0.5 mm zirconium oxide beads 
(Next Advance). Immediately prior to homogenization a 10x volume (10:1 volume:weight tissue) 
of 0.4M HClO4 - 0.5mM EGTA was added to tube and samples were homogenized for 5 minutes 
in a Bullet Blender (Next Advance). After homogenization samples were placed in ice for 3 
minutes and then centrifuged at 3200g, 4°C for 5 minutes. To neutralize homogenate in a new 
tube 400µL of supernatant was added to 136µL of 0.5MK2CO3, vortexed, and maintained on ice 
for 5 minutes. Samples were then centrifuged at 3200g, 4°C for 5 minutes. Supernatants were 
transferred to HPLC tubes and kept at -80°C prior to processing.  
Supernatants were analyzed via HPLC on a Supelco Supelcosil LC18-T column (4.6 by 
250mm, 5μm particle size) with a Waters 490 detector (254nm at 1.0 AUFS) and constant flow 
rate of 0.7mL∙min-1. Adenine nucleotides (AMP, ADP, ATP) from samples and standards were 
spotted using a 12.5min mobile phase A (100nM KH2PO4, pH 6) and a 3.5min mobile phase B 
(90:10 100mM KH2PO4/Methanol), and 44min mobile phase A. Energy charge was calculated 
using the equation ([ATP] + (0.5*[ADP])) / [TAN]. 
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Glycogen 
Liver glycogen content was assessed using the method of Chan and Exton (37). Strips of 
3mm chromatography paper (GE Healthcare Life Sciences, Marlborough, MA, USA) were cut to 
2 inch lengths with 2 strips per sample, standard, and blank then labeled as A and B. ~40-60 mg 
of liver or gastrocnemius muscle were added to 1.5mL Safe-Lock microcentrifuge tubes 
(Eppendorf) containing 0.5 mm zirconium oxide beads (Next Advance) for liver or 0.9-2.0mm 
stainless steel beads (Next Advance) for gastrocnemius. Immediately prior to homogenization a 
8x volume (8:1 volume:weight tissue) of 0.0.03N HCl was added to tubes and samples were 
homogenized for 5 minutes in a Bullet Blender (Next Advance). Samples were then incubated at 
80°C for 15 minutes. Samples were removed from oven, vortexed briefly to ensure even mixing, 
and 200µL volume of homogenate was pipetted on to appropriately labeled chromatography 
strips. Standards of oyster glycogen (MilliporeSigma) were prepared in distilled water and similarly 
pipetted onto chromatography paper. Blanks consisted of 0.03N HCl were prepared similarly. All 
samples, standards, and blanks were allowed time to saturate paper strips (~10 minutes). Strips 
were then added to a glass beaker with a mesh screen sitting above a magnetic stir bar, to 
separate paper strips from moving bar. 70% ethanol was added to the beaker so as to completely 
submerge paper strips. The beaker was placed on a magnetic stirring apparatus and set to a 
medium stirring speed for 40 minutes. This wash step was repeated 2 more times. Upon 
completion of the third ethanol washing step the strips were briefly submerged and rinsed in 
acetone. Samples were then set to dry for at least 2 hours in a ventilated chemical hood.    
After drying, strips were folded accordion style and placed in 13 mL polypropylene tubes 
(Sarstedt, Nümbrecht, GER) tubes. For 50 samples, 250mL of an amyloglucosidase solution 
consisting of 50mL of 0.2M sodium acetate (CH3COONa, NaOAc), 10mg of amyloglucosidase 
from Aspergillus niger (MilliporeSigma), and 200mL of distilled water was prepared for glycogen 
digestion. 5 mL of the amyloglucosidase solution was added to tubes containing paper strips, so 
as to submerge the strips in solution, and incubated at room temperature for at least 16 hours.  
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Glucose concentrations were determined by enzymatic reaction in a 96 well plate. Glucose 
assay buffer was prepared fresh immediately prior to assay. Glucose assay buffer for 1x96 well 
plate contained 26mL of Tris-HCl at pH7.4, 0.542 mL of 500mM MgCl2, 75.83mg of ATP, 54.17mg 
of NADP, and 0.135mL of Hexokinase (HK):Glucose-6-phosphate dehydrogenase (G6PDH) (2:1 
activity) enzyme mixture (Roche Diagnostics, MilliporeSigma). Each sample, standard, and blank 
were added to a 96 well plate at a volume of 20µL in duplicate. For enzymatic determination of 
glucose 200µL of glucose assay buffer was added to each well. Represented below are the 
progressive enzymatic reactions that enable endpoint quantification of NADPH.  
Glucose + ATP 
𝐻𝑒𝑥𝑜𝑘𝑖𝑛𝑎𝑠𝑒
→         Glucose − 6 − phosphate + ADP 
Glucose − 6 − phosphate + ADP 
𝐺6𝑃𝐷𝐻
→     phospho − D − gluconolactone +  NADPH  
 
This reaction proceeded during a 15 minute room temperature incubation on a plate 
shaker at a speed of 125 RPM. After incubation, absorbance of each well was determined at a 
wavelength of 340nm to assess concentrations of NADPH. This allowed calculation of glucose 
content derived from tissue glycogen when compared to the NADPH content produced from 
glucose standard solutions included on each plate.  
 
Hepatic triglycerides, diglycerides, phospholipids, and cholesterol 
Tissue lipid content and speciation were obtained by the Vanderbilt Lipid Core. Lipids were 
extracted using the method of Folch et al. (75). The extracts were filtered, and lipids recovered in 
the chloroform phase. Individual lipid classes were separated by thin layer chromatography using 
Silica Gel 60 A plates developed in petroleum ether, ethyl ether, acetic acid (80:20:1) and 
visualized by rhodamine 6G. Diglycerides, triglycerides and cholesteryl esters were scraped from 
the plates and methylated using BF3/methanol as described by Morrison and Smith (191). 
Determination of total tissue cholesterol was adapted from Rudel et al. (221). 
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Hepatic hexokinase enzyme activities 
Activity of liver hexokinases was assessed using a modified version of the method 
described by Tiedge et al. (253). 10-20mg of frozen liver from 18 hour fasted-6 hour refed mouse 
studies was added to 1.5mL Safe-Lock microcentrifuge tubes (Eppendorf) containing 0.5 mm 
zirconium oxide beads (Next Advance). Immediately prior to homogenization 200µL of 200mM 
Tris-HCl with 10mM MgCl2 was added to tubes and samples were homogenized for 5 minutes in 
a Bullet Blender (Next Advance). Samples were then centrifuged at 13,000g for 15 minutes and 
a temperature of 4°C. Supernatants were then transferred to a new microcentrifuge tube. Protein 
levels from each sample were quantified using Pierce™ BCA Protein Assay Kit (Thermo Fisher 
Scientific). Samples were then diluted to a protein concentration of 1µg/µL in homogenization 
buffer and 20µL of sample were added to a 2 x 96 well plates in duplicate. Glucokinase (GK) and 
hexokinase (HK) assay buffers were prepared consisting of 200mM Tris-HCl at pH7.4, 10mM 
MgCl2, 5.7mM ATP, 2.8mM NADP, 0.5U/mL G6PDH (Roche Diagnostics, MillipopreSigma), and 
either 100mM glucose (GK+HK assay buffer) or 1mM glucose (HK assay buffer). The below 
equation summarizes the enzymatic reactions to determine activities of GK and other HK through 
endpoint NADPH production. 
Determination of GK and HK activities in liver: 
100mM Glucose + ATP 
𝑇𝑖𝑠𝑠𝑢𝑒 𝐺𝐾+𝐻𝐾
→           Glucose − 6 − phosphate + ADP 
Glucose − 6 − phosphate + NADP 
𝐺6𝑃𝐷𝐻
→     phospho − D − gluconolactone +  NADPH  
 
Determination of HK activities in liver: 
1mM Glucose + ATP 
𝑇𝑖𝑠𝑠𝑢𝑒 𝐻𝐾
→        Glucose − 6 − phosphate + ADP 
Glucose − 6 − phosphate + NADP 
𝐺6𝑃𝐷𝐻
→     phospho − D − gluconolactone +  NADPH  
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For assessment of summed activity of liver GK and all other HKs, 200µL of GK+HK assay 
buffer was added to plate #1 containing samples. Immediately following addition of GK+HK assay 
buffer, absorbance of the plate at 340nm to determine resulting NADPH concentrations was 
monitored every minute for 30 minutes. For assessment liver HK activity, 200µL of HK assay 
buffer was added to plate #2 containing samples. Immediately following addition of HK assay 
buffer, absorbance of the plate at 340nm to determine resulting NADPH concentrations was 
monitored every minute for 30 minutes. 
The principle of this assay takes advantage of the lower affinity of GK for glucose 
compared to other HKs. By using assay buffers with low concentrations of glucose, activity of HKs 
can be quantified separate from GK. While using a higher concentration of glucose in the assay 
buffer results in quantification of HK and GK activities simultaneously. By subtracting the results 
of low glucose concentration HK activity from the high glucose concentration GK+HK activity we 
are left with the remaining GK activity. 
 
Blood or plasma processing and analyses 
 
Blood glucose 
Blood glucose was measured using an Accu-Chek® glucometer (Roche Diagnostics, 
Indianapolis, IN, USA).   
 
Insulin 
Plasma insulin was measured by radio-immunoassay (190). Samples and standards were 
incubated with an anti-rat/mouse insulin detection antibody for 3 days. After incubation, 125I-insulin 
was added to the mixture. Secondary antibodies were used to precipitate antibody-bound insulin 
from samples. Samples were then centrifuged, supernatants decanted, and pellet radioactivity 
counts were determined using a Cobra II AutoGamma counter (Packard, IL). Counts in the pellet 
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were inversely proportional to insulin concentrations. A standard curve was constructed to 
calculate unknown insulin concentrations.   
 
Glucagon 
Plasma glucagon was assessed using a solid phase two-site enzyme-linked immuno-
sorbent assay (ELISA) (Mercodia Inc, Winston Salem, NC, USA). 10µL of EDTA plasma and 
standards were added to 96 well plates with anti-glucagon antibodies (clone M5F9S) bound to 
microplate wells. 50µL of HRP-conjugated anti-glucagon antibody (clone E6A11K) is then added 
to each well containing samples and standards. Plates were covered, sealed, and incubated 
overnight at 4°C. Plates were then washed by adding 350µL of wash buffer and inverting plate in 
to sink with gentle tapping 6 times. For development, 200µL of 3,3’,5,5’-tetramethyl-benzidine 
(TMB) substrate is added to wells and incubated at room temperature for 30 minutes. 50µL of 
0.5M H2SO4 stop solution is then added to plate. Spectrophotometric absorbance of the plate is 
then read at 450nm and results are calculated through linear regression analysis of the standard 
curve.  
 
FGF21 
Plasma FGF21 was also quantified using an ELISA (abcam, Cambridge, MA, USA). 50µL 
of EDTA plasma and standards were added to 96 well plates with immobilization anti-tag 
antibodies bound to microplate wells. 50µL of antibody cocktail containing tag-conjugated anti-
FGF21 antibody and HRP-conjugated anti-FGF21 antibody is then added to each well containing 
samples and standards. Plates were covered, sealed, and incubated 1 hour at room temperature 
on a plate shaker at 400 RPM. Plates were then washed by adding 350µL of wash buffer and 
inverting plate in to sink with gentle tapping 3 times. For development, 100µL of TMB substrate is 
added to wells and incubated for 15 minutes at room temperature on a plate shaker at 400 RPM 
in the dark. 100µL of 0.5M H2SO4 stop solution is then added to plate and incubated for 1 minute 
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at room temperature on a plate shaker at 400 RPM. Spectrophotometric absorbance of the plate 
is then read at 450nm and results are calculated through linear regression analysis of the standard 
curve.   
 
Non-esterified fatty acids 
 Tubes for collection of plasma for non-esterified fatty acids (NEFAs) were prepared by 
adding 5μL of a 0.06mg of Tetrahydrolipstatin (THL)/ 1mL of ethanol and allowing to dry prior to 
plasma sample addition. For assessment of plasma NEFAs, 5μL of plasma collected at time=100 
min during steady state period of MFA studies was added to THL tubes and placed at -80°C.  
Plasma NEFAs were assayed using the HR series NEFA-HR (2) kit (FUJIFILM Wako 
Diagnostics U.S.A., Mountain View, CA, USA). Represented below are the progressive enzymatic 
reactions that enable endpoint spectrophotometric quantification of colorimetric product.  
NEFA + ATP + CoA − SH
𝐴𝑐𝑦𝑙−𝐶𝑜𝐴 𝑆𝑦𝑛𝑡ℎ𝑒𝑡𝑎𝑠𝑒
→                 Acyl − CoA + AMP + Pyrophosphate 
Acyl − CoA + O2
𝐴𝑐𝑦𝑙−𝐶𝑜𝐴 𝑂𝑥𝑖𝑑𝑎𝑠𝑒
→               2,3 − trans − Enoyl − CoA + H2O2 
2 H2O2 +MEHA + 4 − aminoantipyrine
𝐻𝑅𝑃
→   Blue purple pigment + 3 H2O 
  
5μL of each plasma sample in THL tubes was diluted 1:1 in H2O and added to a 96 well 
plate in duplicate. Oleic acid standards were also prepared according to manufacturer’s 
instructions and loaded onto the 96 well plate in duplicate. 225μL of Reagent A was added to 
each well, mixed by shaking gently, and incubated at 37°C for 10min. 75μL Reagent B was added, 
mixed by shaking gently, and incubated at 37°C for 10min. Air bubbles were removed by light 
aspiration of air through a clean pipette tip. Endpoint blue-purple pigment was then quantified 
spectophotometrically at 550nm and NEFA concentrations were determined by linear regression 
analysis of the standard curve.   
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Lactate 
Lactate levels in plasma from 5 hour fasted mice and liver of 18 hour fasted-6 hour refed 
mice were determined using an L-Lactate assay kit (abcam, Cat# ab65331). Represented below 
are the enzymatic reactions enabling quantification of lactate through spectrophotometric 
quantification of enpoint colorimetric product.  
Lactate + NAD+
𝐿𝑎𝑐𝑡𝑎𝑡𝑒 𝐷𝑒ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛𝑎𝑠𝑒
→                    Pyruvate + NADH + H+ 
WST − 1 + NADH
𝐷𝑖𝑎𝑝ℎ𝑜𝑟𝑎𝑠𝑒
→         WST − 1 Formazan + NAD+ 
  
β-hydroxybutyrate 
Plasma β-hydroxybutyrate (β-HB) levels in 5 hour fasted mice were quantified using a 
colorimetric assay kit (Cayman Chemical, Ann Arbor, MI, USA, Cat# 700190). Represented below 
are the progressive enzymatic reactions that enable endpoint spectrophotometric quantification 
of colorimetric product. 
β − HB + NAD+
𝛽−𝐻𝐵 𝐷𝑒ℎ𝑦𝑑𝑟𝑜𝑔𝑒𝑛𝑎𝑠𝑒
→                  Acetoacetate + NADH+ H+ 
WST − 1 + NADH
𝐷𝑖𝑎𝑝ℎ𝑜𝑟𝑎𝑠𝑒
→         WST − 1 Formazan + NAD+ 
 
Plasma was initially diluted 1:1 in assay buffer provided by the manufacturer. 50μL of the 
plasma mixture or standards were added to a 96 well plate. β-HB developer solution was 
assembled by combining enzyme (β-HB Dehydrogenase) with colorimetric detector (Water 
Soluble Tetrazolium Salt-1, WST-1). 50μL of β-HB developer solution was then added to each 
well. Platewas then wrapped in tin foil to minize effects of light on development and incubated at 
room temperature for 30 minutes. Endpoint WST-1 Formazan was then quantified 
spectophotometrically at 450nm and β-HB concentrations were determined by linear regression 
analysis of the standard curve.   
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Amino acids and related metabolites 
Plasma amino acids were quantified in the Vanderbilt Hormone Assay and Analytical 
Services Core by ion exchange HPLC with lithium citrate buffer system and post column ninhydrin 
quantification (Biochrom US, Holliston, MA, USA). 
 
2H/13C metabolic flux analysis (MFA)  
Glucose derivatizations, gas chromatography-mass spectrometry analysis, and MFA were 
completed using samples from 120 minutes prior to as well as 90, 100, and 110 minutes following 
the [13C3]propionate bolus as previously described (105, 121).  Fragment ion ranges used for 
determining mass isotopomer distributions were aldonitrile, m/z 173–178, 259–264, 284–289, and 
370–376; methyloxime, m/z 145–149; di-O-isopropylidene, m/z 301–311.  Flux estimates in the 
network for each sample underwent 50 iterations beginning with random initial values to 
determine the best fit based. Goodness-of-fit was accepted according to a chi-square test 
(p<0.05).  By taking multiple samples over time an isotopic steady state is confirmed over the 
interval of 90 to 120 min following the beginning of the [13C3]propionate infusion. Flux values for 
each mouse are an average of estimates at steady state (90, 100, and 110 minutes following the 
[13C3]propionate bolus) and were normalized to body weight. The fractional turnover of the glucose 
pool was defined as steady state glucose production [mg/(kg•min)]/(steady state average blood 
glucose [mg/ml]/200•[mL/kg]) and expressed as a percentage. In a steady state, glucose 
production is equivalent to glucose utilization. 
 
Statistical analyses  
Student’s t-tests with Welch’s correction were used to detect statistical differences 
(p<0.05) between 2 groups. 1-way ANOVA with Brown-Forsythe and Welch correction were used 
to detect statistical differences (P<0.05) between more than 2 groups. All data are reported as 
means ± SEM. 
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Chapter III 
 
HEPTAOCYTE ILK KNOCKOUT MICE EXHIBIT IMPROVED GLUCOSE TOLERANCE 
ACCOMPANIED BY RESISTANCE TO HF-DIET INDUCED OBESITY AND HEPATIC 
STEATOSIS IN AN AGE-DEPENDENT MANNER 
 
Aims 
Hepatocyte integrin-linked kinase (ILK) has been demonstrated as a requirement for 
development of hepatic insulin resistance during diet-induced obesity. Other studies have 
demonstrated that hepatocyte ILK effects a number of outcomes related to histologic organization, 
transcriptional programming, cell proliferation, and hepatic regeneration. However, these effects 
may be age-dependent. Insulin resistance represents a dysfunctional regulation of glucose 
homeostasis and is affected by age and length of exposure to pathologic stimulus. Therefore, two 
aims were constructed for this chapter. The first aim was to determine whether hepatocyte ILK 
determines hepatic glucoregulatory functions and overall glucose homeostasis in an age-
dependent manner consistent with studies of histology and regeneration. The second aim was to 
determine whether ILK effects the progressive dysfunction in glucoregulation and insulin 
resistance brought on by an obesogenic diet.  
 
Introduction  
Integrin-linked kinase (ILK) is necessary for normal liver development. Deletion of ILK from 
hepatic progenitor cells around embryonic day 10.5 (~E10.5), prior to hepatocyte differentiation 
(142), causes increased hepatocyte apoptosis, fibrosis, biliary hyperplasia, and mitosis at 6 weeks 
of age (86). However, by 30 weeks of age these biochemical and histological alterations were 
resolved, but a doubling of the liver to body weight ratio occurred. This was hypothesized to be a 
result of compensatory proliferation due to loss of contact inhibition. Even after morphologic 
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phenotypes are resolved, exposure of these mice to hepatic resection or toxicity results in an 
enhanced regenerative response (7, 17, 64, 66, 86).  
More recently, studies have also shown that hepatocyte ILK contributes to hepatic insulin 
resistance during diet-induced obesity (280). This was shown in mice where ILK was deleted at  
E15.5, after initiation of hepatocyte differentiation (206). There is a clear age dependence for an 
array of hepatic outcomes as they relate to hepatic ILK knockout. However, studies assessing the 
role of ILK in development of hepatic insulin resistance only assessed an individual time point 
(~18-19 weeks) during the lifespan of the mice. As insulin resistance is driven by dysregulated 
glucose homeostatic processes, it was the goal of these studies to assess the role of ILK in 
metabolic and glucose homeostasis as they relate to age.  
These studies demonstrate that hepatocyte-specific ILK knockout (hepILK-KO) in 
C57Bl6/J mice has an age-dependent effect on glucose homeostasis (256). Specifically, hepILK-
KO mice have decreased blood glucose levels after a 5 hour fast and increased glucose tolerance 
at 6 weeks of age. This is accompanied by a significant decrease in fasting insulin and lower 
insulin responses during an oral glucose tolerance test. This effect on glucose homeostasis is 
accompanied by changes to hepatic histology and transcriptional programming. Over time 
glucose tolerance and histology gradually converge between hepILK-KO and ILKlox/lox mice on a 
chow diet. HF-fed hepILK-KO mice are initially resistant to hyperglycemia, obesity, and hepatic 
statosis copared to ILKlox/lox mice. However, hepILK-KO mice gradually match these traits 
compared to ILKlox/lox littermates. Additionally, hepatic transcriptional profiles of hepILK-KO mice 
appear to follow a similar paradigm with stark differences from ILKlox/lox at 6 weeks of age that 
mostly converge by 18 weeks of age, but have differences provoked if mice are fed a HF diet.  
 
Experimental approach 
To assess the aims set forth for Chapter III assessment of mice expressing normal 
hepatocyte ILK (ILKlox/lox) or with a hepatocyte-specific removal of the ILK (ILKlox/loxAlbcre+/- ; 
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HepILK-KO) was started at 6 weeks of age. Mice underwent basic metabolic characterization of 
weight and body composition. Fasting blood glucose levels and oral glucose tolerance tests 
coupled with plasma insulin quantification were used as metrics of glucose homeostasis. After 
initial 6 week assessments mice were either maintained on a chow diet or switched to a HF 
obesogenic diet. Basic metabolic characterizations and assessment of glucose homeostasis were 
repeated at 9, 12, 18, and 32 weeks of age in all groups. At 32 weeks of age, mice were sacrificed 
and tissues were taken for histologic analysis. In conjunction with these studies ILKlox/lox and 
hepILK-KO mice at 6 weeks (chow diet only) and 18 weeks of age (chow and HF diet) were 
sacrificed for assessment of hepatic histology and transcriptomic analysis. 
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Figure 3.1- Overview of experimental timeline for age-dependent analyses of ILKlox/lox and 
hepILK-KO mice fed chow or switched to HF diets.  
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Results 
 
Hepatocyte ILK is required for normal hepatic histology and glucose homeostasis in young 
mice.  
 Initial assessment of hepILK-KO mice at 6 weeks of age revealed a small, but significant 
decrease in body weight compared to ILKlox/lox mice (Table 3.1). While no difference in adipose 
mass as a percentage of total body mass were observed, there was a significant increase in lean 
mass percentage of hepILK-KO mice (Table 3.1). To assess fasting glucose homeostasis ILKlox/lox 
and hepILK-KO mice underwent a 5 hour fasting period for induction of a postabsorptive state. 
Initial blood samples were taken for measurement of blood glucose and plasma insulin. Blood 
glucose levels after a 5 hour fast were decreased by ~30% in hepILK-KO mice at 6 weeks of age 
(Table 3.1; Figure 3.2A). This effect was accompanied by lower fasting insulin (Table 3.1; Figure 
3.2C). OGTTs revealed increased glucose tolerance in hepILK-KO mice at 6 weeks as the 
baseline-corrected area under the glucose curve (AUC) was decreased compared to ILKlox/lox mice 
(Fig 3.2B). Peak insulin responses during OGTT (T=10 minutes) also trended lower in hepILK-
KO mice (p=0.06) before returning to comparable levels for the remainder of the GTT (Figure 
3.2C). 
Previous studies from the Michalopoulos group had demonstrated altered histologic and 
signaling characteristics in early life of an alternative hepatic ILK-KO model (86). As mentioned 
previously, this model may create off target knockout effects as the result early activation of cre 
expression. Our knockout model was designed to minimize developmental effects with later 
initiation and completion of cre recombinase driven knockout. As such, we felt it necessary to 
assess histology in early life as well.  Histological evaluation of livers from hepILK-KO and ILKlox/lox 
were performed at 6 weeks of age. Livers from 6 week old ILKlox/lox and hepILK-KO mice stained 
with H&E (Figure 3.2D & E) were evaluated by a veterinary pathologist (Dr. Kelli L. Boyd). The 
presence of hepatocellular degeneration, inflammation, fibrosis, and biliary hyperplasia were  
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Table 3.1- Basic characterization of control (ILKlox/lox) and hepILK-KO mice at 6 weeks of 
age after a 5 hour fast. 
Gentoype ILKlox/lox hepILK-KO 
N 13-28 11-19 
Weight (g) 21.0 ± 0.5 17.9 ± 0.6# 
Fat mass (%) 4.8 ± 0.4 5.2 ± 0.9 
Lean mass (%)  67.6 ± 0.4 70.8 ± 1.0* 
Study age (wks) 6 6 
Diet duration (wks) - - 
FBG (mg/dL) 148 ± 4 103 ± 5# 
FPI (ng/mL) 0.5 ± 0.05 0.3 ± 0.04** 
 
Data are mean ± SEM. p-values are the result of Student’s t-test with Welch’s correction. *= p<0.05 chow-
fed ILKlox/lox vs. chow-fed hepILK-KO; **= p<0.01 chow-fed ILKlox/lox vs. chow-fed hepILK-KO; # = p<0.001 
chow-fed ILKlox/lox vs. chow-fed hepILK-KO. FBG and FPI are fasting blood glucose and fasting plasma 
insulin, respectively. 
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Figure 3.2- Hepatocyte ILK is required for establishment of normal glucose homeostasis 
and hepatic organization in 6 week old mice. A) Blood glucose levels of 6 week old ILKlox/lox 
(n=30) and hepILK- KO (n=20) mice during OGTTs. B)  Baseline corrected area under the glucose 
curve (A) C) Insulin levels during OGTTs. D) Representative H&E stained liver micrographs at 
40x magnification from 6 week old ILKlox/lox mice. E) Representative H&E stained liver micrographs 
at 40x magnification from 6 week old hepILK-KO mice. F) Representative CK19 IHC liver 
micrographs at 40x magnification from 6 week old ILKlox/lox mice. G) Representative CK19 IHC 
liver micrographs at 40x magnification from 6 week old hepILK-KO mice. H) Representative 
Masson’s trichrome stained liver micrographs at 40x magnification from 6 week old ILKlox/lox mice. 
I) Representative Masson’s trichrome stained liver micrographs at 40x magnification from 6 week 
old hepILK-KO mice. J) Representative Ki67 IHC liver micrographs at 40x magnification from 6 
week old ILKlox/lox mice. K) Representative Ki67 IHC liver micrographs at 40x magnification from 
6 week old hepILK-KO mice. Red circles denote nuclei stained positively for Ki67 in Fig 2E & F. 
**= p<0.01 chow-fed ILKlox/lox vs. chow-fed hepILK-KO  
70 
 
evident. Biliary hyperplasia was demonstrated with immunohistochemistry (IHC) for cytokeratin 
19 (Figure 3.2F & G). Fibrosis was confirmed with Masson’s trichrome staining (Figure 3.2H & I). 
At 6 weeks hepILK-KO mice lack any significant differences in hepatocyte proliferation index 
according to pathologist evaluation and IHC for nuclear Ki-67 (Figure 3.2J & K). 
 Observations at 6 weeks of age demonstrate a role for hepatocyte ILK in glucose 
homeostasis and hepatic organization. Continual basic characterization revealed a normalization 
in weight and body composition of chow-fed hepILK-KO mice at 9 weeks of age (Table 3.2). 
Interestingly, after 3 weeks of HF diet feeding hepILK-KO mice were resistant to obesogenic 
weight gain. HF feeding for 3 weeks only resulted in ~12% weight increase of hepILK-KO mice 
compared to a ~25% increase in control mice (Table 3.2).  Despite normalizations in body weight 
and composition of chow-fed hepILK-KO mice OGTT AUCs remained significantly decreased at 
9 weeks of age (Figure 3.3B) with a trend toward decreased fasting glucose levels as well (Table 
3.2). Accompanying the resistance to weight gain in HF-fed hepILK-KO mice was a resistance to 
fasting hyperglycemia and hyperinsulinemia (Table 3.2). OGTT AUCs were not significantly 
different, but trended lower in the HF-fed hepILK-KO mice as well (Figure 3.3E; p=0.07). 
 12 week old chow-fed hepILK-KO mice have no differences in body weight or fat mass % 
(Table 3.3). These mice do possess a small but significant increase in lean mass as a percentage 
of body weight. OGTTs in chow-fed mice reveal no remaining differences in fasting glucose (Table 
3.3) or glucose tolerance in hepILK-KO mice (Figure 3.3G-I). This represents a near complete 
normalization in body composition and glucose homeostasis in chow-fed hepILK-KO mice relative 
to ILKlox/lox counterparts. HF-fed hepILK-KO mice maintain a resistance to obesogenic weight gain 
at 12 weeks of age. Despite protection from obesity, hepILK-KO mice demonstrated an equivalent 
induction of hyperglycemia, hyperinsulinemia, and glucose intolerance by HF feeding. This 
represents an atypical pathologic progression in hepILK-KO mice as they are metabolically 
equivalent to obese ILKlox/lox mice, but resistant to obesogenic weight gain.   
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Table 3.2- Basic characterization of control (ILKlox/lox) and hepILK-KO mice at 9 weeks of 
age after a 5 hour fast. 
Diet Chow Chow HF HF 
Gentoype ILKlox/lox hepILK-KO ILKlox/lox hepILK-KO 
N 17 7 4-13 7-11 
Weight (g) 24.7±0.5 23.4±0.6 30.0±0.6 26.3±0.7** 
Fat mass (%) 4.7±0.3 5.1±0.5 13.2±0.2 10.0±0.8 
Lean mass (%) 68.1±0.4 68.3±1.2 65.5±1.9 67.5±0.7 
Study age (wks) 9 9 9 9 
Diet duration (wks) - - 3 3 
FBG (mg/dL) 137±5.0 113±7.3 181±10.6 145±7.3‡ 
FPI (ng/mL) 0.6±0.04 0.5±0.09 1.4±0.18 0.7±0.11‡ 
 
Table 3.3- Basic characterization of control (ILKlox/lox) and hepILK-KO mice at 12 weeks of 
age after a 5 hour fast. 
Diet Chow Chow HF HF 
Gentoype ILKlox/lox hepILK-KO ILKlox/lox hepILK-KO 
N 13-15 7-9 4-9 8-11 
Weight (g) 27.2±0.7 25.6±0.6 36.3±0.9 31.8±1.1† 
Fat mass (%) 6.0±0.5 5.4±0.5 21.8±2.0 17.9±2.2 
Lean mass (%) 67.1±0.4 69.3±0.4* 58.3±1.6 61.2±1.4 
Study age (wks) 12 12 12 12 
Diet duration (wks) - - 6 6 
FBG (mg/dL) 142±3.2 120±8.9 185±9.1 159±11.0 
FPI (ng/mL) 0.6±0.06 0.5±0.06 2.5±0.33 2.1±0.45 
 
Data are mean ± SEM. p-values are the result of 1-way ANOVA with Brown-Forsythe and Welch correction. 
*= p<0.05 chow-fed ILKlox/lox vs. chow-fed hepILK-KO; **= p<0.01 chow-fed ILKlox/lox vs. chow-fed hepILK-
KO; # = p<0.001 chow-fed ILKlox/lox vs. chow-fed hepILK-KO; †= p=0.05 HF-fed ILKlox/lox vs. HF-fed hepILK-
KO; ‡= p<0.01 HF-fed ILKlox/lox vs. HF-fed hepILK-KO; Ω=p<0.001 HF-fed ILKlox/lox vs. HF-fed hepILK-KO 
FBG and FPI are fasting blood glucose and fasting plasma insulin, respectively. 
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Figure 3.3- Glucose homeostasis normalizes over time in the absence of hepatocyte ILK.  
A) Blood glucose levels of 9 week old ILKlox/lox (n=17) and hepILK- KO (n=7) mice on chow diet 
during OGTTs. B)  Baseline corrected area under the glucose curve (A) C) Insulin levels during 
OGTTs. D) Blood glucose levels of 9 week old ILKlox/lox (n=8) and hepILK- KO (n=10) mice on HF 
diet during OGTTs. E)  Baseline corrected area under the glucose curve (A) F) Insulin levels 
during OGTTs. G) Blood glucose levels of 12 week old ILKlox/lox (n=15) and hepILK- KO (n=7) 
mice on chow diet during OGTTs. H)  Baseline corrected area under the glucose curve (A) I) 
Insulin levels during OGTTs. J) Blood glucose levels of 12 week old ILKlox/lox (n=9) and hepILK- 
KO (n=11) mice on HF diet during OGTTs. K)  Baseline corrected area under the glucose curve 
(A) L) Insulin levels during OGTTs. *=p<0.05 Chow ILKlox/lox vs. Chow hepILK-KO. *= p<0.05 
chow-fed ILKlox/lox vs. chow-fed hepILK-KO. 
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Physical and glucoregulatory responses were again performed at 18 weeks of age. 
Physical evaluation of chow-fed ILKlox/lox and hepILK-KO mice revealed no significant differences 
to weight or body composition (Table 3.4). HF-fed mice were also lacking in significant weight or 
body composition differences. This was the first time HF-fed hepILK-KO mice did not demonstrate 
a resistance to weight gain relative to ILKlox/lox littermates. Therefore, between 12 weeks of age (6 
weeks of HF feeding) and 18 weeks of age (12 weeks of HF feeding) hepILK-KO mice are no 
longer resistant to obesity induced by HF feeding. Evaluation of glucose homeostasis did not 
reveal significant differences in fasting glucose, fasting insulin, glucose tolerance, or insulin 
responses of hepILK-KO mice on chow or HF diet relative to ILKlox/lox littermates.  
Despite loss of physical and metabolic differences between hepILK-KO and control mice 
within dietary groups at 18 weeks of age there has been a clear difference in the trajectory leading 
to this point of convergence. Therefore, a parallel histological follow up was performed. Histologic 
evaluations were performed on livers from 18 week old ILKlox/lox and hepILK-KO mice maintained 
on chow diet or switched to a HF diet at 3 weeks of age (+3 weeks of HF diet feeding; Figure 3.1). 
Veterinary pathologist revealed  clear indices of biliary hyperplasia in 18 week old chow-fed 
hepILK-KO mice compared to ILKlox/lox littermates (Figure 3.4G & H). Interestingly limited 
inflammation and a distinct lack of fibrosis were demonstrated in 18 week old hepILK-KO livers. 
This indicated a complete recession of fibrosis and improved inflammatory status compared to 6 
week old hepILK-KO mouse livers (3.1D-K). However, hepILK-KO livers did with hepatocyte 
hyperplastic phenotypes, which resulted in adenoma formation in ~40% of samples (Figure 3.4H 
blue circle). Livers from HF-fed ILKlox/lox mice presented with a typical pattern of steatosis. This is 
consistent with an early NAFLD phenotype, which would be expected in a setting of obesity, 
glucose intolerance, and insulin resistance. Opposing this observation was a near lack of 
steatosis in liver from HF-fed hepILK-KO mice (Figure 3.4J). This further emphasizes the 
differential responses of hepILK-KO mice to obesity. Despite a near complete coalescence of 
physical and metabolic phenotypes of hepILK-KO mice, they maintain a clear difference in hepatic  
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Table 3.4- Basic characterization of control (ILKlox/lox) and hepILK-KO mice at 18 weeks of 
age after a 5 hour fast. 
Diet Chow Chow HF HF 
Gentoype ILKlox/lox hepILK-KO ILKlox/lox hepILK-KO 
N 10-15 6-7 9 10 
Weight (g) 30.4±0.7 30.1±0.8 49.0±1.3 44.3±1.4 
Fat mass (%) 6.7±0.8 5.6±0.7 32.1±4.7 29.9±1.9 
Lean mass (%) 66.0±0.7 67.6±1.0 50.4±1.7 52.7±1.6 
Study age (wks) 18 18 18 18 
Diet duration (wks) - - 12 12 
FBG (mg/dL) 145±3.4 135±7.1 209±21.3 185±14.0 
FPI (ng/mL) 0.6±0.06 0.7±0.14 10.9±1.4 7.4±0.1.4 
 
Data are mean ± SEM. p-values are the result of 1-way ANOVA with Brown-Forsythe and Welch correction. 
*= p<0.05 chow-fed ILKlox/lox vs. chow-fed hepILK-KO; **= p<0.01 chow-fed ILKlox/lox vs. chow-fed hepILK-
KO; # = p<0.001 chow-fed ILKlox/lox vs. chow-fed hepILK-KO; †= p=0.05 HF-fed ILKlox/lox vs. HF-fed hepILK-
KO; ‡= p<0.01 HF-fed ILKlox/lox vs. HF-fed hepILK-KO; Ω=p<0.001 HF-fed ILKlox/lox vs. HF-fed hepILK-KO 
FBG and FPI are fasting blood glucose and fasting plasma insulin, respectively. 
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Figure 3.4- ILK contributes to steatosis formation during obesity independent of glucose 
tolerance. A) Blood glucose levels of 18 week old ILKlox/lox (n=15) and hepILK- KO (n=7) mice on 
chow diet during OGTTs. B)  Baseline corrected area under the glucose curve (A) C) Insulin levels 
during OGTTs. D) Blood glucose levels of 18 week old ILKlox/lox (n=9) and hepILK- KO (n=10) mice 
on HF diet during OGTTs. E)  Baseline corrected area under the glucose curve (A) F) Insulin 
levels during OGTTs. G) Representative H&E stained liver micrographs at 20x magnification from 
18 week old chow-fed ILKlox/lox mice. H) Representative H&E stained liver micrographs at 20x 
magnification from 18 week old chow-fed hepILK-KO mice. Adenoma is designated by dashed 
blue border. I) Representative H&E stained liver micrographs at 20x magnification from 18 week 
old HF-fed ILKlox/lox mice. J) Representative H&E stained liver micrographs at 20x magnification 
from 18 week old HF-fed hepILK-KO mice. 
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histology related to lipid deposition. Overall, hepILK-KO mice appear to have a very distinct 
response to a relatively extended HF diet exposure.  
At 32 weeks of age no significant differences in physical characteristics, fasting glucose, 
or fasting insulin were observed between hepILK-KO or ILKlox/lox mice regardless of diet (Table 
3.5). As mice fed a HF diet for 26 weeks are quite obese and glucose intolerant it was necessary 
to alter the experimental design for OGTTs in these mice. Specifically, glucometers are not 
sensitive at glucose concentration >600 mg/dl. Pilot studies with the standard dose had used 
(2.0mg of glucose/ g body weight) exceed the range of the glucometer. Therefore, the glucose 
dosage was reduced by 75% (1.5mg of glucose/ g body weight) was used. hepILK-KO mice 
presented with a similar level of glucose tolerance to ILKlox/lox littermates on both diets (Figure 3.5). 
Possibly indicative of sustained insulin sensitivity was a trend toward a lower insulin peak 
response in HF-fed hepILK-KO mice compared to HF-fed ILKlox/lox controls (Figure 3.5F). This is 
consistent with previous findings from our lab indicating a protective effect of hepILK-KO against 
hepatic insulin resistance in obese mice (280). 
Histologic evaluation of livers from 32 week old chow and HF-fed mice were performed as 
a comparison to analyses performed at 6 and 18 weeks of age. As had been observed at 6 and 
18 weeks of age, livers from chow-fed hepILK-KO mice displayed prominent biliary hyperplasia, 
but were absent of any other characteristics (Figure 3.6A-F; 3.7A-H). This indicates a continued 
recession of fibrosis and a loss of inflammatory phenotypes previously observed at earlier ages, 
despite excessive ductular reactions. HF diet-induced steatosis was prominently displayed in 
ILKlox/lox liver in a relatively organized pattern within zones 1 and 2 of the hepatic lobule (Figure 
3.6 G-I; 3.7O). Livers of HF-fed 32 week old hepILK-KO mice were remarkably steatotic with some 
differences in vacuole size and a prominent azonal organization of lipid depostition (Figure 3.6J-
L; 3.7P). This represents a remarkable shift of hepatic phenotype of HF-fed hepILK-KO mice 
between 18 and 32 weeks of age. Thus, over the course of 14 weeks hepILK-KO mice have 
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Table 3.5- Basic characterization of control (ILKlox/lox) and hepILK-KO mice at 32 weeks of 
age after a 5 hour fast. 
Diet Chow Chow HF HF 
Gentoype ILKlox/lox hepILK-KO ILKlox/lox hepILK-KO 
N 16-18 4-9 9-12 7-9 
Weight (g) 34.8±0.9 32.8±1.5 52.4±1.7 53.8±0.8 
Fat mass (%) 11.5±1.3 7.7±2.0 33.3±1.0 33.2±0.4 
Lean mass (%) 63.8±1.0 66.5±1.4 53.3±0.9 50.6±0.4 
Study age (wks) 32 32 32 32 
Diet duration (wks) - - 26 26 
FBG (mg/dL) 134±4.2 124±8.3 148±10.1 179±14.3 
FPI (ng/mL) 0.9±0.20 1.1±0.52 8.7±1.1 9.8±1.1 
 
Data are mean ± SEM. p-values are the result of 1-way ANOVA with Brown-Forsythe and Welch correction. 
*= p<0.05 chow-fed ILKlox/lox vs. chow-fed hepILK-KO; **= p<0.01 chow-fed ILKlox/lox vs. chow-fed hepILK-
KO; # = p<0.001 chow-fed ILKlox/lox vs. chow-fed hepILK-KO; †= p=0.05 HF-fed ILKlox/lox vs. HF-fed hepILK-
KO; ‡= p<0.01 HF-fed ILKlox/lox vs. HF-fed hepILK-KO; Ω=p<0.001 HF-fed ILKlox/lox vs. HF-fed hepILK-KO 
FBG and FPI are fasting blood glucose and fasting plasma insulin, respectively. 
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Figure 3.5- Hepatocyte ILK does not affect glucose tolerance after extended aging or 
exposure to obesity, but may limit insulin resistance. A) Blood glucose levels of 32 week old 
ILKlox/lox (n=18) and hepILK- KO (n=7) mice on chow diet during OGTTs. B)  Baseline corrected 
area under the glucose curve (A) C) Insulin levels during OGTTs. D) Blood glucose levels of 32 
week old ILKlox/lox (n=12) and hepILK- KO (n=9) mice on HF diet during OGTTs. E)  Baseline 
corrected area under the glucose curve (A) F) Insulin levels during OGTTs.   
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“caught up” to ILKlox/lox littermates in terms of lipid deposition, but display a different pattern of 
steatotic progression.  
 
Hepatocyte ILK determines the transcriptional program of the liver 
Given the difference in glucose homeostasis of 6 and 18 week old hepILK-KO mice on 
chow or HF diet we hypothesized specific differences in hepatic transcriptional profiles relating to 
metabolic functions at these ages. To assess overall sample grouping, similarities, and 
dissimilarities a multi-dimensional scaling analysis was performed on the transcriptome data from 
all groups (Figure 3.8). This revealed a pattern consistent with our glucose tolerance and histology 
data. 6 week old hepILK-KO mice were quite distinct transcriptionally from their control littermates. 
While 18 week old chow-fed hepILK-KO mice were quite similar to their control counterparts if 
exposed to HF diet differences in transcriptional profiles became more evident. Quantification of 
differentially expressed genes from whole livers of 5 hour fasted, 6 week old ILKlox/lox and hepILK-
KO mice revealed a large number (n=6437; 3258=up; 3159=down) of significantly different genes 
in hepILK-KO livers (Figure 3.9) representing broad alterations in transcriptional profiles.  
To evaluate any thematic connections in this considerable difference in transcriptional 
milieu two types of analyses were performed. The first is a gene ontology (GO) analysis. This is 
a classification system whereby gene products are assigned a functional connotation based on 
their documented involvement in biological processes (BPs), molecular functions (MFs), or as 
cellular components (CCs). Additionally, specific gene ontologies describe broad aspects of 
cellular biology. Therefore this analysis can offer insight in to connections between a diverse set 
of individual transcripts. GO analysis of genes that were significantly different in 6 week old 
hepILK-KO livers offered results consistent with our initial hypothesis regarding transcriptional 
programming of metabolic processes (Table 3.6). Specifically, Aspects of mitochondria and 
oxidative metabolic processes were highly downregulated in hepILK-KO livers. In line with our 
genetic manipulation of the ECM-integrin signaling system were significant increases in GOs  
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Figure 3.6- ILK determines zonation and organization of steatosis during extended HF diet 
feeding. A-C) Representative H&E stained liver micrographs at 10x (A) and 20x (B & C) 
magnification from 32 week old chow-fed ILKlox/lox mice. D-F) Representative H&E stained liver 
micrographs at 10x (D) and 20x (E & F) magnification from 32 week old chow-fed hepILK-KO 
mice. G-I) Representative H&E stained liver micrographs at 10x (G) and 20x (H & I) magnification 
from 32 week old HF-fed ILKlox/lox mice. J-L) Representative H&E stained liver micrographs at 10x 
(J) and 20x (K & L) magnification from 32 week old HF-fed hepILK-KO mice. Scale bar = 100 µm.  
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Figure 3.7- Biliary hyperplasia persists and steatosis is confirmed as azonal lipid 
deposition in the absence of hepatocyte ILK. A-H) Representative CK19 IHC liver micrographs 
at 10x (A,C,E,G) and 20x (B,D,F,H )magnification from 32 week old ILKlox/lox (A,B,E,F) or hepILK-
KO (C,D,G,H) mice maintained on a chow (A-D) or HF (E-H) diet. I-L) Representative Ki67 IHC 
liver micrographs at 20x magnification from 32 week old ILKlox/lox (I,J) or hepILK-KO (K,L) mice 
maintained on a chow (I,K) or HF (J,L) diet. M-P) Representative adipophilin IHC with periodic 
acid Schiff co-stained liver micrographs at 20x magnification from 32 week old ILKlox/lox (M,O) or 
hepILK-KO (N,P) mice maintained on a chow (M,N) or HF (O,P) diet. Scale bar = 100 µm. 
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relating to cellular organization and interactions with the ECM. Kyoto encyclopedia or genes and 
genomes (KEGG) also curates a database of pathways representative of cellular processes and 
interactions in relation to health and disease. These pathways are somewhat more conceptually 
oriented. KEGG pathway analysis demonstrated upregulation of pathways related to integrin 
interactions and cell adhesion molecules, which is consistent with GO analyses (Table 3.7). 
Further support for the metabolic underpinnings of altered glucose homoeostasis in hepILK-KO 
mice at this age were significant downregulation of metabolic pathways including oxidative 
phosphorylation. 
Consistent with the immense convergence of physical and metabolic characteristic of 
hepILK-KO mice with ILKlox/lox littermates between 6 and 18 weeks of age transcriptional profiles 
are largely similar in 18 week old chow-fed animals (Figure 3.9). RNA-sequencing of livers from 
5 hour fasted, 18 week old ILKlox/lox and hepILK-KO mice showed far fewer differentially expressed 
genes (n=665; 263=up; 402=down) and the magnitude of differential expression was considerably 
less (Figure 3.9). With considerably fewer differences in transcriptional profiles the magnitude of 
overrepresentation in GO terms were considerably decreased (p-values of 3E-12 or greater vs. 
p-values of 3E-150 or greater in 6 week chow-fed GO analyses) (Tables 3.6 & 3.8). Despite 
decreased magnitude of transcriptional differences enrichment of GO terms remained fairly 
consistent compared with 6 week chow-fed mice. Upregulated GO terms encompassed aspects 
of the extracllular space and cellular interactions with this space. While downregulated GO terms 
were primarily indicative of metabolic shifts aspects of proteasomal function and proteins 
metabolism were more obvious in these mice. Only 10 KEGG pathways were detected as 
significant (p-value <0.001; 2 increased and 8 decreased) in the 18 week old chow-fed hepILK-
KO mice. The focal adhesion pathway was one of the only increased pathways, which is likely 
due to feedback mechanism whereby cells are attempting to restore focal adhesion stability and 
function in the absence of ILK. The glucagon signaling KEGG pathway was significantly 
decreased in hepILK-KO livers from this comparison. We did not observe any differecens in  
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Figure 3.8- RNA seq results produce consistent grouping during multi-dimensional scaling 
(MDS) analysis. This chart spatially represents the similarity and dissimilarity relationships 
between the samples analyzed for RNA seq.  
  
84 
 
 
Figure 3.9- Volcano plot of quantified transcripts via RNA-seq analysis of liver from 6 week 
old chow-fed ILKlox/lox and hepILK-KO mice.  Genes that were non-significantly altered between 
the two groups are indicated in black circles. Genes that were significantly increased 
(“upregulated”) in hepILK-KO mice compared to controls are indicated in blue circles. Genes that 
were significantly decreased (“downregulated”) in hepILK-KO mice compared to controls are 
indicated in red circles. The number of genes present in each category are indicated next to the 
distinguished category within the legend.  
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Table 3.6- Significantly increased and decreased GO terms in 6 week old chow-fed hepILK-
KO mice. 
Acc. Number Term Ont p.Up 
GO:0071944 cell periphery CC 5.55E-104 
GO:0005886 plasma membrane CC 2.61E-96 
GO:0023052 signaling BP 2.92E-77 
GO:0007165 signal transduction BP 1.70E-72 
GO:0007154 cell communication BP 1.72E-72 
GO:0050896 response to stimulus BP 3.22E-71 
GO:0007155 cell adhesion BP 2.04E-65 
GO:0022610 biological adhesion BP 7.52E-65 
GO:0044459 plasma membrane part CC 2.86E-64 
GO:0051716 cellular response to stimulus BP 7.44E-59 
GO:0048583 regulation of response to stimulus BP 1.58E-56 
GO:0032501 multicellular organismal process BP 1.50E-54 
GO:0002376 immune system process BP 1.94E-54 
GO:0006928 movement of cell or subcellular component BP 1.08E-53 
GO:0051239 regulation of multicellular organismal process BP 3.99E-53 
Acc. Number Term Ont p.Down 
GO:0005739 mitochondrion CC 2.40E-150 
GO:0044429 mitochondrial part CC 6.05E-125 
GO:0098798 mitochondrial protein complex CC 7.52E-103 
GO:0005743 mitochondrial inner membrane CC 1.01E-96 
GO:0019866 organelle inner membrane CC 1.08E-86 
GO:0031966 mitochondrial membrane CC 3.93E-86 
GO:0005740 mitochondrial envelope CC 2.76E-85 
GO:0044455 mitochondrial membrane part CC 1.24E-69 
GO:0055114 oxidation-reduction process BP 3.12E-67 
GO:0005759 mitochondrial matrix CC 1.31E-58 
GO:0044281 small molecule metabolic process BP 1.34E-58 
GO:0098800 inner mitochondrial membrane protein complex CC 2.49E-57 
GO:0031967 organelle envelope CC 1.39E-54 
GO:0031975 envelope CC 1.39E-54 
GO:0016491 oxidoreductase activity MF 2.43E-48 
 
The top 15 significantly altered GO terms with overrepresentation of increased (Top half) and 
decreased genes (Bottom half) in chow-fed 6 week old, 5 hour fasted hepILK-KO livers. Acc. 
Number = gene ontology accession number. Term= GO term. BP= Biological process. CC= 
Cellular component. MF= Molecular function. Ont= general gene ontology. p.Up= p-value for 
overrepresentation of increased genes in GO term. p.Down= p-value for overrepresentation of 
decreased genes in GO term. 
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Table 3.7- Significantly increased and decreased KEGG pathways in 6 week old chow-fed 
hepILK-KO mice. 
Acc. Number Pathway P.Up 
path:mmu04514 Cell adhesion molecules (CAMs) 5.80E-16 
path:mmu04512 ECM-receptor interaction 7.54E-15 
path:mmu04060 Cytokine-cytokine receptor interaction 7.54E-15 
path:mmu04510 Focal adhesion 6.13E-14 
path:mmu04810 Regulation of actin cytoskeleton 4.45E-13 
path:mmu04640 Hematopoietic cell lineage 6.33E-11 
path:mmu05140 Leishmaniasis 1.87E-10 
path:mmu05414 Dilated cardiomyopathy (DCM) 2.85E-10 
path:mmu04145 Phagosome 2.93E-10 
path:mmu04360 Axon guidance 4.85E-10 
path:mmu05410 Hypertrophic cardiomyopathy (HCM) 5.10E-10 
path:mmu05323 Rheumatoid arthritis 7.59E-10 
path:mmu05412 Arrhythmogenic right ventricular cardiomyopathy 1.54E-09 
path:mmu04062 Chemokine signaling pathway 4.03E-09 
Acc. Number Pathway P.Down 
path:mmu01100 Metabolic pathways 1.79E-49 
path:mmu00190 Oxidative phosphorylation 1.21E-35 
path:mmu05012 Parkinson disease 1.29E-34 
path:mmu04714 Thermogenesis 8.31E-28 
path:mmu04932 Non-alcoholic fatty liver disease (NAFLD) 4.84E-23 
path:mmu05010 Alzheimer disease 6.60E-23 
path:mmu05016 Huntington disease 6.97E-20 
path:mmu04146 Peroxisome 7.48E-20 
path:mmu00280 Valine, leucine and isoleucine degradation 1.44E-18 
path:mmu03050 Proteasome 1.25E-11 
path:mmu00140 Steroid hormone biosynthesis 3.74E-11 
path:mmu01200 Carbon metabolism 8.63E-11 
path:mmu03010 Ribosome 3.51E-10 
path:mmu04723 Retrograde endocannabinoid signaling 6.94E-10 
path:mmu00630 Glyoxylate and dicarboxylate metabolism 1.81E-09 
 
The top 15 significantly altered KEGG pathways with overrepresentation of increased (Top half) 
and decreased genes (Bottom half) in chow-fed 6 week old, 5 hour fasted hepILK-KO livers. Acc. 
Number = KEGG pathways accession number. p.Up= p-value for overrepresentation of increased 
genes in KEGG pathway. p.Down= p-value for overrepresentation of decreased genes in KEGG 
pathway. 
  
87 
 
glucose tolerance for hepIL-KO mice at this age on a chow diet and previous studies indicated no 
differences in insulin sensitivity of chow-fed mice at this age. However, as hyper-functionality of 
the glucagon pathways is known to contribute to aspects of hyperglycemia, insulin resistance,  
and T2D (264) development while hepILK-KO mice at this age are protected from hepatic insulin 
resistance. A relatively blunted capacity for glucagon action may contribute to a protection from 
hepatic insulin resistance in these mice. 
 18 week old ILKlox/lox and hepILK-KO mice fed a HF diet present with considerable amounts 
of obesity and glucose intolerance compared to chow-fed groups, but were not significantly 
different from each other (Figure 3.3). Despite these similarities HF-fed hepILK-KO mice at this 
age were relatively protected from hepatic steatosis. In line with differential hepatic phenotypes 
in hepILK-KO mice on a HF diet RNA-seq revealed considerably different transcriptional profiles 
of hepILK-KO mice compared to ILKlox/lox mice on a HF diet (Figure 3.10).  While hepatic 
transcriptional profiles of 18 week old hepILK-KO and ILKlox/lox mice fed a HF diet were not as 
starkly different as 6 week old mice they were considerably more differential gene expression 
(n=1554; 804=up; 750=down) than chow-fed comparisons. GO analysis maintained the trend of 
upregulated enrichment of extracellular matrix and adhesion related terms (Table 3.10). Also 
present were a number of ribosomal components and processes indicating possible shifts in 
protein synthesis. Downregulated terms were primarily related to energy metabolism, but 
autophagy and organelle organization were also present. KEGG pathway analysis confirmed 
altered pathways relating to energy metabolism to be downregulated and aspects of cellular 
adhesion to be upregulated. Interestingly the pathway for PI3K-Akt signaling was also upregulated 
(Table 3.11). As these mice are known to have maintained hepatic insulin sensitivity on a HF diet 
(280) it is possible that maintained or elevated function of this pathway relative to HF-fed ILKlox/lox 
counterparts may contribute to this protection.  
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Figure 3.10- Volcano plot of quantified transcripts via RNA-seq analysis of liver from 18 
week old chow-fed ILKlox/lox and hepILK-KO mice. Genes that were non-significantly altered 
between the two groups are indicated in black circles. Genes that were significantly increased 
(“upregulated”) in hepILK-KO mice compared to controls are indicated in blue circles. Genes that 
were significantly decreased (“downregulated”) in hepILK-KO mice compared to controls are 
indicated in red circles. The number of genes present in each category are indicated next to the 
distinguished category within the legend. 
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Table 3.8 - Significantly increased and decreased GO terms in 18 week old chow-fed 
hepILK-KO mice. 
Acc. Number Term Ont P.Up 
GO:0005576 extracellular region CC 5.23E-07 
GO:0030018 Z disc CC 2.28E-06 
GO:0005615 extracellular space CC 2.29E-06 
GO:0043292 contractile fiber CC 3.13E-06 
GO:0009986 cell surface CC 3.24E-06 
GO:0031674 I band CC 4.56E-06 
GO:0009966 regulation of signal transduction BP 4.98E-06 
GO:0044421 extracellular region part CC 5.57E-06 
GO:0051049 regulation of transport BP 5.89E-06 
GO:0030016 myofibril CC 6.76E-06 
GO:0032879 regulation of localization BP 7.69E-06 
GO:0023052 signaling BP 9.21E-06 
GO:0005886 plasma membrane CC 1.00E-05 
GO:0030017 sarcomere CC 1.13E-05 
GO:0010959 regulation of metal ion transport BP 1.27E-05 
Acc. Number Term Ont P.Down 
GO:0043170 macromolecule metabolic process BP 2.55E-12 
GO:0005634 nucleus CC 6.85E-12 
GO:0006464 cellular protein modification process BP 1.20E-11 
GO:0036211 protein modification process BP 1.20E-11 
GO:0044260 cellular macromolecule metabolic process BP 2.56E-11 
GO:0043412 macromolecule modification BP 5.84E-11 
GO:0044267 cellular protein metabolic process BP 2.28E-10 
GO:0140096 catalytic activity, acting on a protein MF 4.02E-10 
GO:0004842 ubiquitin-protein transferase activity MF 8.89E-10 
GO:0005654 nucleoplasm CC 1.07E-09 
GO:0070647 protein modification by small protein conjugation 
or removal 
BP 1.70E-09 
GO:0019787 ubiquitin-like protein transferase activity MF 3.10E-09 
GO:0016567 protein ubiquitination BP 5.84E-09 
GO:0019538 protein metabolic process BP 2.20E-08 
GO:0090304 nucleic acid metabolic process BP 2.33E-08 
 
The top 15 significantly altered GO terms with overrepresentation of increased (Top half) and 
decreased genes (Bottom half) in chow-fed 18 week old, 5 hour fasted hepILK-KO livers. Acc. 
Number = gene ontology accession number. Term= GO term. BP= Biological process. CC= 
Cellular component. MF= Molecular function. Ont= general gene ontology. p.Up= p-value for 
overrepresentation of increased genes in GO term. p.Down= p-value for overrepresentation of 
decreased genes in GO term. 
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Table 3.9- Significantly increased and decreased KEGG pathways in 18 week old chow-fed 
hepILK-KO mice. 
Acc. Number Pathway P.Up 
path:mmu04510 Focal adhesion 0.00015 
path:mmu04974 Protein digestion and absorption 0.00049 
Acc. Number Pathway P.Down 
path:mmu04120 Ubiquitin mediated proteolysis 1.21E-08 
path:mmu05166 Human T-cell leukemia virus 1 infection 0.0004 
path:mmu04720 Long-term potentiation 0.00057 
path:mmu04010 MAPK signaling pathway 0.0007 
path:mmu04922 Glucagon signaling pathway 0.00085 
path:mmu04662 B cell receptor signaling pathway 0.00089 
path:mmu01522 Endocrine resistance 0.00093 
path:mmu05161 Hepatitis B 0.00096 
 
Significantly altered (p-value <0.001) KEGG pathways with overrepresentation of increased (Top) 
and decreased genes (Bottom) in chow-fed 18 week old, 5 hour fasted hepILK-KO livers. Acc. 
Number = KEGG pathways accession number. p.Up= p-value for overrepresentation of increased 
genes in KEGG pathway. p.Down= p-value for overrepresentation of decreased genes in KEGG 
pathway. 
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Discussion 
ILK is a central hub of integrin signaling associated with cellular motility, organization, and 
adhesion to the ECM (212). Recently ECM and downstream integrin signaling systems have been 
associated with metabolically driven pathologies including insulin resistance, NAFLD, and T2D 
(152, 278). Previous studies demonstrated a role for ILK in the progression of hepatic insulin 
resistance during diet induced obesity (280). ILK is also a critical mediator of hepatic organization, 
injury response, transcription, and signaling (7, 17, 63, 65, 86). However, these functions of ILK 
are highly influenced by age (86). Studies linking ILK to hepatic insulin resistance focused on an 
individual time point. Metabolic stress and insulin resistance that are promoted by the obesogenic 
model are inherently dependent on age and length of diet exposure (77, 175). As ILK function is 
known to affect hepatic outcomes in an age-dependent manner it was necessary to assess the 
role of age in contributions of hepatocyte ILK to metabolic homeostasis and obesity related 
pathologic progression.  
These studies demonstrate a clear effect of hepILK-KO on metabolism and glucose 
homeostasis early in life. These effects are age-dependent, but lead to differences in metabolic 
and pathologic trajectories throughout the life of the mouse. At 6 weeks of age hepILK-KO mice 
demonstrated a significant decrease in blood glucose and plasma insulin after a 5 hour fast. Lower 
insulin levels are indicative of an intact physiologic feedback response to decreased circulating 
glucose. Oral glucose tolerance was significantly increased even when accounting for decreased 
fasting glucose concentrations. Postabsorptive circulating glucose is primarily maintained through 
hepatic glucose production to meet glucose utilization requirements throughout the body (266).  
Given the hepatocyte-specific nature of our knockout a difference in hepatic capacity for glucose 
provision from glycogen or gluconeogenesis is hypothesized to underlie decreased circulating 
glucose. Increased glucose utilization may also drive decreased fasting glucose and increased 
glucose tolerance. While this is a hepatocyte-specific knockout the liver is known to communicate  
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Figure 3.11- Volcano plot of quantified transcripts via RNA-seq analysis of liver from 18 
week old HF-fed ILKlox/lox and hepILK-KO mice. Genes that were non-significantly altered 
between the two groups are indicated in black circles. Genes that were significantly increased 
(“upregulated”) in hepILK-KO mice compared to controls are indicated in blue circles. Genes that 
were significantly decreased (“downregulated”) in hepILK-KO mice compared to controls are 
indicated in red circles. The number of genes present in each category are indicated next to the 
distinguished category within the legend. 
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Table 3.10- Significantly increased and decreased GO terms in 18 week old HF-fed hepILK-
KO mice. 
Acc. Number Term Ont P.Up 
GO:0022626 cytosolic ribosome CC 1.12E-31 
GO:0005198 structural molecule activity MF 1.26E-26 
GO:0007155 cell adhesion BP 4.97E-24 
GO:0044421 extracellular region part CC 6.25E-24 
GO:0022610 biological adhesion BP 1.28E-23 
GO:0022625 cytosolic large ribosomal subunit CC 7.75E-23 
GO:0031012 extracellular matrix CC 5.12E-22 
GO:0005576 extracellular region CC 5.62E-22 
GO:0003735 structural constituent of ribosome MF 7.20E-22 
GO:0071944 cell periphery CC 7.63E-20 
GO:0005615 extracellular space CC 2.90E-19 
GO:0044391 ribosomal subunit CC 4.18E-19 
GO:0005886 plasma membrane CC 1.43E-18 
GO:0005840 ribosome CC 3.08E-17 
GO:0007154 cell communication BP 1.38E-16 
Acc. Number Term Ont P.Down 
GO:0012505 endomembrane system CC 5.53E-08 
GO:0044248 cellular catabolic process BP 4.46E-06 
GO:0003824 catalytic activity MF 7.85E-06 
GO:1901565 organonitrogen compound catabolic process BP 8.86E-06 
GO:0009056 catabolic process BP 1.42E-05 
GO:0007034 vacuolar transport BP 3.26E-05 
GO:0044444 cytoplasmic part CC 4.22E-05 
GO:0030242 autophagy of peroxisome BP 4.49E-05 
GO:0045053 protein retention in Golgi apparatus BP 4.49E-05 
GO:0055114 oxidation-reduction process BP 4.67E-05 
GO:0005794 Golgi apparatus CC 5.00E-05 
GO:0015980 energy derivation by oxidation of organic compounds BP 5.01E-05 
GO:0006112 energy reserve metabolic process BP 6.65E-05 
GO:0017016 Ras GTPase binding MF 7.24E-05 
GO:0051020 GTPase binding MF 7.88E-05 
 
The top 15 significantly altered GO terms with overrepresentation of increased (Top half) and 
decreased genes (Bottom half) in HF-fed 18 week old, 5 hour fasted hepILK-KO livers. Acc. 
Number = gene ontology accession number. Term= GO term. BP= Biological process. CC= 
Cellular component. MF= Molecular function. Ont= general gene ontology. p.Up= p-value for 
overrepresentation of increased genes in GO term. p.Down= p-value for overrepresentation of 
decreased genes in GO term. 
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Table 3.11- Significantly increased and decreased KEGG pathways in 18 week old HF-fed 
hepILK-KO mice. 
Acc. Number Pathway P.Up 
path:mmu03010 Ribosome 4.23E-27 
path:mmu04512 ECM-receptor interaction 1.49E-08 
path:mmu04510 Focal adhesion 3.43E-08 
path:mmu04974 Protein digestion and absorption 7.80E-06 
path:mmu05414 Dilated cardiomyopathy (DCM) 8.37E-06 
path:mmu05410 Hypertrophic cardiomyopathy (HCM) 1.86E-05 
path:mmu04514 Cell adhesion molecules (CAMs) 2.11E-05 
path:mmu04360 Axon guidance 4.59E-05 
path:mmu04810 Regulation of actin cytoskeleton 0.00012 
path:mmu04151 PI3K-Akt signaling pathway 0.00018 
path:mmu04640 Hematopoietic cell lineage 0.00022 
path:mmu05412 Arrhythmogenic right ventricular cardiomyopathy 0.00044 
path:mmu05332 Graft-versus-host disease 0.00069 
path:mmu04672 Intestinal immune network for IgA production 0.0008 
Acc. Number Pathway P.Down 
path:mmu00340 Histidine metabolism 0.00057 
path:mmu00640 Propanoate metabolism 0.00084 
path:mmu04120 Ubiquitin mediated proteolysis 0.001 
 
Significantly altered (p-value <0.001) KEGG pathways with overrepresentation of increased (Top) 
and decreased genes (Bottom) in HF-fed 18 week old, 5 hour fasted hepILK-KO livers. Acc. 
Number = KEGG pathways accession number. p.Up= p-value for overrepresentation of increased 
genes in KEGG pathway. p.Down= p-value for overrepresentation of decreased genes in KEGG 
pathway. 
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with peripheral organs and the central nervous system through several mechanisms (42, 183, 
207). Secretion of the hepatokine FGF21 has been linked to increased energy expenditure (198) 
and carbohydrate utilization (288). Understanding factors affecting hepatic glucoregulation in 
hepILK-KO mice at 6 weeks of age will define the role of ILK in overall hepatic metabolism, but 
also in progression of insulin resistance. Therefore, this topic is explored in depth in the following 
chapter. Histologic evaluation of hepILK-KO livers at 6 weeks of age revealed fibrosis and biliary 
hyperplasia, but a lack of hepatocyte proliferation. Fibrosis and biliary hyperplasia were consistent 
with another hepatic ILK-KO model, but the lack of hepatocyte proliferation diverged from previous 
studies. We attribute this to differences in model design and characteristics discussed later in this 
section.  
Maintaining hepILK-KO mice on a chow diet through 9 and 12 weeks of age revealed a 
gradual resolution of differences in fasting glucose, insulin, and glucose tolerance of hepILK-KO 
mice relative to ILKlox/lox littermates. However, maintaining these mice on a HF diet revealed an 
initial resistance to obesity induced hyperglycemia at 9 weeks and a resistance to weight gain 
during HF feeding through 12 weeks in hepILK-KO mice. The resistance to obesity was interesting 
as chow-fed hepILK-KO animals had completely resolved weight differenes from ILKlox/lox mice on 
a chow diet by 9 weeks of age. Several possibilities may underlie this obesity resistance in 
hepILK-KO mice. Obesity is the result of excess nutrient intake relative to energy expenditure. 
Therefore, obesity resistance may indicate a significant increase in energy expenditure of hepILK-
KO mice and limited accumulation of adipose mass. Conversely a decrease in relative energy 
intake of hepILK-KO mice may also drive a resistance to obesity. Decreased drive for food intake 
would certainly limit the accumulation of excess adiposity in hepILK-KO mice. Alternatively an 
alteration in absorption of calories from food may also underlie a resistance to obesity 
progression. Assessment of energy balance and food intake in hepILK-KO mice would clarify the 
underlying contributors to initial obesity resistance in these mice.  
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 Continuing analyses of chow and HF-fed mice to 18 weeks of age resulted in complete 
loss of any physical or metabolic differences assessed in hepILK-KO and ILKlox/lox mice. Despite 
convergence of these characeristics evaluation of hepatic histologic sections of hepILK-KO mice 
maintained on a chow or HF diet revealed novel phenotypes. Livers of chow-fed mice maintained 
their characteristic biliary hyperplasia, but were devoid of fibrosis. Additionally, hepILK-KO chow 
livers presented with hepatocyte hyperplasia with occasional adenoma formation (~40% of 
samples). Excessive proliferation has been documented in other models of epithelial cell ILK 
knockout from liver and other organs (7, 86, 241). This effect is hypothesized as a loss in contact 
inhibition signals in the absence of ILK likely due to diminished capacity for extracellular 
interaction sensing. Hepatocyte contact inhibition, in particular has been linked to the ability of 
cells to fully differentiate and express enzymes of glucose and lipid metabolism (162).  Therefore, 
loss of contact inhibition may have direct impacts on hepatocyte metabolic function leading to a 
shift in hepatic glucoregulatory capacity.  
Typically, the proliferation of liver epithelial cells in the sinusoidal and/or ductular 
compartments is indicative of an injured state (16, 146, 150). Hepatic injury is often accompanied 
by deposition of ECM and can progress to a pathologic level in fibrosis (139, 171). The alleviation 
of fibrosis in the presence of biliary and hepatocyte hyperplasia is somewhat paradoxical, but may 
indicate a characteristic of livers lacking hepatocyte ILK. Loss of ILK may result in an artificial 
decrease in pericellular ECM sensing by hepatocytes. Healthy livers have a limited ECM 
compartment that interacts with the extensive sinusoidal surface area of hepatocytes (21, 158). 
Therefore, receiving limited ECM signal input in absence of ILK may limit injury responses in 
hepatocytes that are known to further promote tissue damage and fibrosis.  
 In assessing livers of HF-fed hepILK-KO mice a distinct lack of steatosis was observed 
when compared to ILKlox/lox mice. This lack of steatosis occurs in the absence of any differences 
in obesity or glucose homeostasis. Additionally hepatocyte proliferation and adenoma formation 
were absent in all except one HF-fed hepILK-KO liver. While chow-fed livers of hepILK-KO mice 
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are hyperproliferative this is corrected in the presence of HF feeding. There is precedent for 
overnutrition to limit hepatocyte proliferation, but these states were often linked to hepatic lipid 
content and steatosis (54, 116, 153, 249). Perhaps relevant to our hepILK-KO model however is 
the known effect of hyper or euglycemia on limiting hepatic regenerative responses (117). While 
this is not a model of regeneration per se hyperglycemia may act independently within the liver to 
limit proliferative drive resulting in a beneficial effect for a model with hepatocyte hyperplasia and 
adenoma.  
Progressing the mice to 32 weeks of age reinforces the metabolic and physiologic 
convergence of hepILK-KO mice with ILKlox/lox littermates regardless of diet. Histologically, 
hepILK-KO mice continue to present with biliary hyperplasia on a chow diet. Opposing the lack of 
steatosis at 18 weeks of age in HF-fed hepILK-KO mice, 32 week old (26 weeks of HF feeding) 
hepILK-KO mice present with an equivalent or greater amount of steatosis compared to ILKlox/lox 
mice. This represents a complete loss of steatotic protection between 18 and 32 weeks of age. In 
addition to the novel steatosis in hepILK-KO mice the lipid deposition patterning is deposited 
throughout the liver with no zonal preferences. ILKlox/lox mice maintain a zonal organization of lipid 
deposition with limited steatosis in hepatic zone 1. This is a typical phenotype in NAFLD as the 
zone 1 hepatocytes are exposed to higher oxygen content and engaging oxidative metabolism at 
higher rates. Lack of this zonation in hepIL-KO mice may represent a shift in metabolic zonation 
or a compromise to oxidative metabolism in hepatocytes of hepILK-KO mice.  
In order to assess underlying drivers of the age-dependent effects of hepILK-KO on 
metabolism and steatosis we conducted a seris of RNA-seq analyses. Full transcriptional profiles 
were generated from livers of ILKlox/lox and hepILK-KO mice (6 week chow-fed, 18 week chow-fed, 
and 18 week HF-fed). Comparison of transcriptional profiles of 6 week old hepILK-KO mice with 
ILKlox/lox mice revealed profound differences. Most informative were GO and KEGG analyses 
revealing potential metabolic drivers of different hepatic glucoregulatory capacity. Pathways 
relating to mitochondrial function and oxidative metabolism were consistently downregulated in 
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hepILK-KO livers. In the field of obesity and NAFLD impaired mitochondrial function is often 
associated with glucose intolerance and insulin resistance. However, oxidative metabolism is also 
a prerequisitie of normal hepatic gluconeogeneic processes through provision of high energy 
phosphate bonds. Additionally, the TCA cycle is housed within the mitochondria and prvisions the 
necessary carbon for gluconeogenesis. Therefore, compromised mitochondrial structure or 
function may underlie decreased fasting glucose and enhanced glucose tolerance in 6 week old 
hepILK-KO mice. 
RNA-seq analysis of livers from 18 week old ILKlox/lox and hepILK-KO mice on chow or HF 
diets revealed a general convergence of transcriptional profiles, which is conisitent with other 
characeristics described in these mice. For 1 week old chow-fed mice the numbers of differentially 
expressed genes was reduced by ~90%. This resulted in a limited enrichment of GO terms and 
KEGG pathways. Terms and pathways that were significant were consistent with themes 
extablished in 6 week old hepILK-KO mice, but to a lesser degree. Increased pathways related to 
cellular adhesion and ECM interactions. Decreased pathways generally related to oxidative 
metabolism. Of particular interest was a significant decrease in the enrichment of genes relating 
to glucagon signaling. Impariment in glucagon signaling would certainly contribute to deficient 
hepatic glucose output and/or oxidative metabolism. While HF-fed hepILK-KO mice at 18 weeks 
presented with more differentially expressed genes thatn their chow-fed counterparts the themes 
and pathways were largely similar.  
Throughout analyses of hepILK-KO mice created using the alb-cre system similarities, but 
also critical differences were observed compared to liver ILK-KO mice created using the alf-alb-
cre system of the Michalopoulos group. As in the alf-alb-cre model we observe a persistence of 
biliary hyperplasia in the alb-cre ILK-KO livers and a relative normalization of the transcriptional 
profiles by 18 weeks of age. It is notable that several phenotypes seen in alf-alb-cre ILK KO mice 
were not recapitulated in the alb-cre ILK-KO model including no changes in hepatocyte 
proliferation at 6 weeks of age and no change in liver to body weight ratio in mice aged to match 
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studies in the alf-alb-cre ILK-KO (0.045±0.001 in controls vs. 0.044±0.002 in alb-cre ILK-KOs). 
These differences are likely attributable to differences in promoter activation timing during 
development. The alf-alb-cre becomes active early in development with expression of cre 
detectable by embryonic day 10.5 (E10.5) (142). This causes cre expression and genetic KO prior 
to differentiation of biliary epithelial cells from the bipotential hepatoblast progenitor population 
(~E13.5) (157, 238), which give rise to hepatocytes later in development. This system results in 
cre expression and consequent KO in hepatocytes derived from the developing hepatoblast 
population, as well as in biliary epithelial cells. Influence of this phenomenon on previous alf-alb-
cre ILK-KO models is acknowledged as a potential contributor to observed phenotypes (86). The 
alb-cre differs from alf-alb-cre as it does not express cre and delete ILK until differentiation of the 
albumin expressing hepatocyte population is complete  (206, 274). Cre expression occurring after 
differentiation of hepatocytes from hepatoblasts combined with dynamic perinatal and postnatal 
changes to the hepatocyte population result in later onset and completion of hepatocyte-specific 
KO (between 3 and 6 weeks of age) (206). Benefits of this delayed KO are 1) an ability to mitigate 
in utero and developmental consequences of earlier gene KO and 2) a truly hepatocyte-specific 
cre expression profile.  These benefits are a powerful conceptual distinction from previous studies 
using the alf-alb-cre lox system to delete ILK. 
In summation, we have shown that hepatocyte ILK is required for establishment of normal 
glucose homeostasis in mice. Hepatocyte specific removal of ILK results in hyperglycemia    
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Chapter IV 
 
HEPATOCYTE ILK IS REQUIRED FOR NORMAL HEPATIC OXIDATIVE METABOLISM AND 
SUPPORT OF GLUCOREGULATORY FUNCTIONS 
 
Aims 
Results form Chapter III demonstrated a functional contribution of hepatocyte ILK to 
glucose homeostasis, transcriptional profiles relating to metabolism, and the progressive 
sequelae of diet induced obesity in mice. In the absence of hepatocyte ILK the most profound 
effects are observed in 6 week old mice. Specifically, hepILK-KO mice have decreased circulating 
glucose, increased glucose tolerance, and a profound downregulation in transcriptional 
programming of mitochondria and oxidative metabolism. The goal of this chapter was to 
determine the metabolic and signaling mechanisms that underlie altered glucose homeostasis of 
6 week old hepILK-KO mice. The hope is that discerning these mechanisms will progress our 
understanding of ILK as it pertains to metabolic pathologies such as insulin resistance and 
NAFLD.   
 
Introduction   
 Studies from Chapter III aimed to unify the understanding of ILK in hepatic insulin 
resistance with previous studies implicating an age-dependent role for hepatic ILK in liver injury 
and regeneration. Results from this work demonstrated metabolically protective phenotypes in 
hepILK-KO mice including increased glucose tolerance, resistance to obesogenic weight gain, 
and limitation in hepatic steatosis. Among these metabolic alterations the changes to glucose 
tolerance and fasting glucose levels in hepILK-KO mice were among the most profound. These 
represent desirable endpoints for the treatment of dysregulation of hepatic glucose metabolism in 
multiple pathologic settings. Therefore, understanding the role of hepatocyte ILK in glucose 
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homeostasis of 6 week old mice is the focus of this Chapter. Assessment of hepatic transcriptional 
profiles of hepILK-KO mice at this age revealed decreased transcriptional signatures for 
mitochondria and oxidative metabolism.  As such, it was hypothesized that ILK is required for 
establishment of functional hepatic oxidative metabolism, which reinforces hepatic 
glucoregulatory functions in vivo.  
 To test this hypothesis, 6 week old hepILK-KO mice were used in studies of oxidative 
function and glucoregulatory processes contributing to altered glucose homeostasis. Through this 
work we demonstrate a clear oxidative deficiency in hepILK-KO hepatocytes despite elevated 
indicators of mitochondrial content. This apparent incongruence is reconciled by markers of 
deficient autophagy or mitophagy. 6 week old hepILK-KO mice are able to maintain elevated 
steady state hepatic glucose output and whole body glucose utilization despite decreased 
circulating glucose. Decreased net glycogen synthetic capacity and hepatic energy charge drive 
an energetically inefficient paradigm of elevated hepatic glucose utilization in the face of deficient 
oxidative metabolism (256). We hypothesize that oxidative deficiency contributes to this energetic 
inefficiency and underlies protection from hepatic insulin resistance during obesity. Deficiencies 
in oxidative metabolism can create beneficial outcomes relating to insulin resistance and glycemic 
control during obesity. While this may appear counterintuitive decreased mitochondrial function 
is the very mechanism by which metformin, the most commonly used drug for insulin resistance, 
acts. 
 
Experimental Approach 
 Studies in chapter IV were conducted using the control (ILKlox/lox) and hepatocyte specific 
ILK knockout (hepILK-KO) mice described in chapter III. Chapter III established a profound 
alteration to glucose homeostasis and transcriptional programming of mitochondrial metabolism 
in hepILK-KO mice. Experiments in chapter IV were designed to assess the functional 
consequences of decreased mitochondrial transcription. Furthermore, these studies evaluated 
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contributions of hepatic glucoregulatory processes to altered glucose homeostasis and the 
metabolic underpinnings of these shifts.  
 
Results 
 
Hepatocyte ILK is necessary for hepatocyte oxidative metabolism  
Hepatic compensation from 6 to 18 weeks was so effective that differences in fibrosis, 
glucoregulation, and the transcriptional profile, were diminished by 18 weeks of age. Thus, we 
focused on metabolic mechanisms underlying altered regulation of circulating glucose in hepILK-
KO mice at 6 week of age. First, we assessed whether decreased expression of genes involved 
in mitochondrial structure and oxidative processes was linked to functional capacity at the cellular 
level. O2 consumption in isolated primary hepatocytes without treatment (Routine), treated with 
oligomycin (Leak), or FCCP (ETS) was lower in hepILK-KO hepatocytes than in ILKlox/lox 
hepatocytes (Figure 4.1A). In hepILK-KO hepatocytes the ratio of O2 consumption during 
oligomycin treatment to O2 consumption in cells without treatment was higher. This reflects a 
greater fraction of O2 consumption uncoupled from ATP production (Figure 4.1B). With apparent 
deficiencies in mitochondrial function of hepILK-KO hepatocytes, protein content of mitochondrial 
oxidative phosphorylation complexes and voltage-dependent anion channel (VDAC) were 
assessed as indicators of mitochondrial content and function. Interestingly, mitochondrial 
complexes were either unchanged (complexes II, III, and V) or increased (complex I and IV) 
(Figure 4.2A & B). VDAC protein was also significantly increased (~two-fold) in hepILK-KO cells 
(Figure 4.2A & B), indicating that hepILK-KO hepatocytes possess no deficiencies in the number 
mitochondria despite decreased functionality.  
Mitochondrial function can be affected by differential management of the mitochondrial 
network. Mitochondrial fission and fusion markers were assessed to evaluate these processes.  
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Figure 4.1- Oxygen consumption is significantly reduced in hepatocytes isolated from ILK-
KO mice. A) Respiration of hepatocytes isolated from ILKlox/lox (n=6) or hepILK-KO (n=7) in basal 
media (Routine), in the presence of oligomycin (Leak), and in the presence of FCCP (ETS). B) 
Ratios of respiration rates in the three conditions represented in (A). Data are mean +/- SEM. 
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Figure 4.2- Increased mitochondrial content coupled with deficient autophagy and 
mitophagy contributes to decreased hepatocyte oxygen consumption of hepILK-KO mice.  
A) Quantification of VDAC and mitochondrial complex protein levels relative to Ponceau total 
protein stain from samples used in (Figure 4.1A). B) Representative images of VDAC, 
mitochondrial complexes, and Ponceau total protein stain in (A) C) Gene expression of optic 
atrophy 1 (opa1), dynamin 1 like protein (dnm1l), and mitofusin 2 (mfn2) in samples used in 
(Figure 4.1A). GAPDH was used as a control gene. D) Quantification of p62 and Bnip3 protein 
relative to Ponceau total protein stain in livers of ILKlox/lox (n=8) and hepILK-KO (n=7), which 
underwent MFA analysis. E) Representative western blots of p62 and Bnip3 protein as well as 
Ponceau staining quantified in (D). Data are mean +/- SEM.  
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Transcript of the fission gene, dynamin 1-like (Dnm1l), and the fusion genes, optic atrophy 
1/mitochondrial dynamin-like GTPase (Opa1) and mitofusin 2 (Mfn2) were not different between 
hepILK-KO and ILKlox/lox mice (Figure 4.2C). Protein content of autophagy (p62) and mitophagy 
(Bnip3) markers demonstrated an increase in p62 and a decrease in Bnip3 content in these livers 
(Figure 4.2D & E). These p62 and Bnip3 levels reflect decreases in autophagy and mitophagy, 
which can decrease mitochondrial function (163, 262).  
Overall, these data reflect poorly functioning hepatocyte mitochondria in hepILK-KO livers. 
This impaired hepatic mitochondrial function is related to an altered transcriptional program and 
impaired autophagy/mitophagy. 
 
Loss of hepatocyte ILK reduces whole-body EE and increases carbohydrate oxidation  
Deficient mitochondrial function in the liver has the capacity to alter whole body metabolism. 
Substrate utilization at the whole body level was assessed using indirect calorimetry. EE (Figure 
4.3A) was decreased in hepILK-KO mice at 6 weeks of age during both the light and dark phases 
(Figure 4.3B). EE remained significantly lower in hepILK-KO after accounting for differences in 
lean mass by ANCOVA (24hr P<0.05; Light Cycle P<0.001; Dark Cycle P<0.01). Therefore, EE 
in hepILK-KO mice was not due to lower lean mass and was driven by a genotype effect. 
Consistent with decreased EE, hepILK-KO mice consume less food and have lower EI overall 
(Figure 4.3C). EI matched controls during the light cycle and remained significantly decreased 
during the dark cycle (Figure 4.3D). This reflects more active feeding behavior during the light 
cycle as quantified by number and length of meals (Figure 4.3E & F). Overall, hepILK-KO maintain 
a positive energy balance (EB; the difference between EI and EE), which is no different from 
control animals (Figure 4.3G). While the RQ during the dark cycle was no different between 
ILKlox/lox and hepILK-KO mice, light cycle RQ was significantly elevated in hepILK-KO mice 
indicating increased utilization of carbohydrates as fuel (Figure 4.3H). The decrease in energy 
expenditure is related to a decrease in activity of hepILK-KO mice (Figure 4.3I & J). FGF21, which  
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Figure 4.3- Energy expenditure is decreased and feeding behavior is altered in hepILK-KO 
mice.  A) Average 24 hour energy expenditure (EE) of ILKlox/lox (n=8) and hepILK-KO (n=7) mice 
measured over a 7 day period. B) EE during 12 hour light and dark phase, ILKlox/lox (n=8) and 
hepILK-KO (n=7). C) 24 hour energy intake (EI) of ILKlox/lox (n=8) and hepILK-KO (n=7) mice. D) 
EI during 12 hour light and dark phase, ILKlox/lox (n=8) and hepILK-KO (n=7). E) 24 hour energy 
balance (EB = EI-EE) in (ILKlox/lox (n=8) and hepILK-KO (n=7) mice. F) Average number of meals 
per day during the light and dark phase, ILKlox/lox (n=8) and hepILK-KO (n=7).  24 hour energy 
intake (EI) of ILKlox/lox (n=8) and hepILK-KO (n=7) mice. G) Average time of each meal period 
during the light and dark phase, ILKlox/lox (n=8) and hepILK-KO (n=7). H) Average respiratory 
quotient during 12 hour light and dark phase, ILKlox/lox (n=8) and hepILK-KO (n=7). I) Average 24 
hour movement of ILKlox/lox (n=8) and hepILK-KO (n=7) mice measured over a 7 day period. J) 
Movement during 12 hour light and dark phase, ILKlox/lox (n=8) and hepILK-KO (n=7). K) 
Concentration of FGF21 in plasma from ILKlox/lox (n=5) and hepILK-KO mice (n=7) after a 5 hour 
fast. L) Gene expression of FGF21 from livers of ILKlox/lox (n=6) and hepILK-KO (n=7) mice after 
a 5 hour fast. GAPDH was used as the control gene. Data are mean +/- SEM.  
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is secreted by the liver and is known to promote glucose utilization, was measured to gain insight 
into the possible mechanism by which hepILK-KO increased carbohydrate oxidation.  Hepatic 
FGF21 transcript levels were increased (~5 fold) and plasma FGF21 was increased (~twofold) in 
6 week-old hepILK-KO mice (Figure 4.3K & L). The increase in circulating FGF21 could explain 
the preference for utilization of carbohydrates in hepILK-KO mice as FGF21 stimulates 
carbohydrate utilization on extrahepatic tissues. 
 
Hepatocyte ILK is necessary for hepatic glucoregulation, glycogen storage, and energy 
status  
Given increased preference for carbohydrates, deficient hepatic mitochondrial function, 
and altered glucose homeostasis of hepILK-KO mice at 6 weeks of age, endogenous glucose 
production (EGP) and metabolic processes contributing to EGP were quantified using stable 
isotopes (Figure 4.4A). Based on reduced blood glucose after a 5 hour fast and impaired 
mitochondrial function we hypothesized that EGP would be decreased. Arterial glucose was 
decreased in the hepILK-KO mice consistent with previous fasting glucose data (Figure 4.4B). 
However, a paradoxical increase in EGP due to accelerated gluconeogenic pathway flux was 
observed (Figure 4.4C). As blood glucose was in a steady state, glucose utilization was increased 
equivalently. Increased glucose utilization from a reduced circulating glucose pool requires a 
marked increase in fractional glucose turnover (Figure 4.4D).  No difference in glycogenolytic 
rates between genotypes were evident (Figure 4.4C). Increases in flux rates associated with the 
tricarboxylic acid cycle (TCA) did not reach significance (Figure 4.4E). Increases in gluconeogenic 
fluxes were not coupled to changes in the expression of gluconeogenic genes, Pck1 and G6pc 
(Figure 4.4F).  
The absence of an increase in hepatic glycogenolysis occurred despite increased plasma 
glucagon (p=0.0501) (Figure 4.5A). As glucagon is known to affect amino acid uptake and 
metabolism to stimulate hepatic glucose output plasma amino acid profiles were assessed in  
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Figure 4.4- Hepatic glucose output is elevated due to increased gluconeogenesis in 
hepILK-KO mice. A) Graphical model of metabolic fluxes contributing to hepatic glucose output 
obtained from metabolic flux analysis (MFA). B) Average blood glucose concentration during 
steady state of MFA for ILKlox/lox (n=8) and hepILK-KO (n=7) mice. C) Rates of fluxes contributing 
to hepatic glucose production in ILKlox/lox (n=8) and hepILK-KO (n=7) mice modeled by MFA. D) 
Fractional turnover of the circulating glucose pool determined by dividing VEGP by the blood 
glucose concentration at each time-point during MFA in ILKlox/lox (n=8) and hepILK-KO (n=7) mice. 
E) Rates of fluxes contributing to hepatic glucose production as well as the TCA cycling in ILKlox/lox 
(n=8) and hepILK-KO (n=7) mice modeled by MFA. F) Gene expression of gluconeogenic genes 
(glucose-6-phosphatase catalytic subunit- G6PC and phosphoenolpyruvate carboxykinase 1- 
PEPCK) from livers of ILKlox/lox (n=8) and hepILK-KO (n=7) mice after undergoing MFA. GAPDH 
was used as the control gene.  Data are mean +/- SEM. 
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Figure 4.5- Glucagon is elevated in hepILK-KO mice, but circulating amino acids remain 
unchanged. A) Plasma glucagon concentrations in ILKlox/lox (n=7) and hepILK-KO (n=9) mice 
during metabolic flux analysis experiments. B) Concentration of higher level plasma amino acids 
and related metabolites in plasma samples taken at t=120 during MFA studies of 6 week old 
ILKlox/lox (n=8) and hepILK-KO (n=7) mice. C) Concentration of lower level plasma amino acids 
and related metabolites in plasma samples taken at t=120 during MFA studies of 6 week old 
ILKlox/lox (n=8) and hepILK-KO (n=7) mice. All amino acids are depicted with standard three letter 
abbreviations. The remaining metabolites are abbreviated as follows (Taur = Taurine; Orn = 
Ornithine; Citru = Citrulline; PE = Phosphoethanolamine; γ-AA = γ-Aminobutyric Acid; 1-mHis = 
1-methyl-Histidine) Data are mean +/- SEM. * = P<0.05.  
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hepILK-KO mice. No significant changes in circulating amino acids or related metbaolites, such 
as urea, were observed in hepILK-KO mice (Figure 4.5B & C). The paradox of increased glucagon 
an elevated hepatic glucose output without aan increase in glycogenolysis led us to evaluate 
glycogen metabolism in hepILK-KO mice. Glycogen content in 5 hour fasted hepILK-KO mice was 
decreased to the point of near depletion (Figure 4.6A). Phosphorylation of glycogen synthase 
kinase 3β (GSK3β) was unchanged (Figure 4.6B). No changes in plasma lactate (Figure 4.6C) or 
β-hydroxybutyrate (Figure 4.6D) were observed despite lower hepatic glycogen. To determine the 
effectiveness by which hepILK-KO mice stored glycogen, fasting-refeeding studies were 
conducted. After 18 hours of fasting, blood glucose was reduced in ILKlox/lox mice to levels in 
hepILK-KO mice (Figure 4.6E). After 6 hours of refeeding, blood glucose rose similarly in both 
groups (Figure 4.6E). Hepatic lactate content (Figure 4.6F), as well as glucokinase and 
hexokinase activities (Figure 4.6G) were no different between hepILK-KO and ILKlox/lox livers after 
refeeding. However, net hepatic glycogen storage was ~50% lower in refed hepILK-KO mice 
(Figure 4.7A).To examine whether there was a deficit in the insulin-stimulated glycogen synthesis 
signaling cascade, levels of total and phosphorylated proteins (Akt, GSK3β, and GS) were 
assessed. Phosphorylation of Akt (ser473) was similar in ILKlox/lox and hepILK-KO mice (Figure 
4.7B & C). Additionally, the inhibitory Akt-dependent phosphorylation of GSK3β (ser9) was similar 
in the two genotypes (Fig 9J & K). The ratio of GS phosphorylated at ser641 to total GS was 
decreased in hepILK-KO mice (Figure 4.7B & C). This GS phosphorylation site is GSK3β-
dependent site and is inhibitory for GS activity. The decrease in phosphorylation of GS (ser641) 
would thereby favor glycogen synthesis. The altered ratio of phosphorylated to total GS was 
primarily due to a ~fourfold increase in total GS protein in hepILK-KO livers (Figure 4.7B & C). A 
signal associated with low hepatic glycogen storage may feedback to upregulate GS protein 
expression.  
As skeletal muscle can account for a significant portion of glucose disposal, we assessed 
the glycogen content and related signaling in gastrocnemius muscle in hepILK-KO and ILKlox/lox  
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Figure 4.6- Hepatic glycogen is decreased in hepILK-KO mice. A) Hepatic glycogen content 
of ILKlox/lox (n=6) and hepILK-KO (n=6) mice after a 5 hour fast. B) Quantification of the ratio of 
GSK3β phosphorylated at ser9 to total GSK3β protein in livers of ILKlox/lox (n=6) and hepILK-KO 
(n=7) mice after a 5 hour fast. C) Plasma lactate concentration of ILKlox/lox (n=5) and hepILK-KO 
(n=5) mice after a 5 hour fast. D) Plasma β-hydroxybutyrate concentration of ILKlox/lox (n=5) and 
hepILK-KO (n=5) mice after a 5 hour fast.  E) Blood glucose concentration of ILKlox/lox (n=4) and 
hepILK-KO (n=4) mice after an 18 hour fast and after 6 hours of ad libitum food access following 
the 18 hour fast. F) Liver lactate content of ILKlox/lox (n=4) and hepILK-KO (n=4) mice following the 
6 hour refeed period.  G) Enzymatic activities of glucokinase (GK) and all other hexokinases (HK) 
in livers of ILKlox/lox (n=4) and hepILK-KO (n=4) mice following the 6 hour refeed period.  
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Figure 4.7 Net glycogen synthesis is decreased despite increased glycogenic signaling tone of 
hepILK-KO livers. A) Hepatic glycogen content of ILKlox/lox (n=4) and hepILK-KO (n=4) mice 
following the 6 hour refeed period. B) Quantification of densitometric ratios for designated 
phosphorylated and total proteins (Panel C). Ratio of total GS protein to β-actin is also shown. C) 
Images of blots for Akt phosphorylated at ser473, total Akt, GSK3β phosphorylated at ser9, total 
GSK3β, Glycogen Synthase (GS) phosphorylated at Ser641, total GS, and β-actin in livers from 
ILKlox/lox (n=4) and hepILK-KO (n=4) mice following the 6 hour refeed period. D) Gastrocnemius 
muscle glycogen content of ILKlox/lox (n=4) and hepILK-KO (n=4) mice following the 6 hour refeed 
period. E) Quantification of densitometric ratios for designated phosphorylated and total proteins 
(Panel F). F) Representative images of blots for Akt phosphorylated at ser473, total Akt, FoxO1 
phosphorylated at ser256, total FoxO1, GSK3β phosphorylated at ser9, total GSK3β, Glycogen 
Synthase (GS) phosphorylated at Ser641, and total GS in livers from ILKlox/lox (n=3) and hepILK-
KO (n=4) mice following the 6 hour refeed period. Data are mean +/- SEM. 
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mice following refeeding. No differences were observed in glycogen content (Figure 4.7D) or 
phosphorylation of FoxO1, GSK3β, and GS in muscle (Figure 4.7E & F). However, a significant 
decrease in muscle Akt phosphorylation was observed in these mice (Figure 4.7E & F). Based on 
results from OGTTs, this may be a result of a reduced insulin response to feeding. Overall the 
hepatic signaling profile favors glycogen synthesis, even though net glycogen accumulation is 
reduced compared to ILKlox/lox mice. The net accumulation of glycogen could be attenuated due 
to simultaneous liver glycogen breakdown. In support of this possibility, the fractional glycogen 
turnover (the ratio of glycogenolysis to liver glycogen) was increased in hepILK-KO mice.  
 
Hepatocyte ILK is necessary for energy status 
Deficient oxidative function coupled with gluconeogenesis decreased energetic content of 
the adenine nucleotide pool. In line with this, ATP content was significantly reduced in livers of 
hepILK-KO mice with a concurrent increase in ADP and AMP (Figure 4.8A). Total adenine 
nucleotides were the same in both hepILK-KO and ILKlox/lox mice (Figure 4.8A). Increased 
AMP/ATP and decreased energy charge were observed in the liver of hepILK-KO mice (Figure 
4.8B). Upon refeeding AMP and ATP in hepILK-KO mouse livers returned to concentrations in 
ILKlox/lox mice; while ADP was elevated (Figure 4.8C). Energy charge of refed hepILK-KO livers 
was restored to levels in ILKlox/lox mice (Figure 4.8D). Decreased energy charge in hepILK-KO 
mice caused a fourfold increase in AMPK phosphorylation after a 5 hour fast (Figure 4.8E & F). 
Phosphorylation of the downstream AMPK target protein, acetyl-CoA carboxylase (ACC), was 
also increased (Figure 4.8E & F) confirming that AMPK phosphorylation leads to functional 
activation. Changes in energy status and inhibitory phosphorylation of the lipogenic enzyme ACC 
prompted the quantification of hepatic and circulating lipids of hepILK-KO mice (Figure 4.9). No 
significant differences in hepatic cholesterol (Figure 4.9E), diglycerides (Figure 4.9C & D), or 
circulating NEFAs (Figure 4.9 F) were observed. Minor species of saturated triglycerides were 
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significantly decreased in hepILK-KO livers (Figure 4.9B), but was not accompanied by changes 
to total liver triglycerides (Figure 4.9A).  
 
Discussion 
 Liver ILK signaling has been proposed as a therapeutic target for several disease states 
including insulin resistance (100, 102, 161, 280) yet there is little known about the physiology or 
metabolism of ILK signaling. These experiments, coupled with results from the previous chapter, 
demonstrate that hepatocyte ILK is required for glucose homeostasis through transcriptional and 
metabolic programming of the liver.  Gene ontology analysis of RNA-seq data showed that liver-
specific deletion of ILK caused an upregulation of genes involved in classic integrin functions such 
as ECM-receptor interactions, focal adhesion, and actin cytoskeleton regulation.  On the other 
hand, these analyses revealed decreased expression of genes encoding proteins involved in 
mitochondrial structure and function. Differential transcriptional profiles in hepILK-KO mice were 
resolved by 18 weeks of age. ILK deletion resulted in functional defects characterized by reduced 
fasting blood glucose, plasma insulin, and more rapid disposal of an oral glucose load at 6 weeks 
of age. As with differential gene expression at 6 weeks, differences in the glucoregulatory 
variables were also resolved by 18 weeks. The liver was, for the most part, histologically, 
transcriptionally, and metabolically reconstituted over time. The results of these studies and the 
temporal organization of hepatocyte-specific knockout in the alb-cre system directed us to focus 
on metabolic regulation in 6 week old mice.  
Consistent with the genetic reprogamming in 6 week old mice, hepatocyte mitochondrial 
O2 consumption and whole body EE were diminished. Mitochondrial function was decreased even 
though protein content indicative of mitchondrial content were either unchanged (mitochondrial 
complexes II, III, and V) or increased (mitochondrial complexes I, IV, and VDAC) in hepatocytes  
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Figure 4.8- Hepatic energy charged is decreased and AMPK signaling is activated in 
hepILK-KO livers. A) Adenine nucleotide levels (ATP, ADP, and AMP) in livers from ILKlox/lox 
(n=8) and hepILK-KO (n=9) mice, which underwent MFA. B) Total adenine nucleotide (TAN) 
levels (sum of ATP, ADP, and AMP levels) in livers from ILKlox/lox (n=8) and hepILK-KO (n=9) 
mice, which underwent MFA. Ratio of AMP to ATP and calculated energy charge from the same 
liver samples. C) Adenine nucleotide levels (ATP, ADP, and AMP) in livers from ILKlox/lox (n=4) 
and hepILK-KO (n=4) mice, which underwent 18 hour fast and 6 hour refeed. D) Total adenine 
nucleotide (TAN) levels (sum of ATP, ADP, and AMP levels) in livers from ILKlox/lox (n=4) and 
hepILK-KO (n=4) mice, which underwent 18 hour fast and 6 hour refeed. Ratio of AMP to ATP 
and calculated energy charge from the same liver samples. E) Quantification of AMPK 
phosphorylated at Thr172 and ACC phosphorylated at Ser79 relative to their respective total 
proteins from livers of 5 hour fasted ILKlox/lox (n=6) and hepILK-KO (n=7). Data are mean +/- SEM. 
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Figure 4.9- Hepatic and circulating lipid profiles are not changed in hepILK-KO mice.  A) 
Total triglyceride content of livers from 5 hour fasted, 6 week old ILKlox/lox (n=7) and hepILK-KO 
(n=8) mice. B) Quantification of triglycerides side chain species from (A). C) Total diglyceride 
content of livers from 5 hour fasted, 6 week old ILKlox/lox (n=7) and hepILK-KO (n=8) mice. D) 
Quantification of diglyceride side chain species from (D). E) Total cholesterol content of livers 
from 5 hour fasted, 6 week old ILKlox/lox (n=7) and hepILK-KO (n=8) mice. F) Concentration of non-
esterified fatty acids in plasma samples taken at t=100 during MFA studies of 6 week old ILKlox/lox 
(n=8) and hepILK-KO (n=7) mice.  
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of hepILK-KO mice. Moreover, hepatic TCA cycle fluxes were not different in the hepILK-KO 
livers.  Results indicate a buildup of poorly functioning mitochondria that contributes to decreased 
respiration. Deficits in autophagy and mitophagy were reflected by increased p62 and decreased 
Bnip3 protein in hepILK-KO livers. Impairments in autophagy and mitophagy can contribute to 
mitochondrial dysfunction as it could underlie ineffective “pruning” of the mitochondrial network 
(164, 263).  
Impaired mitochondrial function resulted in decreased energy charge.  The increased AMP 
and decreased ATP, as observed in these studies, stimulate glycolysis by allosteric mechanisms 
and underlie a striking fourfold increase in AMPK activation. This signal alters the fate of glucose 
by inhibiting glycogen synthase (34) and activating glycolytic flux (167, 168). In this regard, the 
impaired capacity to store liver glycogen shown in the present study suggests glucose is directed 
to glycolysis. AMPK activation also stimulates pathways for substrate oxidation to counter the 
decreased energy state of the cell (83). However, in the presence of impaired mitochondrial 
function even a fourfold increase in AMPK was unable to fully compensate for impaired 
mitochondrial function in hepILK-KO livers. While AMPK activation stimulates lipid oxidation, 
comprehensive analyses revealed no reduction in circulating free fatty acids, total liver 
triglycerides, diglycerides, or cholesterol.  
Glucose fluxes and the hepatic metabolic pathways contributing to it were assessed using 
2H/13C metabolic flux analysis in conscious 5 hour fasted mice. Despite ILK deletion from the 
primary glucose producing organ, the reduced blood glucose in hepILK-KO mice was not due to 
an impairment in EGP but rather an increase in the removal of glucose, as measured by absolute 
and fractional glucose turnover rate.  This finding was consistent with the greater glucose 
tolerance and elevated the light cycle RQ in hepILK-KO mice.  Although blood glucose was 
reduced, overt hypoglycemia was prevented by accelerated gluconeogenic flux rates upstream 
of the pyruvate cycle (e.g. through enolase) in hepILK-KO mice. A reduction in glycogen stores 
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and a decreased capacity to store glycogen is consistent with impaired mitochondrial function and 
a greater reliance on glycolysis.  The liver is simultaneously a glucose consuming and glucose 
producing organ even in the fasted state (268).  We speculate that the liver may be the site of 
both increased glucose utilization and production. Analysis of skeletal muscle insulin signaling 
show that it is not increased making it an unlikely site for the added glucose disposal. Glucagon 
was elevated (p=0.0501) and insulin decreased in hepILK-KO mice in response to the reduced 
blood glucose. Increased glucagon to insulin ratio in hepILK-KO mice can potently stimulate 
gluconeogenesis even in the presence of a reduced hepatic energy state (266).  
FGF21 hepatic gene expression and circulating levels were elevated in hepILK-KO mice. 
FGF21 increases EE (207, 228). However, the effects of FGF21 on EE were offset in the hepILK-
KO mice by decreased physical activity. Energy balance in hepILK-KO mice was in steady state 
as EE and EI were equal at 6 weeks. The elevated FGF21 in the light phase is consistent with 
the relative preference for carbohydrate as a fuel as described above. This is consistent with 
increased glucose turnover and the actions of FGF21. Feeding behavior was also altered in 
hepILK-KO mice. Increased number of meals and length of meals during the light cycle were 
increased in hepILK-KO mice. The increase in light cycle feeding is consistent with the elevated 
circulating FGF21 in this phase (199).  
Although blood glucose is reduced in hepILK-KO mice after a 5 hour fast, blood glucose 
was equal in ILKlox/lox and hepILK-KO mice after an 18 hour fast and rose equally during 
subsequent refeeding. Despite equal glucose loads, net hepatic glycogen storage was reduced 
by 50% in hepILK-KO mice. Impaired net glycogen storage occurred in the despite comparable 
glucokinase activities, metabolite levels, and a signaling profile that favors glycogen synthesis. 
Remarkably, GS protein was elevated nearly fourfold in hepILK-KO livers. Net hepatic glycogen 
storage is the difference between the rate of glucosyl unit incorporation into glycogen and the rate 
of glycogenolysis. Reduced net hepatic glycogen storage in the presence of a signaling 
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environment conducive to glycogen synthesis, suggests increased glycogen breakdown. Using 
MFA we show that glycogenolysis is equal in ILKlox/lox and hepILK-KO mice despite the fact that 
glycogen stores are reduced by ~70% in hepILK-KO mice, indicating the fractional glycogen 
turnover (e.g. glycogenolysis per glycogen mass) is increased in hepILK-KO mice. This supports 
the concept that impaired net liver glycogen storage is a result of concurrent glycogen synthesis 
and breakdown. 
Fibrosis at 6 wks of age results from hepILK-KO regardless of the hepatic/hepatocyte cre 
system (86, 87). Effects of hepatic damage, fibrosis, and cirrhosis to altered glucose homeostasis 
have been well characterized (174, 194, 197). However, these conditions are typically associated 
with impaired glucose tolerance, hyperinsulinemia, and impaired insulin sensitivity. Results of our 
studies in 6 week old hepILK-KO mice reveal improved glucose tolerance and decreased insulin 
in addition to previously documented protection from insulin resistance during over-nutrition in 
mature mice (280). In the absence of acute signals from the fibrotic environment, hepatocyte 
oxidative mitochondrial function is still impaired. The liver is also a central hub for amino acid and 
urea metabolism. Distinct changes in circulating amino acids and related metabolites have been 
linked to fibrogenic severity (69, 112). Plasma profiles of amino acids and these other key 
metabolites were equivalent in hepILK-KO mice. The ability to sustain gluconeogenesis at an 
accelerated rate also indicates that liver damage is not severe. It may be that hepILK-KO limits 
the hepatocyte interpretive capacity of the fibrotic environment by limiting aspects of integrin 
sensing and signaling related to the extracellular matrix. While speculative, it may explain certain 
metabolic protections observed in hepILK-KO mice. 
Previous studies have implicated inhibition of ILK signaling in treatment of a number of 
conditions, including insulin resistance (280), cancer (101, 102, 176, 292), and fibrosis (20, 294).  
This study defines the requirement for ILK in fundamental metabolic processes of the liver. The 
proposed role of ILK and the effects of hepatic-specific ILK KO is summarized in Figure 12. In the 
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present studies we show that although ILK deletion accelerates recovery of the liver from stress, 
ILK deletion compromises hepatic metabolism in healthy, young mice. Specifically, 6 week old 
hepILK-KO mice exhibit differential gene expression and functional changes in hepatic 
metabolism that lead to increased glucose removal, impaired net glycogen storage, impaired 
mitochondrial function, and increased gluconeogenesis.  
In conclusion, our study establishes a role for ILK in maintaining liver metabolism and 
glucoregulatory functions. These effects likely contribute to the role of ILK in mediating insulin 
resistance during diet induced obesity. Furthermore, these findings inform our understanding of 
pathologic conditions affiliated with altered ECM and metabolism including non-alcoholic fatty liver 
disease. As such, it is important to consider the physiological and metabolic effects of ILK when 
targeting the inhibition of integrin-mediated signaling pathways and potentially invoking this 
metabolic influence for therapeutic potential in the future.  
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Figure 4.7- Summary figure for the role of ILK in hepatocyte metabolism and 
glucoregulation. A) Proposed model of ECM-integrin-ILK signaling and contributions to hepatic 
metabolism and glucoregulatory functions. B) Model of altered hepatocyte metabolism and 
glucoregulatory functions upon disruption of integrin signaling via hepILK-KO.  
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Chapter V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
The data presented herein establish ILK as a critical mediator of hepatic metabolic 
responses in an age and diet-dependent manner. The convergence of ILK-mediated effects on 
glucose homeostasis, development of obesity, and indices of NAFLD with control mice in an age 
dependent manner are novel results. Extensive transcriptomic analyses provide insights on the 
mechanisms of ILK action. Additionally, these studies are the first to determine the hepatic 
influence of ILK on oxidative metabolism and energy charge within the liver. Chapter III 
demonstrates a role for ILK in maintaining glucose homeostasis in 6 week old mice while 
contributing to hyperglycemia, obesity progression, and steatotic development in older, HF-fed 
mice. Chapter III also defines transcriptional themes in mice lacking hepatocyte ILK independent 
of age and diet. Specifically, pathways related to cell adhesion are upregulated while pathways 
relating to mitochondria and oxidative metabolism are downregulated in livers of hepILK-KO mice.  
Chapter IV expands on these results to determine metabolic mechanisms contributing to altered 
glucose homeostasis in hepILK-KO mice. This dissertation creates a novel paradigm whereby 
ILK determines the quality of hepatocyte mitochondria and efficiency of oxidative metabolism to 
affect aspects of liver glucose regulation. These studies show how novel pathways controlled by 
ILK may have implications for hepatic diseases, such as NAFLD and insulin resistance, but also 
for other diseases with metabolic and fibrotic comorbidities.  
Hepatic developmental programming determines the immense functional capacity of this 
organ. This programming has been utilized to develop research tools for in depth understanding 
of the liver. In this regard, multiple model systems have been implemented for the hepatocyte 
specific genetic modification of mice. One such model, the alf-alb-cre, was previously utilized in 
the knockout of ILK from hepatocyte, but may also have off target developmental and biliary cell 
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consequences. By utilizing the alb-cre system to perform a truly hepatocyte specific knockout of 
ILK these studies are the first to perform analyses parallel to an alternate developmental model 
cre-recombinase driven knockout. Differential characteristics seen in the alb-cre model system 
included lack of hepatocyte proliferation and hepatomegaly, which differ from the alf-alb-cre model 
used previously (7, 86). However, our studies recapitulated a number of histologic effects of the 
alf-alb-cre model, such as fibrosis and biliary hyperplasia.  These phenotypes are important to 
consider when assessing aspects of metabolism, but may be even more relevant to the study of 
hepatic injury and regeneration.  
Assessment of the age-dependent metabolic phenotypes of hepILK-KO mice 
demonstrated decreased fasting glucose levels and enhanced glucose tolerance of 6 week old 
hepILK-KO mice. We show a convergence of these metabolic characteristics with control mice by 
12 weeks of age. These studies are some of a limited number that assess age-dependence of 
phenotypes relating to an in utero knockout system. Transient effects of genetic knockouts may 
be more common than is currently appreciated. It could even contribute to a failure to reproduce 
data in genetic mouse models. The liver may be particularly resilient against specific genetic 
knockout models as it has high regenerative and compensatory capacity (179–181, 251).  This is 
the first time our lab has systematically looked at a phenotype over time other than by simple 
body weight measurement. We feel that perhaps this should be done with more regularity.  We 
hope that this work will lead to the recognition that age is an important consideration for the study 
of physiology in KO mice. 
Studies assessing hepILK-KO mice over the course of HF feeding were conducted in 
parallel with standard chow feeding. These experiments served to strengthen the understanding 
of age-dependent roles of ILK in metabolism while reinforcing the role of hepatocyte ILK during 
obesity from previously published work (280). Results show initial resistance to hyperglycemia, 
weight gain, and hepatic steatosis brought on by HF feeding relative to ILKlox/lox mice. At 32 weeks 
of age, hepILK-KO mice converge metabolically and physically with their control littermates. 
124 
 
Interestingly, at this time point hepILK-KO mice seem to transition to a state of less glucose 
tolerance and increased hepatic steatosis. This indicates a “flip” from metabolic protection of 
hepILK-KO early in obesity to metabolic compromise after the compounded metabolic stress of 
extended obesity. It is likely that a longer obesogenic paradigm would result in more sever glucose 
intolerance and NAFLD-like phenotypes in hepILK-KO mice.  
Mice with a hepILK-KO on a chow diet demonstrated hepatocyte hyperplasia and 
adenoma formation in certain cases. This correlates with the role of ILK in cellular contact 
inhibition programming demonstrated in other organ systems (241). Interestingly, HF diet leads 
to loss of these phenotypes in hepILK-KO mice. In multiple studies, protein-protein interactions 
between ILK and de novo lipogenesis enzymes including acetyl-coA carboxylase and fatty acid 
synthase have been demonstrated (70, 265). Links have also been made between the inhibition 
of lipogenesis and development of cancer in liver (94, 193). ILK may play a role in maintaining 
hepatic lipogenesis, which coordinates metabolic and proliferative balances within the liver. Upon 
hepILK-KO this balance is disturbed leading enhanced proliferation in the basal state, but also in 
response to injury (7, 17). Augmentation of hepatic lipid balance in hepILK-KO mice by HF feeding 
diminishes hepatocyte proliferative drive in the hepILK-KO setting. Parsing out the mechanistic 
links between ILK, de novo lipogenesis, and hepatocyte proliferation represents a potential 
therapeutic avenue in addressing the spectrum of pathologies linked with NAFLD including 
steatosis and hepatocellular carcinoma.  
This work utilized the unbiased approach of RNA-seq analysis to discover a link between 
hepatocyte ILK and the transcriptional programming of the liver relating to oxidative metabolism. 
These studies denoted stark transcriptional downregulation of oxidative metabolism and 
mitochondria in hepILK-KO mice at 6 weeks of age. In silico analysis of promoter sequence 
enrichment of significantly downregulated genes iin hepILK-KO livers (data not shown) 
demonstrated significant representation of sequence targeted by the transcription factor NRF1. 
Loss of this transcription factor from mouse liver results in hepatic neoplasia and development of 
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NAFLD phenotypes (289). NRF1 is also critical to maintained redox status and hepatocyte 
survival in developing mice (40). These phenotypes directly correlate with those observed in our 
hepILK-KO models. Therefore, it is possible that metabolic and cellular turnover phenotypes 
related to ILK expression are linked to the NRF1 transcription factor and its activity. In the future 
it will be essential to evaluate the role of NRF1 and other transcription factors responsible for such 
drastic transcriptomic alterations in hepILK-KO mice.  The magnitude of transcriptomic changes 
decline with age of hepILK-KO mice. Livers from hepILK-KO mice at 18 weeks of age only have 
~10% of the differentially expressed genes as 6 week old mice. However, 18 week old HF-fed 
hepILK-KO mice, which are resistant to steatosis, present with more pronounced differences in 
transcriptional profiles, ~2.5-fold increase, compared with analyses of chow-fed mice. While raw 
numbers of differentially expressed genes were variable based on age and diet several valuable 
connections were made possible with these studies.  
RNA-seq, glucose homeostasis, weight gain on a HF diet, and histologic characteristics 
of hepILK-KO mice follow a consistent age-dependent paradigm. Specifically, hepILK-KO mice 
present with initially pronounced phenotypes, which gradually subside over time. This is not 
particularly surprising as the liver has a renowned ability to regenerate cellular mass and 
functional capacity in the face of deficiency (179, 251). However, application of provocative stimuli 
in the form of HF diet (280), surgical resection (7), or hepatotoxic challenge (17, 63, 65) reveals 
a clear difference in responses of mature mice lacking hepatic ILK. Therefore, it is critical to 
consider set and setting when dealing with various knockout models. Secondly, oxidative 
metabolism pathways were consistently downregulated in RNA-seq results from livers of hepILK-
KO mice regardless of age or dietary intervention. We also know these mice are resistant to a 
number of metabolic pathologies relating to overnutrition. These results prompted the assessment 
of functional outcomes relating to mitochondria and oxidative metabolism to integrate ILK function 
with metabolic pathologies including insulin resistance and NAFLD.  
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Quantifying oxidative metabolism of isolated hepatocytes revealed the first documentation 
of functional deficits of hepatocyte oxidative metabolism in the absence of ILK. This demonstrated 
a clear connection between transcriptional program and functional capacity of these mice. Despite 
decreased transcription and function relating to mitochondria, several indicators of mitochondrial 
content were maintained or increased in hepatocytes of hepILK-KO mice. In conjunction with 
content, mitochondrial connectivity is a critical component of oxidative metabolism (22, 111). 
Processes mediating this connectivity are intimately linked to the actin cytoskeleton and are 
influenced directly by focal adhesion signaling from integrins (90, 143, 160). Given connections 
between focal adhesion dynamics and mitochondrial network processing we assessed aspects 
of mitochondrial fusion, fission, and autophagy. These experiments were the first indication that 
mitophagy may be deficient in the absence of ILK. This would support our findings related to 
deficient oxidative metabolism in the presence of excess mitochondrial content. Poorly damaged 
mitochondria that are not undergoing appropriate degradation can compromise mitochondrial 
networks and overall function. Going forward it is critical to assess the signaling mechanisms 
linking ILK to altered mitochondrial networking. Mitochondrial networking processes require 
dynamic physical organization and manipulation within the cell. As a result the actin cytoskeleton 
is intimately linked with appropriate function of fission, fusion, autophagy, and mitophagy. ILK is 
linked to cytoskeletal dynamics through its interactions with PINCH and other downstream 
proteins. Therefore going forward the ILK-PINCH signaling network will serve as a mechanistic 
target in assessing the role of ILK in mitochondrial dynamics. 
We have shown decreased 5 hour fasted glucose levels, increased glucose tolerance, 
and deficient oxidative metabolism in 6 week old hepILK-KO mice. Therefore, hepatic glucose 
output and related metabolic fluxes were quantified to assess the hypothesis of deficient hepatic 
glucose output in hepILK-KO mice. Counter to this hypothesis was the discovery that hepatic 
glucose output was significantly upregulated in the postabsorptive state of hepILK-KO mice. This 
elevation in glucose output was derived from gluconeogenesis. This was in line with a trend 
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towards increased TCA cycling. By definition, increased hepatic glucose output must correspond 
to an equal increase in glucose utilization. This increased utilization of glucose occurs despite 
decreased circulating glucose levels, indicating increased fractional turnover of the glucose pool 
in hepILK-KO mice. Mice with hepILK-KO do possess the appropriately functioning endocrine 
control systems as they have elevated insulin during GTTs and also increase glucagon in 
response to reduced fasting glucose relative to ILKlox/lox counterparts. Glycogenolysis increases 
were absent despite increased glucagon in hepILK-KO mice. This represented a potential control 
point for altered glucose homeostasis.  
Fasting/refeeding studies revealed deficient net hepatic glycogen synthesis in hepILK-KO 
mice. This decreased hepatic glycogen storage contributed to altered glucose homeostasis in 
hepILK-KO mice. This deficiency occurred despite cell signaling indicative of elevated hepatic 
glycogen synthesis. This may be an adaptive mechanism, whereby hepILK-KO livers scavenge 
blood glucose for glycogen synthesis during feeding. Perhaps contributing to an inability to store 
glycogen are decreased hepatic energy charge and AMPK activation in hepILK-KO livers. AMPK 
activation can directly inhibit glycogen storage (34). This energetic deficiency and the consequent 
signaling are likely a result of decreased oxidative metabolism. Inefficient processing of oxidative 
substrates would limit the ability to maintain hepatic energy during postabsorption and extended 
fasting. AMPK activation also stimulates the utilization of glucose through glycolysis (167, 168). 
Limited glycogen storage coupled to accelerated glycolysis would extract more circulating glucose 
and cause an increased glucagon to insulin ratio. This would then increase gluconeogenesis. 
Gluconeogenesis being an energetically demanding process would further compound energetic 
stress within the organ. This energetic inefficiency would be observed as a detrimental effect in 
healthy mice. However, energetic inefficiency may act beneficially in a model of overnutrition. This 
creates a sink for excess carbon intake limiting accumulation of lipid in the form of obesity or 
steatosis.  
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Overall these studies show a metabolic role for ILK in mice in vivo. Enhancing the direct 
clinical relevance of ILK in the liver, a set of studies by Dr. C. Robb Flynn at Vanderbilt has 
indicated a link between transitioning of steatosis to NASH with the activation of ILK signaling 
pathways in human liver (unpublished data). Therefore, continuing to elucidate the underlying 
connections of hepatic ILK with normal and pathophysiologic processes could have implications 
for preventing disease progression of NAFLD in humans. Consequently, this body of work further 
implicates the ECM-integrin-metabolism axis as contributors to and a therapeutic target. As such, 
we continue to move forward with models of altered hepatic integrin signaling as a means to better 
understand these connections. 
 
Future directions for integrins in hepatic metabolism and insulin resistance  
 There are a number of possible future directions for the study of integrins in hepatic 
metabolism and insulin resistance. One critical research avenue we are pursuing is determining 
the definitive upstream integrin receptor input for ILK mediated effects on liver metabolism. 
Specifically, we have implemented a hepatocyte specific Integrin β1 (hepItgβ1-KO) knockout 
mouse to assess the role of this protein in glucose homeostasis.  
Integrin β1 (Itgβ1) is a ubiquitously expressed integrin receptor subunit that directly binds 
to and is an upstream signal input for ILK (103, 155). We have begun assessing whether the 
effects of hepILK-KO on glucose homeostasis are due to an inability to transduce upstream 
integrin-ECM signaling. To do this a genetic hepatocyte knockout model of Itgβ1 is currently being 
studied. Similar to hepILK-KO mice, mice lacking hepatocyte Itgβ1 (hepItgβ1-KO) demonstrated 
lower body weights compared to Itgβ1lox/lox littermates. However, this difference did not reach 
statistical significance (Figure 5A).  As was the case with hepILK-KO mice, hepItgβ1-KO did not 
affect % lean and % fat masses (Figure 5B & C). Fasting blood glucose was decreased in 
hepItgβ1-KO mice and the glucose tolerance was increased (Fig 5D & E) similarly to hepILK-KO 
mice (Figure 5E & Figure 3.1A). Fasting plasma insulin in hepItgβ1-KO mice was reduced 
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compared to Itgβ1lox/lox littermates.  This decrease was similar to the decrease in fasting plasma 
insulin in hepILK-KO mice. (Figure 5F & Table 3.1). Overall the effects of hepItgβ1-KO on fasting 
glucose, fasting insulin, and glucose tolerance are nearly identical to the phenotype of hepILK-
KO mice. Findings in the hepItgβ1-KO show that the results seen in the hepILK-KO mice on 
hepatic metabolism and glucose homeostasis is a result of disruption of ECM signals transmitted 
through the Itgβ1 subunit of integrin receptors. These studies will continue in order to further 
understand the role of integrins in normal and pathologic hepatic metabolism.  
 
 
Figure 5.1- Hepatocyte Itgβ1 operates upstream of ILK to mediate glucose homeostasis.  
A) Body weight of Itgβ1lox/lox (n=17) and hepItgβ1-KO (n=14) mice at 6 weeks of age. B) Lean 
mass body composition of Itgβ1lox/lox (n=17) and hepItgβ1-KO (n=14) mice at 6 weeks of age. 
C) Adipose mass body composition of Itgβ1lox/lox (n=17) and hepItgβ1-KO (n=14) mice at 6 
weeks of age. D) Blood glucose levels of 6 week old Itgβ1lox/lox (n=17) and hepItgβ1-KO (n=14) 
mice during oral glucose tolerance tests. E)  Baseline corrected area under the glucose curves of 
6 week old Itgβ1lox/lox (n=17) and hepItgβ1-KO (n=14) mice during oral glucose tolerance tests. 
F) Plasma insulin concentrations of 6 week old Itgβ1lox/lox (Baseline; n=17, 10 min; n=17) and 
hepItgβ1-KO (Baseline; n=11, 10 min; n=13) mice during oral glucose tolerance tests. Data are 
mean +/- SEM.  
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APPENDIX 
 Depicted below is the code written in the “R” language for analysis of differentially 
expressed genes as well as gene ontology and KEGG pathway analyses. Additionally there are 
several figure creation aspects included that operate through the standard R visualization 
methods as well as ggplot and plotly programs. With the correct files and directories this code will 
run start to finish and produce all data, tables, and figures present in Chapter III (Table 3.6-3.11; 
Figures 3.8-3.11). Also included are scripts for the production of heatmap type figures, which were 
not included in the dissertation. Lines with # at the start will not run in a session of R. Many of 
these lines are descriptive of the following code and its goals in relation to manipulating data, 
performing statistical analyses, or creating figures. Certain lines with # at the front are indications 
to install a program with R. These were excluded as they are not necessary after initial installation 
in R. A de novo R installation and attempt to use this code would require the “unmasking” of these 
installation code lines.  
#edgeR gene analysis  
 
#set the folder to work from wherever it is located. I've designated mine below 
setwd("C:/Users/treftse/Dropbox (VUMC)/RNA-seq documents/HTseq count files") 
 
#Assemble a table denoting all designating characteristics of each of your 
#samples and read that into R 
 
Pheno_data <- read.delim("181206 Pheno_data.txt", stringsAsFactors=FALSE) 
 
#designate a novel characteristic of this table which combines all 
#attributes into a single item for mine it is Genotype,Age, and Diet 
 
group <- paste(Pheno_data$Genotype, Pheno_data$Age,  
Pheno_data$Diet, sep="") 
 
group <- factor(group) 
 
table(group) 
 
#Read in a table containing all samples and counts with sample names in header 
#and the gene identifiers in the first column 
GenewiseCounts <- read.delim("181206 HTSeqcounts-no_details.txt", 
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row.names="ensemblID") 
 
colnames(GenewiseCounts) <- substring(colnames(GenewiseCounts),2) 
 
library(edgeR) 
 
#Create the specific item needed for edgeR differential gene expression analysis 
y <- DGEList(GenewiseCounts, group=group, 
             genes=GenewiseCounts[,1,drop=FALSE]) 
 
options(digits=3) 
y$samples 
 
#contingencies for altering the ensemblIDs with version identifier 
library(tidyr) 
library(dplyr) 
library(data.table) 
 
#Next command removes version identifier from ensembl ID rownames.  
#This command is a simple text altering command and so is simply working from 
#the script in the name and removing everything after and including a period 
#more advanced alterations can be performed, but would have to be looked in to. 
 
# create list of versionless ensembl IDs 
ensemblIDS<-nth(tstrsplit(row.names(y), split ="\\."),n=1) 
 
#Add column of versionless ensembl IDs to y DGE object 
y$genes$ensemblIDS<-ensemblIDS 
 
#Convert ensembl IDs to entrez IDS and add a column to the DGE object 
library(org.Mm.eg.db) 
y$genes$entrezid <- mapIds(org.Mm.eg.db, y$genes$ensemblIDS, 
                          keytype="ENSEMBL", column="ENTREZID") 
 
#Remove any genes which did not map between ensembl and entrez IDS 
y <- y[!is.na(y$genes$entrezid), ] 
 
#Add gene symbol names as well to DGE object 
y$genes$symbol <- mapIds(org.Mm.eg.db, y$genes$ensemblIDS, 
                          keytype="ENSEMBL", column="SYMBOL") 
 
#remove genes without symbols 
y <- y[!is.na(y$genes$symbol), ] 
 
#determine dimensions of y (DGE object) so as to assess loss of genes  
dim(y) 
 
#want counts/library of ~10 so match counts per million (cpm) to average library size 
#I have actually gone with a counts per million cutoff here, but there is no real consensus on the 
appropriate cutoff 
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keep <- rowSums(cpm(y$counts)>=0.417) >= 5 
 
y <- y[keep, , keep.lib.sizes=FALSE] 
 
y <- calcNormFactors(y) 
 
y$samples 
 
design <- model.matrix(~0+group) 
 
colnames(design) <- levels(group) 
 
design 
 
#install.packages("statmod") 
#library(statmod) 
y <- estimateDisp(y, design, robust=TRUE) 
 
plotBCV(y) 
 
fit <- glmQLFit(y, design, robust=TRUE) 
head(fit$coefficients) 
 
plotQLDisp(fit) 
 
summary(fit$df.prior) 
 
#MDS (similar to PCA) plot 
points <- c(0,1,2,15,16,17) 
colors <- rep(c("blue", "darkgreen", "red"), 2) 
plotMDS(y, col=colors[group], pch=points[group]) 
legend("topright", legend=levels(group), pch=points, col=colors, ncol=2) 
 
#once plot is organized to appropriate appearance output as SVG file.  
svg("190315 ILK RNA seq MDS.svg",width=7,height=7) 
points <- c(0,1,2,15,16,17) 
colors <- rep(c("blue", "darkgreen", "red"), 2) 
plotMDS(y, col=colors[group], pch=points[group]) 
legend("topright", legend=levels(group), pch=points, col=colors, ncol=2) 
dev.off() 
 
#Define comparison to make between gene sets 
 
WT6chxKO6ch <- makeContrasts(KO6wkChow-WT6wkChow, levels=design) 
 
Chow6results <- glmQLFTest(fit, contrast=WT6chxKO6ch) 
 
#show top 10 P value DEGs and log FCs 
topTags(Chow6results) 
 
#determine differential expression test 
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is.de.Chow6wk <- decideTestsDGE(Chow6results,adjust.method="BH", p.value=0.05) 
summary(is.de.Chow6wk) 
 
#make results table from DGE analysis a data frame 
DGE.Chow6wk <- data.frame(Chow6results$table) 
 
#add DGE binary marker to data frame 
DGE.Chow6wk$DE <- is.de.Chow6wk 
 
#Write table 
write.table(DGE.Chow6wk, file= "190315 Dissertation 6wk chow DGE.tsv", row.names=TRUE, 
            col.names=NA, sep="\t") 
 
 
plotMD(Chow6results, status=is.de.Chow6wk, values=c(1,-1), col=c("red","blue"), 
legend="topright") 
 
 
# dependencies: 
#install.packages("ggplot2") 
#install.packages("gridExtra") 
#install.packages("plotly") 
#install.packages("dplyr") 
#install.packages("orca") 
#install.packages("processx") 
#suppressPackageStartupMessages(library("plotly")) 
library(ggplot2) 
library(gridExtra) 
library(plotly) 
library(dplyr) 
library(orca) 
library(processx) 
Sys.setenv('MAPBOX_TOKEN' = 
'pk.eyJ1IjoiZXRyZWZ0cyIsImEiOiJjanRhc214dDYwZWduNDltZWZ5c3JqemIyIn0.YoiKAvwoZR
BJQVptAWJ9Pg') 
 
 
# path to the gene file 
setwd("C:/Users/treftse/Dropbox (VUMC)/Defense/") 
Chow6wkVolcano <- "C:/Users/treftse/Dropbox (VUMC)/Defense/190315 Dissertation 6wk chow 
DGE.tsv" 
 
# graph 6 wk Chow analysis 
diff_df_Chow6wk <- read.delim(file = Chow6wkVolcano,header = TRUE,row.names=1,sep = '\t') 
#add column of -log10p values to table 
diff_df_Chow6wk$negLog10P <- (-log10(diff_df_Chow6wk$PValue)) 
# edit the dataframe to contain the main information used for analysis 
diff_df_Chow6wk <- diff_df_Chow6wk[c("logFC", "DE", "negLog10P")] 
 
#edit the data frame to add a column and establish criteria for significance and fold change 
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diff_df_Chow6wk[which(diff_df_Chow6wk['DE'] < -0.5 & abs(diff_df_Chow6wk['logFC']) > 0 
),"group"] <- "Downregulated" 
diff_df_Chow6wk[which(diff_df_Chow6wk['DE'] > -0.5 & diff_df_Chow6wk['DE'] < 0.5 ),"group"] <- 
"Non-significant" 
diff_df_Chow6wk[which(diff_df_Chow6wk['DE'] > 0.5 & abs(diff_df_Chow6wk['logFC']) > 0 
),"group"] <- "Upregulated" 
 
#Define color scheme 
palChow6wk <- c("blue", "black", "red") 
 
palChow6wk <- setNames(palChow6wk, c("Upregulated", "Non-significant", "Downregulated")) 
 
#plot differentially expressed gene data on a volcano plot 
pChow6wk <- plot_ly(data=diff_df_Chow6wk, x=~logFC, y= ~negLog10P,  type="scatter",  
mode="markers", symbol=0, color=~group, colors=pal,width=500, height=600)%>% 
layout(margin= (pad=0), 
title= "<b>6 Week Chow ILK <sup>lox/lox</sup> Vs. hepILK-KO RNA-seq</b>",  
titlefont = list(family="Arial", size=20, color = "black"), 
xaxis = list(title = '<b>log<sub>2</sub> Fold Change</b>', 
autotick = FALSE, ticks = "outside", tick0 = 0,  
dtick = 5, ticklen = 5, tickwidth = 2,tickcolor = toRGB("white"), 
showticklabels=TRUE,tickfont=list(family="Arial", size=20, color = "black"), 
titlefont = list(family="Arial", size=20, color = "black"),  
zeroline = TRUE, range = c(-10, 10)), showlegend=TRUE, 
legend=list(x=0.9,y=0.9,traceorder='normal',font=list(family='Arial',size=20, 
color='#000'),bordercolor='#FFFFFF',borderwidth=2), 
yaxis = list(title = '<b>-log<sub>10</sub> <i>p</i>-value</b>', 
autotick = FALSE, ticks = "outside", tick0 = 0,  
dtick = 3, ticklen = 5, tickwidth = 2,tickcolor = toRGB("white"), 
showticklabels=TRUE,tickfont=list(family="Arial", size=20, color = "black"),  
titlefont = list(family="Arial", size=24, color = "black"),  
range = c(0,13))) 
pChow6wk 
 
#export plotly object "volcano plot" as svg 
orca(pChow6wk, "190315 Chow 6wk Volcano.svg") 
 
 
#save graph as html 
 
htmlwidgets::saveWidget(p, "190315 Chow 6wk Volcano.html") 
 
 
# Heat map synthesis for top 40 DE genes 
#Create a CPM arrangement of the DGE object count matrix 
logCPM <- cpm(y, prior.count=2, log=TRUE) 
#Change the colummn names to a representation of samples with groups and numbers 1-5 
colnames(logCPM) <- paste(y$samples$group, 1:5, sep="-") 
#Replace rownames of CPM object with gene symbols  
rownames(logCPM) <- paste(y$genes$symbol) 
#Order the Pvalues based on the comparison denoted  
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o <- order(Chow6results$table$PValue) 
#Index the logCPM object based on the highest 40 PValues from previous order function 
logCPM <- logCPM[o[1:40],] 
 
#scale each row (each gene) to have mean zero and standard deviation one 
logCPM <- t(scale(t(logCPM))) 
 
#plotting program contingency 
library(gplots) 
 
#Establish color panel to be used for heat map 
col.pan <- colorpanel(100, "blue", "white", "red") 
 
#order of colummns for heat map 
cn<-c("WT6wkChow-1","WT6wkChow-2","WT6wkChow-3","WT6wkChow-4","WT6wkChow-5", 
      "KO6wkChow-1","KO6wkChow-2","KO6wkChow-3","KO6wkChow-4","KO6wkChow-5") 
 
#heat mapping function 
heatmap.2(logCPM[,cn], col=col.pan,Colv=FALSE, Rowv=TRUE, scale="none",  
          trace="none", dendrogram="none",cexRow=1.2, cexCol=1.2,labCol = FALSE,  
          density.info="none", margin=c(2,10), lhei=c(2,8), lwid=c(2,6)) 
 
#GO and KEGG analysis 
library(GO.db) 
 
#GO analysis of res("loose") analysis 
go6chow <- goana(Chow6results, geneid=y$genes$entrezid, species="Mm") 
#display 15 GO terms of highest P-value 
topGO(go6chow, n=15) 
 
 
#write table of GO analysis 
write.table(go6chow, file= "190315 Dissertation 6wk chow GO.tsv", row.names=TRUE, sep="\t") 
 
#KEGG pathway analysis 
kegg6chow <- kegga(Chow6results, geneid = y$genes$entrezid, species="Mm") 
topKEGG(kegg6chow, n=15, truncate=34) 
 
#write table of KEGG analysis 
write.table(kegg6chow, file= "190315 Dissertation 6wk chow kegg.tsv",  
           row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
go6chowup <- go6chow[go6chow$P.Up < 0.001,] 
#order in ascending order p-values 
go6chowup <- go6chowup[order(go6chowup$P.Up),] 
topGO(go6chowup, n=15,sort="up") 
write.table(go6chowup, file= "190315 Dissertation 6wk chow GO up.tsv", row.names=TRUE,  
           sep="\t") 
 
#enables indexing of data frame based on logical constraint 
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go6chowdown <- go6chow[go6chow$P.Down < 0.001,] 
#order in ascending order p-values 
go6chowdown <- go6chowdown[order(go6chowdown$P.Down),] 
topGO(go6chowdown, n=15,sort="down") 
write.table(go6chowdown , file= "190315 Dissertation 6wk chow GO down.tsv",  
            row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
kegg6chowdown <- kegg6chow[kegg6chow$P.Down < 0.001,] 
#order in ascending order p-values 
kegg6chowdown <- kegg6chowdown[order(kegg6chowdown$P.Down),] 
topKEGG(kegg6chowdown, n=15,sort="down") 
write.table(kegg6chowdown, file= "190315 Dissertation 6wk chow KEGG down.tsv",  
           row.names=TRUE, sep="\t") 
 
kegg6chowup <- kegg6chow[kegg6chow$P.Up < 0.001,] 
#order in ascending order p-values 
kegg6chowup <- kegg6chowup[order(kegg6chowup$P.Up),] 
topKEGG(kegg6chowup, n=15,sort="up") 
write.table(kegg6chowup, file= "190315 Dissertation 6wk chow KEGG up.tsv",  
           row.names=TRUE, sep="\t") 
 
 
 
#Continuing this script will provide analysis and figures for the Chow-fed 18 week old group 
############################################################################
# 
 
 
 
 
#Establish new comparison for 18wk chow mice 
 
WT18chxKO18ch <- makeContrasts(KO18wkChow-WT18wkChow, levels=design) 
 
Chow18results <- glmQLFTest(fit, contrast=WT18chxKO18ch) 
 
#show top 10 P value DEGs and log FCs 
topTags(Chow18results) 
 
#determine differerntial expression test 
is.de.Chow18wk <- decideTestsDGE(Chow18results) 
summary(is.de.Chow18wk) 
 
#make results table from DGE analysis a data frame 
DGE.Chow18wk <- data.frame(Chow18results$table) 
 
#add DGE binary marker to data frame 
DGE.Chow18wk$DE <- is.de.Chow18wk 
 
#Write table 
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write.table(DGE.Chow18wk, file= "190315 Dissertation 18wk chow DGE.tsv", row.names=TRUE, 
            col.names=NA, sep="\t") 
 
plotMD(Chow18results, status=is.de.Chow18wk, values=c(1,-1), col=c("red","blue"), 
legend="topright") 
 
# dependencies: 
#install.packages("ggplot2") 
#install.packages("gridExtra") 
#install.packages("plotly") 
#install.packages("dplyr") 
#install.packages("orca") 
#install.packages("processx") 
#suppressPackageStartupMessages(library("plotly")) 
library(ggplot2) 
library(gridExtra) 
library(plotly) 
library(dplyr) 
library(orca) 
library(processx) 
Sys.setenv('MAPBOX_TOKEN' = 
'pk.eyJ1IjoiZXRyZWZ0cyIsImEiOiJjanRhc214dDYwZWduNDltZWZ5c3JqemIyIn0.YoiKAvwoZR
BJQVptAWJ9Pg') 
 
 
# path to the gene file 
setwd("C:/Users/treftse/Dropbox (VUMC)/Defense/") 
Chow18wkVolcano <- "C:/Users/treftse/Dropbox (VUMC)/Defense/190315 Dissertation 18wk 
chow DGE.tsv" 
 
# graph 18 wk Chow analysis 
diff_df_Chow18wk <- read.delim(file = Chow18wkVolcano,header = TRUE,row.names=1,sep = 
'\t') 
#add column of -log10p values to table 
diff_df_Chow18wk$negLog10P <- (-log10(diff_df_Chow18wk$PValue)) 
# edit the dataframe to contain the main information used for analysis 
diff_df_Chow18wk <- diff_df_Chow18wk[c("logFC", "DE", "negLog10P")] 
 
#edit the data frame to add a column and establish criteria for significance and fold change 
diff_df_Chow18wk[which(diff_df_Chow18wk['DE'] < -0.5 & abs(diff_df_Chow18wk['logFC']) > 0 
),"group"] <- "Downregulated" 
diff_df_Chow18wk[which(diff_df_Chow18wk['DE'] > -0.5 & diff_df_Chow18wk['DE'] < 0.5 
),"group"] <- "Non-significant" 
diff_df_Chow18wk[which(diff_df_Chow18wk['DE'] > 0.5 & abs(diff_df_Chow18wk['logFC']) > 0 
),"group"] <- "Upregulated" 
 
#Define color scheme 
palChow18wk <- c("blue", "black", "red") 
 
palChow18wk <- setNames(palChow18wk, c("Upregulated", "Non-significant", "Downregulated")) 
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#plot differentially expressed gene data on a volcano plot 
pChow18wk <- plot_ly(data=diff_df_Chow18wk, x=~logFC, y= ~negLog10P,  type="scatter",  
mode="markers", symbol=0, color=~group, colors=pal,width=500, height=600)%>% 
layout(margin= (pad=0), 
title= "<b>18 Week Chow ILK <sup>lox/lox</sup> Vs. hepILK-KO RNA-seq</b>",  
titlefont = list(family="Arial", size=20, color = "black"), 
xaxis = list(title = '<b>log<sub>2</sub> Fold Change</b>', 
autotick = FALSE, ticks = "outside", tick0 = 0,  
dtick = 5, ticklen = 5, tickwidth = 2,tickcolor = toRGB("white"), 
showticklabels=TRUE,tickfont=list(family="Arial", size=20, color = "black"), 
titlefont = list(family="Arial", size=20, color = "black"),  
zeroline = TRUE, range = c(-10, 10)), showlegend=TRUE, 
legend=list(x=0.9,y=0.9,traceorder='normal',font=list(family='Arial',size=20, 
color='#000'),bordercolor='#FFFFFF',borderwidth=2), 
yaxis = list(title = '<b>-log<sub>10</sub> <i>p</i>-value</b>', 
autotick = FALSE, ticks = "outside", tick0 = 0,  
dtick = 3, ticklen = 5, tickwidth = 2,tickcolor = toRGB("white"), 
showticklabels=TRUE,tickfont=list(family="Arial", size=20, color = "black"),  
titlefont = list(family="Arial", size=24, color = "black"),  
range = c(0,13))) 
pChow18wk 
 
#export plotly object "volcano plot" as svg 
orca(p, "190315 Chow 18wk Volcano.svg") 
 
 
#save graph as html 
 
htmlwidgets::saveWidget(p, "190315 Chow 18wk Volcano.html") 
 
 
# Heat map synthesis for top 40 DE genes 
#Create a CPM arrangement of the DGE object count matrix 
logCPM <- cpm(y, prior.count=2, log=TRUE) 
#Change the colummn names to a representation of samples with groups and numbers 1-5 
colnames(logCPM) <- paste(y$samples$group, 1:5, sep="-") 
#Replace rownames of CPM object with gene symbols  
rownames(logCPM) <- paste(y$genes$symbol) 
#Order the Pvalues based on the comparison denoted  
o <- order(Chow18results$table$PValue) 
#Index the logCPM object based on the highest 40 PValues from previous order function 
logCPM <- logCPM[o[1:40],] 
 
#scale each row (each gene) to have mean zero and standard deviation one 
logCPM <- t(scale(t(logCPM))) 
 
#plotting program contingency 
library(gplots) 
 
#Establish color panel to be used for heat map 
col.pan <- colorpanel(100, "blue", "white", "red") 
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#order of colummns for heat map 
cn<-c("WT18wkChow-1","WT18wkChow-2","WT18wkChow-3","WT18wkChow-
4","WT18wkChow-5", 
      "KO18wkChow-1","KO18wkChow-2","KO18wkChow-3","KO18wkChow-4","KO18wkChow-
5") 
 
#heat mapping function 
heatmap.2(logCPM[,cn], col=col.pan,Colv=FALSE, Rowv=TRUE, scale="none",  
          trace="none", dendrogram="none",cexRow=1.2, cexCol=1.2, density.info="none", 
          margin=c(10,9), lhei=c(2,8), lwid=c(2,6)) 
 
#GO and KEGG analysis 
library(GO.db) 
 
#GO analysis of res("loose") analysis 
go18chow <- goana(Chow18results, geneid=y$genes$entrezid, species="Mm") 
#display 15 GO terms of highest P-value 
topGO(go18chow, n=15) 
 
 
#write table of GO analysis 
write.table(go18chow, file= "190315 Dissertation 18wk chow GO.tsv", row.names=TRUE, 
sep="\t") 
 
#KEGG pathway analysis 
kegg18chow <- kegga(Chow18results, geneid = y$genes$entrezid, species="Mm") 
topKEGG(kegg18chow, n=15, truncate=34) 
 
#write table of KEGG analysis 
write.table(kegg18chow, file= "190315 Dissertation 18wk chow kegg.tsv",  
           row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
go18chowup <- go18chow[go18chow$P.Up < 0.001,] 
#order in ascending order p-values 
go18chowup <- go18chowup[order(go18chowup$P.Up),] 
topGO(go18chowup, n=15,sort="up") 
write.table(go18chowup, file= "190315 Dissertation 18wk chow GO up.tsv", row.names=TRUE,  
           sep="\t") 
 
#enables indexing of data frame based on logical constraint 
go18chowdown <- go18chow[go18chow$P.Down < 0.001,] 
#order in ascending order p-values 
go18chowdown <- go18chowdown[order(go18chowdown$P.Down),] 
topGO(go18chowdown, n=15,sort="down") 
write.table(go18chowdown , file= "190315 Dissertation 18wk chow GO down.tsv",  
            row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
kegg18chowdown <- kegg18chow[kegg18chow$P.Down < 0.001,] 
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#order in ascending order p-values 
kegg18chowdown <- kegg18chowdown[order(kegg18chowdown$P.Down),] 
topKEGG(kegg18chowdown, n=15,sort="down") 
write.table(kegg18chowdown, file= "190315 Dissertation 18wk chow KEGG down.tsv",  
           row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
kegg18chowup <- kegg18chow[kegg18chow$P.Up < 0.001,] 
#order in ascending order p-values 
kegg18chowup <- kegg18chowup[order(kegg18chowup$P.Up),] 
topKEGG(kegg18chowup, n=15,sort="up") 
write.table(kegg18chowup, file= "190315 Dissertation 18wk chow KEGG up.tsv",  
           row.names=TRUE, sep="\t") 
 
 
 
 
#Continuing this script will provide analysis and figures for the HF-fed 18 week old group 
############################################################################
# 
 
 
 
 
#Establish new comparison for 18wk chow mice 
 
WT18HFxKO18HF <- makeContrasts(KO18wkHF-WT18wkHF, levels=design) 
 
HF18results <- glmQLFTest(fit, contrast=WT18HFxKO18HF) 
 
#show top 10 P value DEGs and log FCs 
topTags(HF18results) 
 
#determine differerntial expression test 
is.de.HF18wk <- decideTestsDGE(HF18results) 
summary(is.de.HF18wk) 
 
#make results table from DGE analysis a data frame 
DGE.HF18wk <- data.frame(HF18results$table) 
 
#add DGE binary marker to data frame 
DGE.HF18wk$DE <- is.de.HF18wk 
 
#Write table 
write.table(DGE.HF18wk, file= "190315 Dissertation 18wk HF DGE.tsv", row.names=TRUE, 
            col.names=NA, sep="\t") 
 
 
plotMD(HF18results, status=is.de, values=c(1,-1), col=c("red","blue"), legend="topright") 
 
# dependencies: 
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#install.packages("ggplot2") 
#install.packages("gridExtra") 
#install.packages("plotly") 
#install.packages("dplyr") 
#install.packages("orca") 
#install.packages("processx") 
#suppressPackageStartupMessages(library("plotly")) 
library(ggplot2) 
library(gridExtra) 
library(plotly) 
library(dplyr) 
library(orca) 
library(processx) 
Sys.setenv('MAPBOX_TOKEN' = 
'pk.eyJ1IjoiZXRyZWZ0cyIsImEiOiJjanRhc214dDYwZWduNDltZWZ5c3JqemIyIn0.YoiKAvwoZR
BJQVptAWJ9Pg') 
 
 
# path to the gene file 
setwd("C:/Users/treftse/Dropbox (VUMC)/Defense/") 
HF18wkVolcano <- "C:/Users/treftse/Dropbox (VUMC)/Defense/190315 Dissertation 18wk HF 
DGE.tsv" 
 
# graph 18 wk Chow analysis 
diff_df_HF18wk <- read.delim(file = HF18wkVolcano,header = TRUE,row.names=1,sep = '\t') 
#add column of -log10p values to table 
diff_df_HF18wk$negLog10P <- (-log10(diff_df_HF18wk$PValue)) 
# edit the dataframe to contain the main information used for analysis 
diff_df_HF18wk <- diff_df_HF18wk[c("logFC", "DE", "negLog10P")] 
 
#edit the data frame to add a column and establish criteria for significance and fold change 
diff_df_HF18wk[which(diff_df_HF18wk['DE'] < -0.5 & abs(diff_df_HF18wk['logFC']) > 0 ),"group"] 
<- "Downregulated" 
diff_df_HF18wk[which(diff_df_HF18wk['DE'] > -0.5 & diff_df_HF18wk['DE'] < 0.5 ),"group"] <- 
"Non-significant" 
diff_df_HF18wk[which(diff_df_HF18wk['DE'] > 0.5 & abs(diff_df_HF18wk['logFC']) > 0 ),"group"] 
<- "Upregulated" 
 
#Define color scheme 
palHF18wk <- c("blue", "black", "red") 
 
palHF18wk <- setNames(pal, c("Upregulated", "Non-significant", "Downregulated")) 
 
#plot differentially expressed gene data on a volcano plot 
pHF18wk <- plot_ly(data=diff_df_HF18wk, x=~logFC, y= ~negLog10P,  type="scatter",  
mode="markers", symbol=0, color=~group, colors=pal,width=500, height=600)%>% 
layout(margin= (pad=0), 
title= "<b>18 Week HF ILK <sup>lox/lox</sup> Vs. hepILK-KO RNA-seq</b>",  
titlefont = list(family="Arial", size=20, color = "black"), 
xaxis = list(title = '<b>log<sub>2</sub> Fold Change</b>', 
autotick = FALSE, ticks = "outside", tick0 = 0,  
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dtick = 5, ticklen = 5, tickwidth = 2,tickcolor = toRGB("white"), 
showticklabels=TRUE,tickfont=list(family="Arial", size=20, color = "black"), 
titlefont = list(family="Arial", size=20, color = "black"),  
zeroline = TRUE, range = c(-10, 10)), showlegend=TRUE, 
legend=list(x=0.9,y=0.9,traceorder='normal',font=list(family='Arial',size=20, 
color='#000'),bordercolor='#FFFFFF',borderwidth=2), 
yaxis = list(title = '<b>-log<sub>10</sub> <i>p</i>-value</b>', 
autotick = FALSE, ticks = "outside", tick0 = 0,  
dtick = 3, ticklen = 5, tickwidth = 2,tickcolor = toRGB("white"), 
showticklabels=TRUE,tickfont=list(family="Arial", size=20, color = "black"),  
titlefont = list(family="Arial", size=24, color = "black"),  
range = c(0,13))) 
pHF18wk 
 
#export plotly object "volcano plot" as svg 
orca(p, "190315 HF 18wk Volcano.svg") 
 
 
#save graph as html 
 
htmlwidgets::saveWidget(p, "190315 HF 18wk Volcano.html") 
 
 
 
# Heat map synthesis for top 40 DE genes 
#Create a CPM arrangement of the DGE object count matrix 
logCPM <- cpm(y, prior.count=2, log=TRUE) 
#Change the colummn names to a representation of samples with groups and numbers 1-5 
colnames(logCPM) <- paste(y$samples$group, 1:5, sep="-") 
#Replace rownames of CPM object with gene symbols  
rownames(logCPM) <- paste(y$genes$symbol) 
#Order the Pvalues based on the comparison denoted  
o <- order(HF18results$table$PValue) 
#Index the logCPM object based on the highest 40 PValues from previous order function 
logCPM <- logCPM[o[1:40],] 
 
#scale each row (each gene) to have mean zero and standard deviation one 
logCPM <- t(scale(t(logCPM))) 
 
#plotting program contingency 
library(gplots) 
 
#Establish color panel to be used for heat map 
col.pan <- colorpanel(100, "blue", "white", "red") 
 
#order of colummns for heat map 
cn<-c("WT18wkHF-1","WT18wkHF-2","WT18wkHF-3","WT18wkHF-4","WT18wkHF-5", 
      "KO18wkHF-1","KO18wkHF-2","KO18wkHF-3","KO18wkHF-4","KO18wkHF-5") 
 
#heat mapping function 
heatmap.2(logCPM[,cn], col=col.pan,Colv=FALSE, Rowv=TRUE, scale="none",  
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          trace="none", dendrogram="none",cexRow=1.2, cexCol=1.2, density.info="none", 
          margin=c(10,9), lhei=c(2,8), lwid=c(2,6)) 
 
#GO and KEGG analysis 
library(GO.db) 
 
#GO analysis of res("loose") analysis 
go18HF <- goana(HF18results, geneid=y$genes$entrezid, species="Mm") 
#display 15 GO terms of highest P-value 
topGO(go18HF, n=15) 
 
 
#write table of GO analysis 
write.table(go18HF, file= "190315 Dissertation 18wk HF GO.tsv", row.names=TRUE, sep="\t") 
 
#KEGG pathway analysis 
kegg18HF <- kegga(HF18results, geneid = y$genes$entrezid, species="Mm") 
topKEGG(kegg18HF, n=15, truncate=34) 
 
#write table of KEGG analysis 
write.table(kegg18HF, file= "190315 Dissertation 18wk HF kegg.tsv",  
           row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
go18HFup <- go18HF[go18HF$P.Up < 0.001,] 
#order in ascending order p-values 
go18HFup <- go18HFup[order(go18HFup$P.Up),] 
topGO(go18HFup, n=15,sort="up") 
write.table(go18HFup, file= "190315 Dissertation 18wk HF GO up.tsv", row.names=TRUE,  
           sep="\t") 
 
#enables indexing of data frame based on logical constraint 
go18HFdown <- go18HF[go18HF$P.Down < 0.001,] 
#order in ascending order p-values 
go18HFdown <- go18HFdown[order(go18HFdown$P.Down),] 
topGO(go18HFdown, n=15,sort="down") 
write.table(go18HFdown , file= "190315 Dissertation 18wk HF GO down.tsv",  
            row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
kegg18HFdown <- kegg18HF[kegg18HF$P.Down < 0.001,] 
#order in ascending order p-values 
kegg18HFdown <- kegg18HFdown[order(kegg18HFdown$P.Down),] 
topKEGG(kegg18HFdown, n=15,sort="down") 
write.table(kegg18HFdown, file= "190315 Dissertation 18wk HF KEGG down.tsv",  
           row.names=TRUE, sep="\t") 
 
#enables indexing of data frame based on logical constraint 
kegg18HFup <- kegg18HF[kegg18HF$P.Up < 0.001,] 
#order in ascending order p-values 
kegg18HFup <- kegg18HFup[order(kegg18HFup$P.Up),] 
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topKEGG(kegg18HFup, n=15,sort="up") 
write.table(kegg18HFup, file= "190315 Dissertation 18wk HF KEGG up.tsv",  
           row.names=TRUE, sep="\t") 
 
